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ABSTRACT 
 Within the field of drug design, there is a great interest in the development of 
synthetic libraries that mimic the structural complexity of natural product scaffolds. Recent 
cheminformatic analyses have revealed that 83% of the core ring scaffolds found in natural 
products are absent among commercially available drug molecules. Spirocycles are one of 
these cores presumably due to the difficulty found in synthesizing this scaffold. In order to 
address the limitation in synthetic technology, a novel approach to spiroethers, azaspiro-
ring systems, spirocarbocycles, spiroketals, and spiroaminals has been developed using 
metal carbene initiated cascade reactions. 
 The identification of two novel catalytic systems were critical to the success of 
synthesizing these varying spirocycles. The first development was identification of 
Rh2(esp)2 as a catalyst for the efficient insertion of carboxylic acids into acceptor/acceptor 
diazocarbonyls. The second development was the identification of Rh2(esp)2/PPh3AuOTf as 
a synergistic catalytic combination for an O–H insertion/Conia-ene cascade for the 
stereoselective synthesis of tetrahydrofurans and g-butyrolactones. 
 These systems were applied to the synthesis of spiroethers using an O–H 
insertion/Conia-cascade and azaspiro-ring systems using an N–H insertion/Conia-ene 
cascade. Subsequently, the Rh(II)/Au(I) system was applied to the synthesis of 5-, 6-, and 
7-membered oxindole hybridized spirocarbocycles. Lastly, direct access to spiroketals and 
spiroaminals using a metal carbene initiated cascade reaction dependent on the use of a-
diazoketones was developed. Within each synthetic effort, valuable mechanistic insights 
were obtained to justify stereochemistry and applicability to a substrate scope. 
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CHAPTER 1 
 
 
 
Natural Products as Inspiration for the  
Synthesis of Bioactive Spirocycles in Drug Discovery 
 
1.1 INTRODUCTION 
 
 If one were to probe today’s American population and ask, “What is your greatest 
issue with healthcare in the United States?” an opinion that would often be expressed is, 
“Drugs are too costly”.  To date, the cost of drug development, including the price of failure 
and the opportunity cost, has more than doubled in the past decade. [1]  A study published 
in the Journal of Health Economics showed that the annual price for new drug development 
costs $2.6 billion, a 145% increase (accounting for inflation) since a widely cited study in 
2003.[2]  The higher price tag can be attributed to a variety of factors, but the major 
contributing factor is the higher failure rates of new drug molecules that are entering 
clinical trials.[2] The business of developing innovative drugs is extremely risky and it is well 
understood in our society that the development of a new drug requires major investment 
of capital, human resources, and technological expertise.  However, what is not well 
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understood by the majority is the impact of ineffective research and development efforts 
at the chemical level on the price of the drugs that are purchased at local pharmacies.   
New drug development, from the synthesis of a compound to approval of a New 
Drug Application, can take on average 10–15 years.[1] With this timeframe and the 
aforementioned amount of money required to develop a new drug annually, it is easy to 
understand why the price paid at the pharmacy for drugs is on a steady incline.  The drug 
approval process in the United States can be categorized into three sections (Figure 1.1) : 
1) Preclinical testing and research and development; 2) Clinical research and development; 
and 3) New Drug Application review.[3]  The stage where more effective research and 
development efforts can have the greatest impact, devoid of human safety concerns, can 
be found at the “Preclinical testing and research and development” stage.  This is the stage 
in which drug molecules are initially being discovered and/or synthesized and tested for 
hit-compound identification by high-throughput screening of chemical libraries 
 
Figure 1.1. Visual depiction of drug approval process in the United States 
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Currently in the field of drug design and delivery, a significant number of scientists 
believe it is necessary to make drug molecules that more closely mimic the complexity of 
molecules derived from nature.[4] There is great interest in the development of synthetic 
libraries that mimic the structural complexity of natural product scaffolds. The reasoning 
for this interest was inspired by cheminformatic analyses that revealed that many natural 
product scaffolds remain underexploited in probe and drug discovery.[5] Presently, 83% of 
the core ring scaffolds found in natural products are absent among commercially available 
drug molecules and drug candidate screening libraries.[6] Therefore, designing molecules 
for screening that contain scaffolds found in natural products but are absent from current 
drug molecules is an ideal starting point when designing chemical libraries or developing 
the foundation of a synthetic chemistry research program.[7] This is due to the fact that 
molecules with three-dimensional features such as stereochemistry and bond saturation 
have increased binding specificity, decreased toxicological liabilities, and favorable 
pharmacological properties.[5] 
The chemo-diversity, structural complexity, and three-dimensionality of natural 
products provides scientists with molecular scaffolds that the human mind oftentimes 
cannot fathom piecing together in a laboratory setting. This described uniqueness of 
natural products is what allows these scaffolds to occupy regions of chemical space that 
current drug molecules are not accessing. Due to the high structural diversity of molecules 
obtained from terrestrial and marine organisms, natural products have been the source of 
many successful drug leads.[8] In the last 25 years, of the 877 novel drug molecules 
developed 33% were natural products or their derivatives, evidence of the importance of 
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biogenic structural motifs.[9] However, the major challenge in accessing scaffolds found in 
complex natural products is the development of efficient synthetic routes to obtain these 
molecules.[5] Given this rising challenge, synthetic chemists must identify methods to 
quickly and efficiently synthesize complex molecules and scaffolds that are inspired by 
natural products. One example of a complex scaffold that is currently underrepresented in 
chemical space and difficult to access using known literature protocols are ring systems 
possessing a spirocenter. 
Spirocyclic ring systems are found in a variety of bioactive natural products and 
approved drugs (Figure 1.2).[10] Spirocyclic ring systems contain a “spirocenter” which is a 
tetra-substituted carbon atom that is used to perpendicularly fuse two ring systems to 
create a highly rigid scaffold.[11] The rigidity of this system allows molecules to possess well-
defined conformations in biological systems.[11g] The spirocyclic scaffold increases the 
metabolic stability of drug compounds and allows them to have higher probabilities of 
interaction with protein binding sites.[12] Key classes of spirocycles include spiroethers[13], 
spirolactones[14], spiroamines[15], spirolactams[15c], spirooxindoles[16], spiroketals[17], and 
spiroaminals. Spiroethers such as the pseurotin family, are secondary microbial 
metabolites isolated from a culture broth of Pseuderotium ovalis.[18] They possess a wide 
range of biological activities including antibiotic, antifungal, anti-angiogenic, and anti-
cancer activities.[19] Also, the spiroether drug griseofulvin is on the World Health 
Organization’s (WHO)’s list of essential medicines.[20] The spirolactone core is found in the 
hyperolactone natural products, which were isolated from the leaves of the plant 
Hypericum Chinese L.[21] In particular, hyperlactone C and biyouyanagin A are of significant 
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Figure 1.2. Biologically active natural products containing a spirocenter 
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interest because of their anti-HIV activity.[22] In addition, g-butyrolactones are very 
common structural motifs found in about 10% of all-natural products.[23]  
Despite the impressive biological pedigree of spirocyclic molecules, not many of 
these scaffolds have advanced to clinical use due to low isolated yields or synthetic 
challenges associated with the stereoselective installation of the spirocenter. As a result, 
most of these drugs are either semi-synthetic natural product derivatives or synthetic 
molecules in which the spirocenter is achiral. Thus, there remains a tremendous 
opportunity to exploit the biological capabilities of spirocycles in chemical biology and drug 
discovery, provided that the synthetic challenges associated with the stereoselective 
synthesis of these molecules can be overcame. 
 
1.2 TOTAL SYNTHESES OF SPIROCYCLIC NATURAL PRODUCTS 
In this section, recent representative developments made toward the synthesis of 
spirocyclic natural products are described. Most of these methods involve the synthesis of 
a densely functionalized core which needs multiple synthetic steps to obtain prior to setting 
the spirocenter. With insights from these total syntheses, one can conclude that a general 
approach to all classes of spirocycles is of great need in the chemical community. This 
dissertation hopes to establish a method that solves this need. 
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1.2.1 TOTAL SYNTHESIS OF HYPEROLACTONE C – SPIROETHER  
 In 2009, Du et al. completed the total synthesis of hyperlactone C through the 
efficient construction of two vicinal quaternary carbon centers.[25] The authors were able 
to accomplish this daunting task by using a palladium-catalyzed asymmetric allylic 
alkylation reaction. This strategy enabled the concise and efficient total synthesis of their 
desired natural product, hyperolactone C (depicted in Scheme 1.1)  and also (–)-
biyouyanagin A in overall 20% and 8% yields, respectively. Starting from methyl 
acetoacetate 1 and benzaldehyde, the authors synthesized 2 through the formation of a 
 
Scheme 1.1. Total synthesis of hyperlactone C by Du et al. 
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insertion of the enol-form of 3. With this key intermediate in hand, a Pd(II) catalyzed allylic 
alkylation was conducted to set the desired quaternary centers with high stereoselectivity. 
The desired spirocenter was set through a lactonization reaction of 5 to obtain 
hyperolactone C. 
 
1.2.2  TOTAL SYNTHESIS OF AMATHASPIRAMIDE F – AZASPIRO-RING SYSTEM 
 A unique [2,3]-Stevens rearrangement which was prompted by a palladium-
catalyzed allylic amination gave way to the diastereoselective total synthesis of 
amathaspiramide F by Tambar and coworkers (Scheme 1.2).[26] The authors were 
interested in utilizing a diastereoselective [2,3]-Stevens rearrangement to construct the 
two contiguous stereocenters of the natural product prior to setting the desired 
spirocenter. An easily obtainable prenylated proline derivative 6 underwent an allylic 
alkylation using carbonate 7 under Pd(II) conditions. Intermediate 8 underwent an 
immediate rearrangement to the desired product 9 whose N-prenyl group was cleaved 
under olefin isomerization conditions. The desired intermediate 10 was treated with 
trifluoroacetic acid to conduct a global deprotection followed by treatment with TMSCHN2 
to furnish 11. This intermediate was known in a previous total synthesis of 
amathaspiramide F and the spirocenter was set through ozonolysis of 11 followed by 
spirohemiaminal formation using MeNH2 to obtain 13. Four subsequent steps were 
necessary to obtain the desired natural product amathaspiramide F. 
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Scheme 1.2. Total synthesis of amathaspiramide F completed by Tambar et al. 
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occurred through an substitution reaction in 99.5% ee. With the optically pure 
spirocarbocycle 18 in hand, a palladium catalyzed carbonylation was conducted to 
synthesize carboxylic acid 19 which was then coupled with the pre-synthesized lactam (20) 
portion of the natural product. This synthesis successfully made over 100 kilograms of 
ubrogepant in an overall 43% yield. 
 
Scheme 1.3. Total synthesis of ubrogepant by Yasuda et al. 
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construction of chroman spiroacetals which proceeded through the in situ formation of an 
exo-enol ether and ortho-quinonemethide. These two intermediates underwent a [4+2] 
annulation to form the desired products. This methodology was applied to the total 
synthesis of berkelic acid by starting with compound 22 and 23. However, upon 
optimization it was realized that their desired spiroketalization could be achieved with Ag(I) 
catalysis instead of Pd(II) catalysis. After spiroketalization, the desired product was 
immediately reduced to give 24 to avoid decomposition of the unstable intermediate. Once 
this highly complex molecule underwent iodination only a few more straightforward 
synthetic steps were needed to make the natural product. Compound 25 underwent an 
umpolung alkylation in the presence of 26 and LDA. This reaction delivered the berkelic 
acid methyl ester which was exposed to selective benzylic ester cleavage to achieve the 
total synthesis of berkelic acid in a 38% overall yield. 
 
Scheme 1.4. Total synthesis of berkelic acid by Fañanàs et al. 
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1.3  GOALS OF THIS DISSERTATION 
 
  The representative synthetic efforts presented in the previous section were 
successful in achieving their respective molecules in an efficient and concise manner. 
However, the key spirocyclization step for each scaffold was extremely specific and thereby 
could not be applied in a general manner to obtain all classes of spirocycles. Envisaging a 
strategy to construct every class of spirocycle through similar retrosynthetic bond 
disconnections would aid the evolution of synthetic planning and reaction development for 
the construction of more complex and diverse chemical libraries for drug screening 
programs. With the desire to develop methodology in alignment with this strategy in our 
mind, we dissected spirocycles down the middle to create a simple and straightforward 
retrosynthetic design (Figure 1.3). This disconnection would provide convergent access to 
all classes of spirocycles if two ambiphilic reacting partners were used to convergently set 
the desired spirocenter. We hypothesized that through the use of metal carbenes derived 
from diazo compounds, a cascade reaction with a tethered nucleophile and electrophile 
could give access to a wide range of spirocycles. Therefore, the goal of this dissertation is 
to successfully utilize metal carbene initiated cascade reactions to achieve the efficient 
synthesis of spirocyclic scaffolds.  
 
Figure 1.3. Novel disconnection to spirocycles developed by Sharma Lab 
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CHAPTER 2 
 
Identification of Rh(II)/Au(I)  
Synergistic Cascade Catalysis 
 
 
2.1  INTRODUCTION 
 
Recently in the field of synthetic chemistry, synergistic cascade catalysis has 
become an effective method to install molecular complexity in methodology development 
and the total synthesis of natural products.[1] Synergistic catalysis is a mode of catalysis in 
which two catalysts and two catalytic cycles cooperatively work to create a new single 
bond.[2] This mode of catalysis provides opportunities to efficiently and selectively 
assemble molecules with high levels of molecular complexity when compared to mono-
catalytic systems. In mono-catalysis one substrate is catalytically activated, altering the 
energy of only a single component of the reaction system. However, in synergistic catalysis 
both the HOMO and LUMO of the reacting system are concurrently activated using distinct 
catalysis, thereby creating two catalytic cycles that must simultaneously work together 
(Figure 2.1).[2b] 
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Figure 2.1. The classification of synergistic catalysis and the difference between 
traditional catalytic systems. 
Synergistic catalysis enables transformations that are usually impossible or 
inefficient using traditional mono-catalytic systems. While there are many benefits to 
synergistic cascade catalysis, this mode of catalysis has been underexplored due to the 
difficulty in ensuring that the metal catalysts needed in the transformation are redox 
compatible in order to avoid catalyst deactivation. The development of synergistic catalytic 
cascades stands as a challenging feat in synthetic chemistry.[1c, 2a, 2b, 3] When nature 
implements synergistic catalysis, enzymes typically have the advantage of physical 
separation between catalytic sites within the enzyme.[3a] Conversely, in laboratory 
syntheses, the catalysts are free to interact with each other, thereby leading to the 
possibility of deactivation of both catalysts.[2b]  However, it is important to note that the 
molecular freedom of each individual catalyst in the reaction system allows one to optimize 
the reaction easily through modification of individual catalysts separately.  
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Recently the use of diazo derived rhodium carbenes in synergistic catalysis has 
gained recognition in the chemical community. It has been widely known since the early 
1970s that dirhodium(II) catalysts are the most effective catalysts for the formation of 
rhodium carbenes from diazo compounds due to the control of reactivity and selectivity 
that is induced by the bridging carboxylate ligands in the paddlewheel metal-ligand 
complex.[4] Rhodium carbenes are attractive partners for synergistic transformations due 
to their ease of formation, relative stability, controlled reactivity in typical catalytic 
reactions, and redox compatibility with a variety of transition metals.[5] 
 
Figure 2.2. a) Overview of diazocarbonyl stabilization and metal carbene reactivity; 
 b) dirhodium(II) paddlewheel complex. 
Rhodium carbenes are typically formed from diazo compounds which are inherently 
unstable substrates. However, the stability of diazo compounds can be attenuated through 
substitution of proper electron withdrawing groups at the diazo functionality. Carbonyl 
compounds have been used throughout history as electron withdrawing groups to create 
stable “diazocarbonyl” compounds that are highly useful in synthetic transformations due 
to their ease of formation, relative stability, and controlled reactivity in catalytic reactions. 
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Diazocarbonyl compounds can be categorized into three subgroups: 1) acceptor/acceptor 
[A/A] - possessing two carbonyl groups, 2) acceptor [A] - possessing a single carbonyl group, 
3) acceptor/donor [A/D] - possessing a single carbonyl group and a vinyl or aromatic group. 
The order of stability toward diazo decomposition and subsequent metal-carbene 
formation has A/D diazocarbonyls as the most reactive while A/A diazocarbonyls are the 
least reactive. However, in the case of metal carbene reactivity, this trend is reversed 
(Figure 2.2a).  
Metal carbene formation from diazocarbonyls using dirhodium(II) catalysts 
proceeds through a unique mechanism. Dirhodium(II) catalysts have an open axial 
coordination site on each terminal end of the paddlewheel complex that serves as a Lewis 
acidic center (Figure 2.2b). This characteristic allows the catalyst to undergo electrophilic 
addition to the diazo compound at the a-carbon (Scheme 2.1). Subsequent loss of 
dinitrogen  
 
Scheme 2.1. General mechanism for synergistic catalysis in rhodium carbene chemistry. 
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from the rhodium-associated diazocarbonyl prompts formation of an electrophilic rhodium 
carbene intermediate. The rhodium carbene is transferred to a coupling partner and the 
catalyst is regenerated. Within this dissertation, the coupling partner is a “X–H” bond (X = 
O, N, S, sp2-C). Upon X–H insertion into the rhodium carbene, a highly reactive zwitterionic 
intermediate is formed prior to catalyst extrusion. This zwitterionic intermediate has the 
ability to proceed down two different pathways: 1) undergo 1,2-proton 
transfer/protodemetalation to provide the formal X–H insertion product, or 2) be trapped 
by an adequately activated electrophilic species in a synergistic catalytic cascade (Scheme 
2.1). The objective of this research is to understand the reactivity of rhodium carbenes and 
their application in synergistic cascade reactions where the active zwitterionic 
intermediate is trapped by an activated electrophilic species. 
We hypothesized that in order to have a viable synergistic cascade, the initial step 
of the catalytic cycle must be proficient. Therefore, when initiating our studies toward the 
development of a synergistic catalytic cocktail for spirocyclizations, it was important to 
identify a catalyst that could efficiently decompose diazocarbonyls to produce a stable 
carbene intermediate that was able to undergo X–H (X = O, N, sp2 C–H) insertions 
efficiently. 
It was decided that optimization of the initial X–H insertion step would begin with 
A/A diazocarbonyls as our model substrates. A/A diazocarbonyls are important chemical 
building blocks in organic synthesis that are capable of novel transformations such as 
cyclopropanation, cyclopropenation, sp3 and sp2 C–H activations, and various cascade 
rearrangements.[6] Although these substrates have been applied in a wide variety of 
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transformations, their stability, requires harsh conditions in order to extrude N2 and 
generate a metal carbene reactive species. These harsh conditions are not suitable for the 
development of synergistic catalytic cascades. Due to this limitation, the implementation 
of A/A diazocarbonyls in many cascade transformations is scarce.  
When surveying the literature, it was observed that O–H insertion reactions of 
alcohols into A/A diazocarbonyls were thoroughly investigated. However, only a few 
examples of O–H insertion reactions of carboxylic acids had been reported in the literature 
(Scheme 2.2).[7] In 2005 Jørgensen et al. identified Rh2(OAc)4 as a catalyst for the O–H 
insertion of carboxylic acids into a-diazo-b-ketoesters (Scheme 2.2a).[7a] To enable the 
desired transformation, the reaction needed to be heated at 40 ºC for 16 hours to provide 
compound 1a in a 75% yield. These conditions are not adequately efficient for use in a 
synergistic catalytic cascade. Later in 2011, Kitamura et al. identified Pd(OAc)2 as an 
efficient catalyst for carboxylic acid O–H insertion into A/A diazocarbonyls (Scheme 
2.2b).[7b] However, the reaction conditions necessitated the use of the carboxylic acid as 
solvent and a heightened temperature of 70 ºC. These conditions are extremely harsh 
when considering including an additional highly reactive organometallic intermediate for 
the development of a synergistic cascade. Most recently in 2014, Dong et al. identified a 
catalytic cocktail of Cu(OAc)2 and isocyanide for the carboxylic acid O–H insertion into A/A 
diazocarbonyls (Scheme 2.2c).[7c] Although the identification of an earth abundant Cu(II) 
catalyst was appreciated by the chemical community, the need of the carboxylic acid as a 
solvent and the use of a reactive isocyanide made these conditions unsuitable for the 
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development of a synergistic cascade. Additionally, the reaction was conducted at 100 ºC, 
a temperature that initiates thermal decomposition for many organometallic complexes. 
 
Scheme 2.2. Previous methods for the carboxylic acid O–H insertion into metal carbenes. 
 
2.2 IDENTIFICATION OF “Rh2(esp)2” AS AN EFFICIENT CARBOXYLIC 
ACID O–H INSERTION CATALYST 
2.2.1  INITIAL SCREENING OF CATALYTIC CONDITIONS 
Confronted by the aforementioned limitations in reaction conditions we decided to 
develop reaction conditions that would enable the efficient O–H insertion of highly 
functionalized carboxylic acids into A/A diazocarbonyls. For the initial optimization diethyl 
diazomalonate 2a and Boc-protected phenylalanine 3a were selected as model substrates 
and exposed to the most efficient catalyst known in literature, Rh2(OAc) (Table 2.1, entry 
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1)4.[7a] To our delight the desired insertion compound 4a was obtained in 64% yield after 
stirring at room temperature for 12 hours. The Pd(II) conditions[7b] were also screened and 
after refluxing in dichloromethane for 8 hours, the desired compound was obtained in a  
 
Table 2.1: Optimization of Carboxylic O–H Insertion into A/A Diazocarbonyls 
 
entry catalyst system solvent, T (ºC), t 4a (yield%)b 
1 Rh2(OAc)4 CH2Cl2, rt, 12h 64 
2 Pd(OAc)2 CH2Cl2, reflux, 8h 58 
3 Cu(OAc)2/ CNCH2CO2Et DCE, reflux, 12h 55 
4 Rh2(TFAc)4 CH2Cl2, rt, 6h 46 
5 Rh2(HFBd)4 CH2Cl2, rt, 6h 67 
6 Rh2(esp)2 CH2Cl2, rt, 10 min 94 
7 - TFEe, reflux, 12h NR 
8 Hoveyda Grubbs2nd CH2Cl2, reflux, 10h 40 
9 Cu(acac)2 DCE, reflux, 5h 62 
10 Cu(OAc)2 DCE, reflux, 5h 43 
aAll optimization reactions were performed with 2a (1.5 equiv), 3a (1 equiv) and catalyst (1 mol%). 
bIsolated yields after column chromatography. NR = no reaction; cTFA = trifluoroacetate; dHFB = 
heptafluorobutyrate; eTFE = trifluoroethanol. 
 
mediocre 58% yield (Table 1, entry 2). Next the Cu(II) conditions[7c] were screened and after 
refluxing in dichloroethane for 12 hours, the desired compound was obtained in 55% yield 
(Table 1, entry 3). 
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Inspired by the preliminary efficiency and ambient reaction temperature of 
Rh2(OAc)4, we decided to screen more electrophilic Rh(II) catalysts (Table 2.1, entries 4–5). 
We hypothesized that through increasing the electrophilicity of the Rh(II) paddlewheel  
ligand-metal complex, an increased rate of diazo decomposition would occur[8], thereby 
enabling a more efficient transformation. The electrophilic catalysts Rh2(TFA)4 and 
Rh2(HFB)4, primed with trifluoroacetate (TFA) and heptafluorobutyrate (HFB) ligands 
respectively, decreased the time of the desired transformation to 6 hours with no 
significant change in yield from Rh2(OAc)4. However, to our surprise, Rh2(esp)2, which was 
developed by the Du Bois group for C–H amination[9], provided the desired compound at 
room temperature within minutes in an excellent 94% yield (Table 2.1, entry 6). Various 
other conditions were also screened such as trifluoroethanol as a solvent, the Hoveyda–
Grubbs catalyst, and different Cu(II) catalysts, but these conditions were met with limited 
success or no reaction. 
2.2.2  APPLICATION TO SUBSTRATE SCOPE 
Encouraged by the identification of optimized conditions we undertook a thorough 
study of the substrate scope of the reaction. We began by examining diethyl diazomalonate 
and its applicability to a range of amino acids (Scheme 2.3). Sterically hindered Boc-
protected proline inserted in a good 83% yield (4b). Next, the reaction showed high levels 
of chemoselectivity when Boc-protected serine, which possesses a free hydroxyl side chain, 
 
† The work within Section 2.2 was published in 2016 as a featured cover article for European 
Journal of Organic Chemistry, see reference: Hunter, A. C.; Chinthapally, K.; Sharma, I., 
Rh2(esp)2: An Efficient Catalyst for O-H Insertion Reactions of Carboxylic Acids into 
Acceptor/Acceptor Diazo Compounds. Eur. J. Org. Chem. 2016, 2016 (13), 2260–2263. 
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gave the desired compound 4c in 74% yield. The undesired double insertion into the free 
hydroxyl sidechain (highlighted in orange) of 4c was only observed in a minimal 18% yield. 
After that, we screened Boc-protected tryptophan that has highly electron rich and reactive 
C–sp2 and N–H indole centers. The varying electron rich reactive sites of the indole moiety 
had little effect on the efficiency of the transformation, producing the desired compound 
4d in 62%.  
After screening different amino acids, a wide variety of carboxylic acids with 
differing functionality were also studied. Aliphatic carboxylic acids underwent the desired 
transformation efficiently (4e–4f). Next we screened alkynyl- and alkenyl-carboxylic acids 
that are primed with functionality known to undergo cyclopropenation and 
cyclopropanation[6o] in the presence of Rh(II) carbenes. These carboxylic acids underwent 
the desired transformation efficiently to give the alkynyl substrate 4g in 94% yield and the 
alkenyl substrates 4h and 4i in 90% and 93% yields, respectively. Lastly, we screened the 
electronic effects of aryl substituents on the reactivity of various benzoic acids. Benzoic 
acid produced the desired compound 4j in 87% yield. However, the decreased 
nucleophilicty of 4-nitrobenzoic acid had a resounding effect on the efficiency of the 
reaction. The desired product 4k was produced in a lessened 69% yield and a slow addition 
of diethyl diazomalonate via syringe pump was needed in order to avoid unproductive 
decomposition of the diazocarbonyl. Conversely, the electron-rich 4-methoxybenzoic acid 
was highly reactive and provided the desired insertion product 4l in an excellent 94% yield. 
Finally, as another probe for chemoselectivity, we screened salicylic acid which has a free 
phenolic O–H. The desired carboxylic acid O–H insertion product 4m was obtained in an 
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excellent yield with no production of the double insertion product into the free phenolic 
O–H in 4m.  
 
Scheme 2.3. Scope of Rh2(esp)2-catalyzed room temperature O–H insertion reactions of 
carboxylic acid in diethyldiazomalonates. 
 
Once we completed screening of various carboxylic acids, we examined the 
applicability of numerous diazocarbonyls (Scheme 2.4). The bulky dibenzyl diazomalonate, 
O
OEt
O
EtO
O
O
O
OEt
O
EtO
O
O
O
OEt
O
EtO
O O
N
OHBoc
H
O
OEt
O
EtO
O O
N
Boc
H
O
OEt
O
EtO
O O
O
OEt
O
EtO
O
O
O
OEt
O
EtO
O
O
NH
NO2
O
OEt
O
EtO
O O
OMe
O
OEt
O
EtO
O O
OH
O
OEt
O
EtO
O O
N Boc
O
OEt
O
EtO
O
O
O
OEt
O
EtO
O O
Ph
4b,	83% 4c,	74% 4d,	62% 4e,	92% 4f,	86%
4g,	94% 4h,	90% 4i,	93% 4j,	87%
4k,	69% 4l,	94% 4m,	94%
Rh2(esp)2	(1	mol%)
O
OEt
O
EtO
O
OEt
O
EtO
O O
R
HO O
RN2
+
CH2Cl2,	rt,	10	min
2a 3 4
Ch. 2 – Identification of Rh(II)/Au(I) Synergistic Cascade Catalysis 
 
27 
primed with benzylic C–H bonds susceptible to intramolecular sp3–C activation, underwent 
the desired transformation to provide 4n in 83% yield. The highly stable a-diazo-b-
amidoesters provided the desired insertion compounds 4o and 4p in 73% and 96% yields 
respectively. The a-diazo-b-ketoester and a-diazo-1,3-diketone substrates efficiently 
provided compounds 4q in 86% yield and 4r in 85% yield. Next, the cyclic A/A 
diazocarbonyl, 1,3-indanone diazo, provided 4s in 73% yield, however, a longer reaction 
time of 3 hours was needed due to this diazocarbonyls increased stability. 
As a final effort in expanding the substrate scope, we investigated whether these 
conditions could apply to A/D and A-diazocarbonyls (Scheme 2.4). N-methyl isatin diazo 
and free N–H isatin diazo both underwent the desired transformation to provide oxindole 
scaffolds 4t and 4u in 82% and 78% yields. Lastly, commercially available ethyldiazoacetate 
gave the desired compound 4v in 78% yield. 
The identification of Rh2(esp)2 as an efficient catalyst for the O–H insertion of 
carboxylic acids into a wide variety of diazocarbonyls provided us with reaction conditions 
that are mild, efficient and highly chemoselective in the presence of alkenes, alkynes, 
hydroxyl and phenolic O–H’s, and electron rich arenes. The characteristics of this catalytic 
system were ideal for application in a synergistic catalytic cascade, which was the next feat 
in our research efforts. 
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Scheme 2.4. Scope of Rh2(esp)2-catalyzed room temperature O–H insertion reactions of 
Boc-proctected phenylalanine into various diazocarbonyls 
 
2.3 INDENTIFICATION OF “Rh2(esp)2” AND “PPh3AuOTf” FOR O–H 
INSERTION/CONIA-ENE SYNERGISTIC CASCADES† 
During the identification of Rh2(esp)2 as a highly efficient catalyst for the O–H 
insertion of carboxylic acids into diazocarbonyls[10], we observed an unexpected side 
product 5a during the insertion of 3-butynoic acid into methylbenzoylacetate diazo. This g-
butyrolactone, produced in < 5% yield, formed presumably from the Rh(II) catalyzed Conia-
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ene cyclization of the zwitterionic intermediate that formed during the O–H insertion 
reaction (Scheme 2.5). 
 
Scheme 2.5. Preliminary observation of Rh(II)-catalyzed Conia-ene cyclization to form 5a 
in trace amounts. 
  
This observation allowed us to hypothesize a direct method for the formation of g-
butyrolactones from readily available homo-propargylic acids and diazocarbonyl 
compounds.[11] If we were able to stabilize the zwitterionic intermediate while 
simultaneously activating the alkyne moiety through addition of an appropriate Lewis acid, 
we could promote a one-pot O–H insertion/Conia-ene cascade through synergistic 
catalysis. The design of cascade reactions, such as this, can provide novelty and efficiency 
in a synthetic strategy that would typically require multiple individual reaction steps to 
achieve.[2b] Although the carboxylic acid O–H insertion into diazocarbonyls and the Conia-
ene cyclization are known individually, their existence in concerted synergism was 
previously unreported, thereby providing us with the opportunity to make a novel 
advancement in the field of synthetic chemistry. 
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2.3.1  SCREENING OF LEWIS ACIDS FOR STEPWISE CONIA-ENE CYCLIZATION 
To begin our work, we decided to optimize the individual Conia-ene cyclization of 
a-acyloxy diazocarbonyl compound 4w to form g-butyrolactone 5a (Table 2.2). Similar to 
the hypothesis that led to the identification of Rh2(esp)2 as an efficient catalyst for O–H 
insertion of carboxylic acids into diazocarbonyls, we believed it was necessary to also 
identify a highly efficient catalyst for the stepwise Conia-ene cyclization if we hoped to 
create an efficient synergistic catalytic cascade.  
For the initial optimization, 4w was exposed to a variety of conditions known in 
literature to promote Conia-ene cyclizations (Table 2.2).[12] When exposed to Zn(II) salts, 
ZnCl2 and Zn(OTf)2, the reaction was extremely sluggish and after 20 hours at room 
temperature the conversion of these reactions did not reach above 15% (Table 2.2, entries 
1–2). Next, we screened copper salts Cu(OTf)2 and (CuOTf)2-toluene (Table 2.2, entries 3–
4). While Cu(II) triflate provided a negligible 14% conversion after 20 hours at room 
temperature, the more active Cu(I) triflate gave 100% conversion after 20 hours at room 
temperature.  Other metal salts such as Pd(OAc)2, Yb(OTf)3,  In(OTf)3, and PPh3AuCl were 
screened, but none of them provided 100% conversion. Lastly, taking inspiration from 
Toste’s seminal identification of cationic Au(I) for the Conia-ene cyclization of  b-ketoesters 
with alkynes[13], we exposed 4w to a mixture of AgOTf/PPh3AuCl at room temperature 
(Table 2.2, entry 10). In under 2 hours, these conditions provided complete conversion of 
4w into 5a.  
† The work within Section 2.3 was published in 2016 in Chemistry a European Journal, see 
reference:  Hunter, A.C.; Schlitzer, S.C.; Sharma, I., Synergistic Diazo-OH Insertion/Conia-
Ene Cascade Catalysis for the Stereoselective Syntheis of g-Butyrolactones and 
Tetrahydrofurans. Chem. Eur. J. 2016, 22(45), 16062–16065. 
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Table 2.2: Optimization of Step-wise Conia-ene Cyclization 
 
entry Lewis acid solvent, T (ºC), t 4a (%conversion)b 
1 ZnCl2 CH2Cl2, rt, 20 h 12 
2 Zn(OTf)2 CH2Cl2, rt, 20 h 9 
3 Cu(OTf)2 CH2Cl2, rt, 20 h 14 
4 (CuOTf)2.tol CH2Cl2, rt, 20 h 100 
5 Pd(OAc)2 CH2Cl2, rt, 20 h 77 
6 Yb(OTf)3 CH2Cl2, rt, 20 h 10 
7 In(OTf)3 CH2Cl2, rt, 20 h 41 
8 AgOTf CH2Cl2, rt, 20 h 27 
9 PPh3AuCl CH2Cl2, rt, 20 h 18 
10 AgOTf/PPh3AuCl CH2Cl2, rt, 2 h 100 
aAll optimization reactions were performed with 0.2M solution of 3a, Lewis acid (10 mol%) and 4 Å 
molecular sieves; bConversion (%) was determined from the crude 1H NMR spectrum. 
 
After establishing the optimized conditions for the Conia-ene cyclization, we 
decided to study the possibility of a tandem synergistic Rh(II)/Au(I) catalyzed O–H 
insertion/Conia-ene cascade (Table 2.3). For the initial optimization, 3-butynoic acid and 1 
mol% of Rh2(esp)2 were mixed with 10 mol% of PPh3AuOTf in dichloromethane and allowed 
to stir for 5 minutes at room temperature. Next, a solution of the diazo was added to the 
reaction dropwise over 1 minute and immediate emittance of N2 was observed. The desired 
product 5a formed instantly (under 1 minute) without any trace of the insertion product 
4w observed. This reaction was repeated with a decreased loading of 1 mol% of PPh3AuOTf, 
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and the reaction was found to be equally efficient. However, a 10 mol% catalytic loading of 
PPh3AuOTf was used for future reactions due to ease of experiment set up.  
 
Table 2.3: Optimization of Synergistic O–H Insertion/Conia-ene Cascade 
 
entry Rh(II)/Lewis acid timeb 3a:4ac 
1 Rh2(esp)2/AgOTf/PPh3AuCl Instant 0:100 
2 Rh2(esp)2/AgOTf/PPh3AuCld Instant 0:100 
3 Rh2(OAc)4/AgOTf/PPh3AuCl 5 h 44:56e 
4 Rh2(TFA)4/AgOTf/PPh3AuCl 2.5 h 38:62 
5 Rh2(HFBf) 4/AgOTf/PPh3AuCl 2.5 h 41:59 
6 Rh2(esp)2/(CuOTf)2.tol 10 min 93:7 
7 Rh2(esp)2/AgOTf 10 min 93:7 
8 Rh2(esp)2/PPh3AuCl 10 min 96:4 
9 AgOTf/PPh3AuCl 10 min 0:0g 
aAll optimization reactions were performed in 0.1 M CH2Cl2 with 1a (1.20 equiv.), 2a (1 equiv.), Rh2L4 
(1 mol%), and Lewis acids (10 mol%) along with 4 Å molecular sieves; btime required for the 
complete consumption of 1a;   cConversion (%) was determined from the crude 1H NMR spectrum;              
dAgOTf/PPh3AuCl (1 mol%) was used; e6-endo-dig product was also observed; fHFB = 
heptafluorobutyrate; g5-endo-dig lactonization to form furan-2(3H)-one. 
 
To follow, we screened other Rh(II) catalysts known for OH insertion into 
diazocarbonyls in the presence of PPh3AuOTf (Table 2.3, entries 35). It was observed that 
none of these catalysts had a synergistic effect with PPh3AuOTf as observed with Rh2(esp)2. 
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multiple hours of reaction time. This study highlighted the importance and necessity of 
Rh2(esp)2 in the synergistic catalytic cascade. Next, we screened Rh2(esp)2 with various 
Group 11 metals (Cu(I), Au(I) alone, Ag(I) alone) and these combinations provided negligible 
amounts of conversion to the cyclized product 5a (Table 2.3, entries 68). Lastly, we decided 
to negate Rh2(esp)2 from the reaction mixture to determine if PPh3AuOTf was active 
enough to catalyze the entire transformation on its own (Table 2.3, entry 9). However, to 
our surprise, premixing of 3-butynoic acid with PPh3AuOTf resulted in the formation of 
furan-2(3H)-one presumably via a 5-endo-dig-lactonization prior to the addition of the 
diazocarbonyl. The culmination of these studies suggest that this catalyst system is 
extremely specific, novel, and effective in the O–H insertion/Conia-ene cascade.  
 
2.3.2  APPLICATION TO SUBSTRATE SCOPE 
Once the optimized conditions were identified and thoroughly studied, we began 
to explore the generality of this transformation with differing A/A diazocarbonyls to 
provide a variety of g-butyrolactones (Scheme 2.6). Increasing the bulk of the ester group 
to tert-butyl slightly decreased the yield of 5b to 73%. The diazo derived from 
ethylacetoacetate, which possesses a methylene group active toward intramolecular C–H 
activation[14], provided 5c in 76% yield. Lastly, the highly reactive diazo derived from 
pentane-2,4-dione gave 5d in a 76% yield also. Next, we screened the same diazocarbonyls 
with the corresponding 3-butynol for a hydroxyl-OH insertion/Conia-ene cascade, and the 
reaction was observed to be equally efficient to provide a range of tetrahydrofurans (5e–
5h).  
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Scheme 2.6. Scope of Rh2(esp)2/PPh3AuOTf catalyzed O–H insertion/Conia-ene cyclization 
for the synthesis of g-butyrolactones and tetrahydrofurans. 
  
Subsequently, we began to investigate substituents on the alkynoic acids and 
alkynols. Sterically hindered carboxylic acids and the corresponding neo-pentyl alcohol 
afforded the corresponding g-butyrolactone 5i in 91% yield and tetrahydrofuran 5j in 87% 
yield. Mono-substituted alcohols with phenyl groups also participated in the reaction 
efficiently (5k–5l) and when exposed to unsymmetrical diazocarbonyls the corresponding 
products were obtained as single diastereomers (5m–5n). Lastly, when the enantiopure R- 
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and S- isomers of an alcohol were used in two separate transformations with the same 
diazo, 5o and 5p were produced as single diastereomers. When their optical rotations were 
taken, they were observed to be equal and opposite, proving that the pair were 
enantiomers. This study shows that we are able to induce asymmetry in this transformation 
using a chiral pool for our nucleophiles.  
 
Scheme 2.7. Scope of Rh2(esp)2/PPh3AuOTf catalyzed O–H insertion/Conia-ene cascade 
using A/D diazos. The corresponding insertion compounds (4) are unable to undergo 
stepwise cyclization to form the cyclic scaffolds. 
 
To further probe the generality of this transformation we exposed alkynoic acids 
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was observed to be diastereoselective (5s). Lastly, 2-tetralone diazo, which is a cyclic A/D 
diazocarbonyl, provided the desired spiroether 5t in 71% yield.  
 
2.3.3  MECHANISTIC INSIGHTS 
For mechanistic insights into the reactivity of A/D diazocarbonyls in this system, we 
decided to synthesize the insertion compounds from each of the aforementioned A/D 
diazocarbonyls. When these substrates were exposed to PPh3AuOTf in a stepwise fashion 
there was no observed Conia-ene cyclization even after reacting for 12 hours. This 
observation proved that the synergism of Rh(II)/Au(I) was necessary to invoke the desired 
transformation with A/D diazocarbonyls. 
Next, to gain a deeper level of understanding for this transformation, non-terminal 
homopropargylic acid 3w was subjected to the stepwise and synergistic catalysis conditions 
(Scheme 2.8). However, under the synergistic Rh(II)/Au(I) condition we did not observed 
any insertion or Conia-ene product. Instead we observed a completely unexpected [3.1.0]-
fused ring system 7 as the exclusive product and single diastereomer (Scheme 2.9). The 
product forms presumably through the stereoselective cyclopropanation of the resulting 
unsaturated furanone that is produced when 3-pentynoic acid was premixed with the 
catalyst solution via a 5-endo-dig lactonization. It is important to note that non-terminal 
homopropargylic acids self-lactonize at a rate 5x faster than the terminal 3-butynoic 
acid.[15]  
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Scheme 2.8. Limitation of synergistic transformation when applied to non-terminal 
alkynes. 
 
Lastly, to further substantiate our observations, we conducted 1H and 13C NMR 
experiments for mechanistic insights. When 3-butynoic acid was exposed to Rh2(esp)2 
alone, there was an observed loss of the carboxylic acid proton HA (Figure 2.3). When 3-
butynoic acid was mixed with a stoichiometric amount of Rh2(esp)2/AgOTf/PPh3AuCl in 
CD2Cl2 at room temperature, alongside disappearance of HA,  we also observed a complete 
loss of the alkyne proton HC within minutes and formation of a new proton in the alkene 
region (5.82 ppm) having coupling with the HB protons. This suggests the formation of a 
gold acetylide/gold vinylidene as the reactive intermediate.[16] When the acid was exposed 
to either Rh/Ag or Rh/Au alone there was no distinct proton losses observed that differed 
from what was seen with Rh2(esp)2 alone. Lastly, when the acid was exposed to 
AgOTf/PPh3AuCl without Rh2(esp)2 present, furan-2(3H)-one was observed via 5-endo-dig 
lactonization.  
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Figure 2.3. NMR experiments for mechanistic insights 
 
These findings, alongside the other mechanistic insights, allowed us to propose a 
reaction mechanism wherein upon formation of a dually activated zwitterionic 
intermediate a Conia-ene cyclization occurs. However, when added in a stepwise fashion 
Rh(II) and Au(I) work independently of each other without exerting any synergistic effect 
(Scheme 2.9). 
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Scheme 2.9. Proposed mechanism for the synergistic transformation 
 
2.4  SUMMARY  
After completion of this work we have developed strategies to prepare a-acyloxy 
carbonyl scaffolds, y-butyrolactones, and tetrahydrofurans from readily available starting 
materials. We have also identified two novel catalytic systems that were critical to our 
success: 1) Rh2(esp)2 as a single catalyst for the efficient insertion of carboxylic acids into 
A/A diazocarbonyls[10] and 2) Rh2(esp)2/PPh3AuOTf as a synergistic catalytic combination 
for the O–H insertion/Conia-ene cascade.[17] The reactivity and stereoselectivity of the O–
H insertion/Conia-ene cascade was proven to be quite general and even expanded to 
substrates that were unable to undergo the corresponding stepwise transformation, 
thereby proving the synergism of the Rh(II)/Au(I) catalyst system.  
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2.6  EXPERIMENTAL SECTION 
2.6.1  GENERAL PROCEDURES FOR CARBOXYLIC ACID INSERTION 
General Procedure I: Carboxylic acid (1 equiv.) and Rh2(esp)2 (1 mol%) were added to a 
round bottom flask, dissolved in anhydrous dichloromethane (0.5 M), and sonicated to 
ensure solubility. The acceptor-acceptor (1.5 equiv.) diazo was then added drop-wise via 
syringe over a span of 5 minutes. Once the release of N2 gas ceased, reaction was observed 
to be complete by TLC (10 min–2 h). After completion rotary evaporation provided the 
crude compound. Purification by flash chromatography (4:1 – 2:3 Hex/EtOAc) afforded the 
pure compound.  
General Procedure II: Carboxylic acid (1 equiv.) and Rh2(esp)2 (1 mol%) were added to a 
round bottom flask and half of the anhydrous dichloromethane (0.2 M) was added. The 
flask was sonicated to ensure solubility of the reagents. The acceptor-acceptor diazo (1.5 
equiv.) was dissolved in the other half of the anhydrous dichloromethane and added to the 
reaction flask via syringe pump (2–4 h addition time). Once addition was complete rotary 
evaporation provided the crude product. Purification by flash chromatography (4:1–1:1 
Hex/EtOAc) provided the pure product.  
 
Diethyl 2-(((tert-butoxycarbonyl)-L-phenylalanyl)oxy)malonate (4a). Prepared from 
diethyl 2-diazomalonate and Boc-L-phenylalanine using general procedure EI. Colorless 
O
OEt
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N
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H
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liquid (42 mg, 94%). TLC: Rf 0.37 (4:1 hexanes/EtOAc). IR (NaCl): 3390, 2933, 1752, 1716, 
1502, 1452, 1369, 1249, 1165, 1087, 1028, 858, 702. 1H NMR (400 MHz) δ 7.33 – 7.19 (m, 
5H), 5.56 (s, 1H), 4.90 (d, J = 8.0 Hz, 1H), 4.75 (d, J = 8.0 Hz, 1H), 4.30 (ddq, J = 10.2, 6.6, 3.2 
Hz, 4H), 3.29 (dd, J = 14.0, 5.1 Hz, 1H), 3.08 (dd, J = 4.0, 12.0 Hz, 1H), 1.39 (s, 9H), 1.31 (t, J 
= 7.1 Hz, 6H). 13C NMR (101 MHz) δ 170.63, 164.06, 163.92, 154.95, 135.64, 129.38, 128.52, 
127.01, 80.01, 71.96, 62.62, 54.07, 37.77, 30.87, 28.20, 13.93, 13.91. HRMS (ESI) m/z calcd 
for C21H29NO8Na ([M+Na]+) 446.1790; found 446.1777.  
 
1-(Tert-butyl) 2-(1,3-diethoxy-1,3-dioxopropan-2-yl) (S)-pyrrolidine-1,2-dicarboxylate 
(4b). Prepared from diethyl 2-diazomalonate and Boc-L-proline using general procedure EI 
and obtained as a mixture of rotamers (1:1). Colorless liquid (28 mg, 83%). TLC: Rf 0.24 (4:1 
hexanes/EtOAc). IR (NaCl): 3511, 2981, 2939, 2884, 1763, 1701, 1368, 1245, 1162, 1123, 
1091. 1H NMR (400 MHz) δ 5.52 (s, 1H), 5.48 (s, 1H), 4.43 (dd, J = 4.0, 8.0 Hz, 1H), 4.34 (dd, 
J = 8.6, 3.8 Hz, 1H), 4.29 – 4.17 (m, 8H), 3.51 (ddq, J = 16.8, 8.3, 4.6 Hz, 2H), 3.42 – 3.38 (m, 
1H), 3.36 – 3.29 (m, 1H), 2.28 – 2.10 (m, 4H), 1.99 – 1.80 (m, 4H), 1.40 (s, 7H), 1.35 (s, 9H), 
1.24 (tq, J = 7.1, 3.9 Hz, 12H). 13C NMR (101 MHz) δ 171.73, 171.42, 165.71, 164.37, 164.20, 
164.16, 164.12, 153.60, 80.13, 79.88, 71.82, 71.67, 62.52, 62.40, 62.23, 58.68, 58.43, 46.56, 
46.28, 30.69, 29.73, 28.37, 28.19, 24.13, 23.43, 13.95, 13.92. HRMS (ESI) m/z calcd for 
C17H27NO8Na ([M+Na]+) 396.1634; found 396.1634.  
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Diethyl 2-(((tert-butoxycarbonyl)-L-seryl)oxy)malonate (4c). Prepared from diethyl 2- 
diazomalonate and Boc-L-serine using general procedure EII. clear oil (161 mg, 74%). TLC: 
Rf 0.52 (1:1 hexanes/EtOAc). IR (NaCl): 3505, 2927, 1754, 1719. 1H-NMR (400 MHz): δ 4.39 
– 4.22 (m, 4H), 3.89 – 3.80 (m, 1H), 2.82 (s, 1H), 1.45 (s, 9H), 1.36 – 1.28 (m, 6H). 13C-NMR 
(101 MHz, Chloroform-d) δ 169.89, 72.08, 63.22, 62.95, 28.25, 13.92, 13.90. HRMS (ESI) 
m/z calcd for C15H25NO9 ([M+Na]+) 386.1427; found 386.1418. Diethyl 2-((N-(tert-
butoxycarbonyl)-O-(1,3-diethoxy-1,3-dioxopropan-2-yl)-L- seryl)oxy)malonate (4c-bis). 
Prepared from diethyl 2-diazomalonate and Boc-L-serine using general procedure EII. Clear 
oil (48 mg, 16%). TLC: Rf 0.6 (1:1 hexanes/EtOAc). IR (NaCl): 2981, 1749, 1718, 1508, 1369, 
1296, 1244, 1159, 1095, 1028. 1H-NMR (400 MHz): δ 5.78 – 5.62 (m, 1H), 5.59 (s, 1H), 4.68 
– 4.60 (m, 1H), 4.57 (s, 1H), 4.26 (dddd, J = 12.7, 11.2, 6.5, 3.8 Hz, 8H), 4.14 (dd, J = 10.0, 
3.6 Hz, 1H), 4.05 (d, J = 2.9 Hz, 1H), 1.45 (s, 9H), 1.34 – 1.25 (m, 12H). 13C-NMR (101 MHz): 
168.78, 165.79, 163.92, 163.90, 155.35, 155.27, 80.13, 79.19, 72.14, 70.70, 70.67, 62.60, 
62.53, 62.10, 62.05, 53.78, 28.26, 13.99, 13.94, 13.92, 13.89. HRMS (ESI) m/z calcd for 
C22H35NO13 ([M+Na]+) 544.2006; found 544.2015.  
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Diethyl 2-(((tert-butoxycarbonyl)-L-tryptophyl)oxy)malonate (4d). Prepared from diethyl 
2- diazomalonate and Boc-L-tryptophan from general procedure EII. clear oil (171 mg, 
62%). TLC: Rf 0.47 (1:1 hexanes/EtOAc). IR (NaCl): 3061, 2980, 2927, 1750, 1503, 1460. 1H-
NMR (400 MHz): δ 8.13 (s, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.21 – 7.05 
(m, 3H), 5.53 (s, 1H), 5.02 (d, J = 8.5 Hz, 1H), 4.82 (d, J = 7.5 Hz, 1H), 4.38 – 4.20 (m, 6H), 
3.57 – 3.23 (m, 2H), 1.40 (s, 9H), 1.31 (td, J = 7.1, 2.6 Hz, 10H). 13C-NMR (101 MHz) δ 170.95, 
123.31, 123.28, 122.12, 122.11, 119.63, 118.67, 118.66, 111.14, 111.12, 111.10, 109.99, 
109.74, 72.01, 62.61, 54.14, 28.26, 27.50, 13.96, 13.93. HRMS (ESI) m/z calcd for 
C23H30N2O8 ([M+Na]+) 485.1900; found 485.1899.  
 
 
 
Diethyl 2-acetoxymalonate (4e). Prepared from diethyl 2-diazomalonate and acetic acid 
using general procedure EI. clear oil (21.5 mg, 92%). TLC: Rf 0.31 (4:1 hexanes/EtOAc) IR 
(NaCl): 2925, 1751. 1H-NMR (400 MHz): δ 5.51 (s, 1H), 4.29 (qq, J = 7.4, 3.6 Hz, 4H), 2.22 (s, 
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3H), 1.30 (t, J = 7.1 Hz, 6H). 13C-NMR (101 MHz) δ 169.44, 164.44, 71.81, 62.51, 29.67, 20.37, 
13.94. HRMS (ESI) m/z calcd for C9H14O6 ([M+Na]+) 241.0688; found 241.0905.  
 
Diethyl 2-(pentanoyloxy)malonate (4f). Prepared from diethyl 2-diazomalonate and 
pentanoic acid using general procedure EI. Colorless liquid (22 mg, 86%) .TLC: Rf 0.54 (4:1 
hexanes/EtOAc). IR (NaCl): 2963, 2875, 1754, 1467, 1373, 1181, 1160, 1113, 1031, 858. 1H 
NMR (400 MHz) δ 5.51 (s, 1H), 4.28 (tdt, J = 10.8, 8.0, 3.6 Hz, 4H), 2.48 (t, J = 7.5 Hz, 2H), 
1.70 – 1.63 (m, 2H), 1.42 – 1.34 (m, 2H), 1.29 (t, J = 7.1 Hz, 6H), 0.91 (t, J = 7.3 Hz, 3H). 13C 
NMR (101 MHz) δ 172.31, 164.55, 71.61, 62.45, 33.33, 26.71, 22.07, 13.93, 13.62. HRMS 
(ESI) m/z calcd for C12H20O6Na ([M+Na]+) 283.1157; found 283.1155.  
 
 
 
Diethyl 2-(pent-4-ynoyloxy)malonate (4g). Prepared from diethyl 2-diazomalonate and 4-
pentynoic acid using general procedure EII. clear oil (182 mg, 94%). TLC: Rf 0.5 (4:1 
hexanes/EtOAc). IR (NaCl): 3284, 2983, 2924, 2357, 1747, 1373, 1153, 1093, 1028. 
1
H-NMR 
(300 MHz): δ 5.53 (s, 1H), 4.32 – 4.23 (m, 4H), 2.76 – 2.71 (m, 2H), 2.57 – 2.51 (m, 2H), 2.02 
– 2.01 (m, 1H), 1.29 (t, J = 7.1 Hz, 6H). 
13
C-NMR (75 MHz): δ 170.26, 164.15, 81.79, 71.73, 
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69.20, 62.48, 32.64, 14.03, 13.84. HRMS (ESI) m/z calcd for C12H16O6 ([M+Na]+) 279.0845; 
found 279.0847.  
 
Diethyl 2-(pent-4-enoyloxy)malonate (4h). Prepared from diethyl 2-diazomalonate and 
pent-4- enoic acid using general procedure EI. clear oil (25 mg, 90%). TLC: Rf 0.87 (7:3 
hexanes/EtOAc). IR (NaCl): 3152, 2927, 2855, 1751, 1676, 1465. 1H-NMR (400 MHz) δ 
5.84 (ddt, J = 16.7, 10.2, 6.4 Hz, 1H), 5.53 (s, 1H), 5.19– 4.96 (m, 2H), 4.28 (dt, J = 7.2, 3.6 
Hz, 4H), 2.69 – 2.56 (m, 2H), 1.30 (t, J = 7.1 Hz, 6H). 13C-NMR (101 MHz) δ 171.56, 
164.45, 136.08, 115.80, 71.69, 62.50, 32.87, 28.50, 13.95. HRMS (ESI) m/z calcd for 
C12H18O6 ([M+Na]+) 281.1001; 281.1000 found.  
 
Diethyl 2-(((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-
2,4,6,8- tetraenoyl)oxy)malonate (4i). Prepared from diethyl 2-diazomalonate and retinoic 
acid using general procedure EI. Pale yellow oil (21 mg, 93%). TLC: Rf 0.14 (9:1 
hexanes/EtOAc). IR (NaCl): 2658, 2927, 1749, 1722, 1583, 1371, 1230, 1182, 1136, 1095, 
1029. 1H NMR (400 MHz) δ 7.05 (dd, J = 15.0, 11.5 Hz, 1H), 6.30 (d, J = 15.3 Hz, 2H), 
6.16 (s, 1H), 6.13 (d, J = 8.0 Hz, 1H), 5.94 (s, 1H), 5.57 (s, 1H), 4.29 (dd, J = 7.0, 5.4 Hz, 
4H), 2.36 (s, 3H), 2.00 (s, 3H), 1.71 (s, 3H), 1.64 – 1.57 (m, 3H), 1.51 – 1.42 (m, 2H), 1.31 
(t, J = 7.1 Hz, 6H), 1.02 (s, 6H). 13C NMR (101 MHz) δ 165.13, 164.89, 155.90, 140.47, 
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137.61, 137.12, 134.54, 132.16, 130.19, 129.33, 129.12, 116.02, 71.39, 62.38, 39.58, 34.23, 
33.09, 28.93, 21.72, 19.18, 14.15, 13.96, 12.91. HRMS (ESI) m/z calcd for C27H38O6Na 
([M+Na]+) 481.2566; found 481.2568.  
 
Diethyl 2-(benzoyloxy)malonate (4j). Prepared from diethyl 2-diazomalonate and benzoic 
acid using general procedure EI. clear oil (26.1 mg, 87%). TLC: Rf 0.43 (4:1 hexanes/EtOAc). 
IR (NaCl): 2927, 2855, 1752, 1684. 1H-NMR (400 MHz): δ 8.21 – 8.08 (m, 2H), 7.61 (t, J = 7.4 
Hz, 1H), 7.47 (t, J = 7.8 Hz, 2H), 5.75 (s, 1H), 4.33 (qq, J = 7.4, 3.6 Hz, 4H), 1.33 (t, J = 7.1 Hz, 
6H). 13C-NMR (101 MHz) δ 165.10, 164.50, 133.77, 130.16, 128.49, 72.11, 62.54, 29.69, 
13.99 HRMS (ESI) m/z calcd for C14H16O6 ([M+Na]+) 303.0845; found 303.0847.  
 
Diethyl 2-((4-nitrobenzoyl)oxy)malonate (4k). Prepared from diethyl 2-diazomalonate and 
4- nitro benzoic acid from general procedure EII. clear oil (81 mg, 69%). TLC: Rf 0.55 (7:3 
hexanes/EtOAc). IR (NaCl): 1H-NMR (400 M Hz): δ 8.31 (s, 4H), 5.76 (s, 2H), 4.34 (qd, J = 7.1, 
4.3 Hz, 4H), 1.33 (t, J = 7.1 Hz, 6H). 13C-NMR (101 MHz): δ 163.93, 163.28, 151.00, 133.83, 
131.31, 123.65, 77.39, 77.20, 77.06, 72.49, 62.82, 14.03, 13.98. HRMS not mass active.  
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Diethyl 2-((4-methoxybenzoyl)oxy)malonate (4l). Prepared from diethyl 2-diazomalonate 
and 4-methoxy benzoic acid using general procedure EI. Colorless liquid (29.7 mg, 94%). 
TLC: Rf 0.29 (9:1 hexanes/EtOAc). IR (NaCl): 3528, 2982, 2939, 2845, 1751, 1719, 1607, 
1513. 1H NMR (400 MHz) δ 8.08 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.72 (s, 1H), 4.31 
(qq, J = 7.5, 3.6 Hz, 4H), 3.86 (s, 3H), 1.31 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz) δ 164.74, 
164.67, 164.02, 132.28, 120.73, 113.75, 71.93, 62.44, 55.44, 13.96. HRMS (ESI) m/z calcd 
for C15H18O7Na ([M+Na]+) 333.0950; found 333.0949  
 
Diethyl 2-((2-hydroxybenzoyl)oxy)malonate (4m). Prepared from diethyl 2-diazomalonate 
and salicylic acid from general procedure EII. clear oil (127 mg, 94%). TLC: Rf 0.55 (7:3 
hexanes/EtOAc). IR (NaCl): 1H-NMR (400 MHz): δ 10.57 – 10.44 (m, 1H), 10.13 (s, 1H), 8.02 
(dd, J = 8.0, 1.6 Hz, 1H), 7.64 – 7.46 (m, 1H), 7.00 (d, J = 7.9 Hz, 1H), 6.96 – 6.90 (m, 1H), 
5.74 (s, 1H), 4.34 (tq, J = 7.1, 3.9 Hz, 4H), 1.34 (t, J = 7.1 Hz, 6H). 13C-NMR (101 MHz): δ 
168.30, 164.01, 161.76, 136.72, 136.66, 136.64, 130.77, 130.60, 119.56, 119.43, 117.75, 
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117.66, 111.15, 72.02, 62.79, 13.98. HRMS (ESI) m/z calcd for C15H25NO9 ([M+Na]+) 
386.1427; found 386.1418.  
 
Dibenzyl 2-(((tert-butoxycarbonyl)-L-phenylalanyl)oxy)malonate (4n). Prepared from 
dibenzyl 2-diazomalonate and Boc-L-phenylalanine using general procedure EI. Colorless 
liquid (34 mg, 83%). TLC: Rf 0.31 (4:1 hexanes/EtOAc). IR (NaCl): 3396, 2974, 2927, 1753, 
1716, 1498, 1456, 1367, 1251, 1215, 1163, 1083, 1028, 748. 1H NMR (400 MHz) δ 7.33 – 
7.27 (m, 7H), 7.25 – 7.19 (m, 6H), 7.17 (d, J = 6.6 Hz, 2H), 5.68 (s, 1H), 5.23 (s, 4H), 4.90 (d, 
J = 8.0 Hz, 1H), 4.75 (d, J = 6.3 Hz, 1H), 3.25 (dd, J = 14.1, 5.3 Hz, 1H), 3.03 (dd, J = 14.0, 7.0 
Hz, 1H), 1.39 (s, 9H). 13C NMR (101 MHz) δ 170.58, 163.78, 163.63, 135.58, 134.42, 129.36, 
128.62, 128.60, 128.51, 128.28, 126.99, 80.03, 71.90, 68.15, 54.07, 37.75, 28.21. HRMS 
(ESI) m/z calcd for C31H33NO8Na ([M+Na]+) 570.2103; found 570.2108.  
 
Ethyl 2-(((tert-butoxycarbonyl)-L-phenylalanyl)oxy)-3-(methoxy(methyl)amino)-3 
oxopropanoate (4o) . Prepared from ethyl 2-diazo-3-(methoxy(methyl)amino)-3-
oxopropanoate and Boc-L-phenylalanine using general procedure EI and obtained as a 
mixture of diasteromers (1:1).  Light yellow oil (106 mg, 73%). TLC: Rf 0.66 (1:1 
O
OBn
O
BnO
O O
N
PhBoc
H
O
OEt
O
N
O O
N
PhBoc
H
O
Ch. 2 – Identification of Rh(II)/Au(I) Synergistic Cascade Catalysis 
 
53 
hexanes/EtOAc). IR (NaCl) 2980. 2936, 1751, 1717, 1507, 1392. 1H-NMR (400 MHz) δ 7.34 
– 7.27 (m, 4H), 7.24 – 7.18 (m, 6H), 6.01 (s, 1H), 5.95 (s, 1H), 4.92 (d, J = 6.6 Hz, 2H), 4.72 
(d, J = 6.9 Hz, 2H), 4.28 (p, J = 7.2 Hz, 4H), 3.75 (s, 3H), 3.73 (s, 3H), 3.30 (dd, J = 13.8, 6.1 
Hz, 2H), 3.24 (s, 6H), 3.08 (dt, J = 14.5, 7.7 Hz, 2H), 1.38 (s, 18H), 1.30 (td, J = 7.1, 3.9 Hz, 
6H).  13C-NMR (101 MHz) δ 170.83, 164.48, 154.97, 135.88, 135.78, 129.50, 129.46,128.57, 
128.51, 128.49, 126.98, 126.91, 79.95, 77.21, 70.55, 70.17, 62.39, 61.64, 38.04, 37.78, 
32.49, 28.22, 28.13, 14.02, 13.99. HRMS (ESI) m/z calcd for C21H30O8 ([M+Na]+) 461.1900; 
found 461.1903. 
 
Ethyl 3-(((S)-1-(benzyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-(((tert-butoxycarbonyl)-
L- phenylalanyl)oxy)-3-oxopropanoate (4p). Prepared from ethyl (S)-3-((1-(benzyloxy)-1-
oxo-3- phenylpropan-2-yl)amino)-2-diazo-3-oxopropanoate and Boc-L-phenylalanine using 
general procedure EI and obtained as a mixture of diastereomers (1:1). Light yellow oil (204 
mg, 96%). TLC: Rf 0.46 (1:1 hexanes/EtOAc). IR (NaCl): 2981, 2935, 1750, 1700, 1584, 1168. 
1H-NMR (400 MHz): δ 7.41 – 7.26 (m, 8H), 7.26 – 7.12 (m, 9H), 7.06 – 6.88 (m, 3H), 5.50 (s, 
1H), 5.44 (s, 1H), 5.24 – 5.09 (m, 2H), 4.96 – 4.84 (m, 2H), 4.23 (ddt, J = 14.2, 7.1, 3.5 Hz, 
2H), 3.18 (dddt, J = 26.4, 20.8, 13.8, 6.7 Hz, 3H), 3.02 (dd, J = 13.9, 7.2 Hz, 1H), 1.42 (s, 18H), 
1.27 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz): δ 170.42, 170.37, 129.41, 129.33, 129.29, 
128.65, 128.64, 128.61, 128.54, 127.21, 127.13, 72.92, 72.80, 67.46, 67.38, 62.77, 62.71, 
O
N
H
O
EtO
O O
N
PhBoc
H
CO2Bn
Ph
Ch. 2 – Identification of Rh(II)/Au(I) Synergistic Cascade Catalysis 
 
54 
54.36, 53.48, 53.33, 37.52, 28.25, 13.93, 13.91. HRMS (ESI) m/z calcd for C35H40N2O9 ([M–
H]–) 631.2656; found 631.2677.  
 
Ethyl 2-(((tert-butoxycarbonyl)-L-phenylalanyl)oxy)-3-oxobutanoate (4q). Prepared from 
ethyl 2-diazo-3-oxobutanoate and Boc-L-phenylalanine using general procedure EI and 
obtained as a mixture of diastereomers (1:1). Colorless powder (25 mg, 86%). TLC: Rf 0.31 
(4:1 hexanes/EtOAc). IR (NaCl): 3371, 2950, 2853, 1755, 1733, 1505, 1538, 1524. 1H NMR 
(400 MHz) δ 7.30 (t, J = 7.0 Hz, 4H), 7.25 – 7.18 (m, 5H), 5.49 (s, 1H), 5.47 (s, 1H), 4.93 (s, 
1H), 4.72 (d, J = 6.5 Hz, 2H), 4.28 (p, J = 6.7 Hz, 4H), 3.25 (td, J = 15.7, 15.2, 5.8 Hz, 2H), 3.10 
(dt, J = 14.0, 6.8 Hz, 2H), 2.28 (s, 3H), 2.24 (s, 3H), 1.39 (s, 18H), 1.30 (td, J = 7.1, 3.1 Hz, 6H). 
13C NMR (101 MHz) δ 170.78, 164.16, 163.98, 155.05, 135.66, 129.35, 129.29, 128.63, 
128.58, 127.12, 127.08, 80.17, 80.16, 78.06, 78.02, 62.59, 54.32, 54.20, 38.03, 37.75, 28.21, 
27.08, 13.97, 13.94. HRMS (ESI) m/z calcd for C20H27NO7Na ([M+Na]+) 416.1685; found 
416.1685.  
 
2,4-Dioxopentan-3-yl (tert-butoxycarbonyl)-L-phenylalaninate (4r). Prepared from 3- 
diazopentane-2,4-dione and Boc-L-phenylalanine using general procedure EI and obtained 
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as a mixture of keto-enol form. Colorless powder (32 mg, 85%). TLC: Rf 0.36 (4:1 
hexanes/EtOAc). IR (NaCl): 3367, 2978, 2929, 1757, 1716, 1504, 1452, 1363, 1278, 1251, 
1165, 1078, 748. 1H NMR (400 MHz) δ 7.30 (q, J = 5.7, 5.2 Hz, 2H), 7.27 – 7.21 (m, 3H), 5.45 
(s, 1H), 4.96 (d, J = 7.7 Hz, 1H), 4.75 – 4.66 (m, 1H), 3.22 (dd, J = 14.0, 6.4 Hz, 1H), 3.09 (ddd, 
J = 29.6, 13.9, 7.5 Hz, 1H), 2.22 (s, 3H), 2.19 (s, 3H), 1.40 (s, 9H). 13C NMR (101 MHz) δ 
198.70, 198.27, 171.43, 170.74, 155.09, 135.72, 135.38, 129.26, 129.19, 128.84, 128.67, 
127.39, 127.17, 85.16, 80.45, 80.27, 54.50, 54.40, 38.06, 37.62, 28.21, 28.17, 27.24, 27.16, 
20.67. HRMS (ESI) m/z calcd for C19H25NO6Na ([M+Na]+) 386.1579; found 386.1577.  
 
1,3-Dioxo-2,3-dihydro-1H-inden-2-yl (tert-butoxycarbonyl)-L-phenylalaninate (4s). 
Prepared from 2-diazo-1H-indene-1,3(2H)-dione and Boc-L-phenylalanine using general 
procedure EI. Orange oil (110 mg, 70%). TLC: Rf 0.44 (7:3 hexanes/EtOAc). IR (NaCl): 2978, 
2926, 2855, 1808, 1768, 1725, 1507. 1H-NMR (400 MHz) δ 8.07 – 7.96 (m, 2H), 7.91 (dd, J 
= 5.7, 3.1 Hz, 2H), 7.38 – 7.27 (m, 4H), 5.37 (s, 1H), 4.86 (dd, J = 13.6, 7.1 Hz, 2H), 3.26 (dd, 
J = 13.8, 5.4 Hz, 1H), 3.14 (dd, J = 13.8, 5.4 Hz, 1H), 1.40 (s, 9H). 13C-NMR (101 MHz) δ 
192.06, 192.02, 139.74, 136.46, 135.38, 135.37, 129.77, 129.76, 129.72, 129.68, 128.76, 
128.58, 128.51, 127.06, 123.89, 123.84, 123.83, 80.05, 80.03, 53.69, 53.67, 38.20, 28.24. 
HRMS (ESI) m/z calcd for C23H23NO6 ([M+Na]+) 432.1423; found 432.1425.  
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1-Methyl-2-oxoindolin-3-yl (tert-butoxycarbonyl)-L-phenylalaninate (4t). Prepared from 
3- diazo-1-methylindolin-2-one and Boc-L-phenylalanine using general procedure EI and 
obtained as a mixture of diastereomers (1:1). Red liquid (25 mg, 82%). TLC: Rf 0.33 (7:3 
hexanes/EtOAc). IR (NaCl): 3438, 2980, 2931, 1751, 1719, 1617, 1496, 1164. 1H NMR (400 
MHz) δ 7.36 (t, J = 7.7 Hz, 2H), 7.27 – 7.21 (m, 5H), 7.12 (d, J = 7.0 Hz, 2H), 7.05 (t, J = 7.5 
Hz, 2H), 6.83 (d, J = 7.7 Hz, 2H), 6.08 (s, 1H), 5.97 (s, 1H), 4.98 (s, 1H), 4.77 – 4.66 (m, 1H), 
3.22 (s, 6H), 3.16 – 3.05 (m, 2H), 1.42 (s, 7H), 1.38 (s, 9H). 13C NMR (101 MHz) δ 171.34, 
144.50, 135.57, 130.49, 129.57, 129.51, 128.54, 128.48, 127.01, 126.07, 125.86, 123.63, 
123.59, 123.12, 122.99, 108.46, 79.98, 70.42, 70.11, 54.41, 54.29, 38.02, 38.00, 37.88, 
37.87, 28.23, 26.34. HRMS (ESI) m/z calcd for C23H26N2O5Na ([M+Na]+) 433.1739; found 
433.1730.  
 
2-Oxoindolin-3-yl (tert-butoxycarbonyl)-L-phenylalaninate (4u). TLC: Rf 0.50 (1:1 
hexanes/EtOAc). Prepared from 3-diazoindolin-2-one and Boc-L-phenylalanine using 
general procedure EI and obtained as a mixture of diastereomers (1:1).  Red liquid (25 mg, 
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78%). IR (NaCl): 3273, 2978, 2927, 1732, 1622, 1500, 1471, 1367, 1165, 1055, 1026, 910, 
752. 1H NMR (400 MHz) δ 8.26 (d, J = 22.8 Hz, 2H), 7.32 – 7.21 (m, 9H), 7.16 – 7.14 (m, 2H), 
7.06 – 7.01 (m, 3H), 6.87 (d, J = 7.8 Hz, 2H), 4.99 (d, J = 8.1 Hz, 2H), 4.77 – 4.70 (m, 2H), 3.27 
– 3.10 (m, 4H), 1.42 (s, 10H), 1.38 (s, 9H). 13C NMR (101 MHz) δ 173.54, 171.40, 171.37, 
155.03, 141.57, 135.59, 135.56, 130.51, 129.59, 129.56, 128.59, 128.53, 127.07, 126.34, 
126.18, 124.15, 124.10, 123.16, 123.03, 110.29, 80.09, 70.73, 70.40, 54.41, 54.33, 38.05, 
37.89, 28.26. HRMS (ESI) m/z calcd for C22H24N2O5Na ([M+Na]+) 419.1582; found 419.1570. 
 
2-Ethoxy-2-oxoethyl (tert-butoxycarbonyl)-L-phenylalaninate (4v), Prepared from ethyl 2- 
diazoacetate and Boc-L-phenylalanine using general procedure EI. White powder (160 mg, 
78%). TLC: Rf 0.44 (4:1 hexanes/EtOAc). IR (NaCl): 3375, 2855, 1763, 1719, 1684. 1H-NMR 
(400 MHz): δ 7.30 (dd, J = 7.8, 6.4 Hz, 2H), 7.25 – 7.13 (m, 3H), 4.93 (d, J = 7.7 Hz, 2H), 4.79 
– 4.48 (m, 5H), 4.24 (q, J = 7.1 Hz, 2H), 3.25 (dd, J = 14.1, 5.3 Hz, 3H), 3.06 (dd, J = 14.0, 7.0 
Hz, 3H), 1.39 (s, 9H), 1.29 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz) δ 171.47, 167.28, 155.05, 
135.90, 129.38, 129.00, 128.52, 128.19, 126.99, 79.97, 61.54, 61.13, 54.16, 37.99, 28.24, 
14.09. HRMS (ESI) m/z calcd for C18H25NO6 ([M+Na]+) 374.1580; found 374.1583.  
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1-Methoxy-1,3-dioxo-3-phenylpropan-2-yl but-3-ynoate (4w). Prepared from methyl 2-
diazo-3-oxo-3-phenylpropanoate and but-3-ynoic acid using general procedure F1. Yellow 
oil (26 mg, 93%). TLC: Rf 0.42 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 7.72–7.37 (m, 
5H), 6.37 (s, 1H), 3.79 (s, 3H), 3.49 (t, J = 2.9 Hz, 2H), 2.21 (t, J = 2.7 Hz, 1H). 13C NMR (101 
MHz) δ 188.8, 166.7, 165.1, 134.4, 133.9, 129.3, 128.9, 75.0, 74.3, 72.5, 53.3, 25.4. ESI-MS 
m/z calcd for C14H12O5 ([M+Na]+) 283.5; found 283.1. 
 
2.6.2 GENERAL PROCEDURE FOR THE SYNTHESIS OF g-BUTYROLACTONES AND 
TETRAHYDROFURANS 
Alkynoic acid/alkynol (1 equiv.), Rh2(esp)2 (1 mol%), AgOTf (10 mol%), PPh3AuCl (10 mol%), 
and activated 4Å molecular sieves (36 mg per mL of solvent) were added to a round bottom 
flask, dissolved in anhydrous dichloromethane (0.2 M), and allowed to pre-mix for 5 
minutes. The diazo (1.2 equiv.) was dissolved in anhydrous dichloromethane (0.2 M making 
a total 0.1 M solution for the reaction) was then added drop-wise via syringe manually over 
a span of 2 minutes. Once the release of N2 gas ceased, reaction was observed to be 
complete by TLC and TLC-MS. After completion, molecular sieves were removed by 
filtration over a pad of celite and rotary evaporation provided the crude compound. 
Purification by flash chromatography (9:1–7:3 Hex/EtOAc) afforded the pure compound. 
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Methyl 2-benzoyl-3-methylene-5-oxotetrahydrofuran-2-carboxylate (5a). Prepared from 
methyl 2-diazo-3-oxo-3-phenylpropanoate and 3-butynoic acid using general procedure EI.  
Yellow liquid (28 mg, 83%). TLC: Rf 0.54 (7:3 hexanes/EtOAc). IR (NaCl): 2957, 2920, 2850, 
1808, 1744, 1698, 1597. 1H NMR (400 MHz) δ 8.01–7.95 (m, 2H), 7.59 (ddt, J = 7.9, 6.9, 1.3 
Hz, 1H), 7.52 – 7.42 (m, 2H), 5.68 (td, J = 2.8, 1.0 Hz, 1H), 5.62 (td, J = 2.5, 1.0 Hz, 1H), 3.81 
(s, 3H), 3.39 (td, J = 2.6, 1.7 Hz, 2H). 13C NMR (101 MHz) δ 188.4, 172.3, 167.4, 134.4, 130.0, 
129.1, 116.7, 90.1, 54.1, 33.7. HRMS (ESI) m/z calcd for C14H12O5 ([M+Na]+) 283.0583; found 
283.0584. 
 
tert-Butyl 2-benzoyl-3-methylene-5-oxotetrahydrofuran-2-carboxylate (5b). Prepared 
from tert-butyl 2-diazo-3-oxo-3-phenylpropanoate and 3-butynoic acid using general 
procedure EI.  Yellow liquid (68 mg, 73%) .TLC: Rf 0.67 (7:3 hexanes/EtOAc). IR (NaCl): 2980, 
2926, 2852, 1811, 1748, 1700, 1598, 1581. 1H NMR (400 MHz) δ 8.07–7.89 (m, 2H), 7.46 (t, 
J = 7.6 Hz, 3H), 5.65 (d, J = 2.4 Hz, 1H), 5.60 (t, J = 2.5 Hz, 1H), 3.38 (q, J = 2.0, 1.6 Hz, 2H), 
1.36 (s, 9H). 13C NMR (101 MHz) δ 191.2, 170.0, 143.8, 134.3, 133.3, 129.7, 128.4, 112.6, 
90.2, 68.9, 53.0, 32.9. HRMS (ESI) m/z calcd for C17H18O4 ([M+Na]+) 325.1052; found 
325.1034. 
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Ethyl 2-acetyl-3-methylene-5-oxotetrahydrofuran-2-carboxylate (5c). Prepared from 
ethyl 2-diazo-3-oxobutanoate and 3-butynoic acid using general procedure EI.  Yellow oil 
(47.3 mg, 76%). TLC: Rf 0.37 (7:3 hexanes/EtOAc). IR (NaCl): 2965, 2925, 2880, 2683, 1734, 
1712, 1659. 1H-NMR (400 MHz) δ 5.66 (td, J = 2.4, 1.3 Hz, 1H), 5.45 (dt, J = 2.5, 1.5 Hz, 1H), 
4.28 (qdd, J = 7.2, 3.4, 0.7 Hz, 2H), 3.47 – 3.21 (m, 2H), 2.32 (d, J = 0.6 Hz, 3H), 1.29 (td, J = 
7.1, 0.6 Hz, 3H). 13C-NMR (101 MHz) δ 197.7, 172.1, 165.3, 133.9, 118.5, 115.4, 91.0, 63.2, 
33.4, 25.9, 13.9. HRMS (ESI) m/z calcd for C10H12O5 ([M+Na]+) 235.0583; found 235.0579. 
 
1,1'-(3-Methylene-5-oxotetrahydrofuran-2,2-diyl)bis(ethan-1-one) (5d). Prepared from 3-
diazopentane-2,4-dione and 3-butynoic acid using general procedure EI. Yellow oil (55 mg, 
76%). TLC: Rf 0.57 (7:3 hexanes/EtOAc). IR (NaCl): 2923, 2851, 1806, 1737, 1718, 1665, 
1638. 1H-NMR (400 MHz): δ 5.60 (tt, J = 2.8, 1.1 Hz, 1H), 5.43 (dt, J = 2.5, 1.2 Hz, 1H), 3.31 
– 3.26 (m, 2H), 2.31 (s, 6H). 13C-NMR (101 MHz) δ 198.9, 172.5, 164.5, 133.9, 115.2, 33.6, 
26.3. HRMS (ESI) m/z calcd for C9H10O4 ([M+Na]+) 205.0477; found 205.0476. 
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Methyl 2-benzoyl-3-methylenetetrahydrofuran-2-carboxylate (5e). Prepared from methyl 
2-diazo-3-oxo-3-phenylpropanoate and 3-butynoic acid using general procedure EI.  Yellow 
liquid (52 mg, 86%). 1H NMR (400 MHz) δ 8.05–7.99 (m, 2H), 7.57–7.51 (m, 1H), 7.46–7.39 
(m, 2H), 5.50 (t, J = 2.1 Hz, 1H), 5.41 (t, J = 2.3 Hz, 1H), 4.21 (q, J = 7.8 Hz, 1H), 4.08 (dt, J = 
8.3, 6.4 Hz, 1H), 3.74 (s, 3H), 2.73 (ddt, J = 7.5, 4.4, 1.4 Hz, 2H).13C NMR (101 MHz) δ 191.2, 
170.0, 143.8, 134.3, 133.2, 129.7, 128.4, 112.6, 90.2, 68.9, 53.0, 32.9. Compound matched 
literature known values 
 
tert-Butyl 2-benzoyl-3-methylenetetrahydrofuran-2-carboxylate (5f). Prepared from tert-
butyl 2-diazo-3-oxo-3-phenylpropanoate and 3-butynol using general procedure EI. Yellow 
oil (47 mg, 80%). TLC: Rf 0.5 (4:1 hexanes/EtOAc). IR (NaCl): 2958, 2924, 2854, 2127, 1722, 
1598, 1583. 1H NMR (400 MHz) δ 8.07–8.03 (m, 2H), 7.57–7.50 (m, 1H), 7.47–7.39 (m, 2H), 
5.50 (t, J = 2.1 Hz, 1H), 5.41 (t, J = 2.2 Hz, 1H), 4.23 (q, J = 7.8 Hz, 1H), 4.07 (dt, J = 8.2, 6.3 
Hz, 1H), 2.73 (ddt, J = 8.3, 4.4, 1.7 Hz, 2H), 1.32 (s, 9H). 13C NMR (101 MHz) δ 191.3, 168.5, 
144.3, 134.8, 132.9, 129.6, 128.3, 111.9, 90.1, 83.1, 68.8, 33.2, 29.7, 27.6. ESI-MS m/z calcd 
for C17H20O4 ([M+Na]+) 311.1; found 311.1. 
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Ethyl 2-acetyl-3-methylenetetrahydrofuran-2-carboxylate (5g). Prepared from ethyl 2-
diazo-3-oxobutanoate and 3-butynol using general procedure EI.  Yellow oil (45 mg, 64%). 
TLC: Rf 0.60 (7:3 hexanes/EtOAc). IR (NaCl): 2963, 2925, 1745, 1662. 1H NMR (400 MHz) δ 
5.32 (t, J = 2.4 Hz, 1H), 5.30 (t, J = 2.2 Hz, 1H), 4.17 (qd, J = 7.1, 2.9 Hz, 2H), 4.09–3.97 (m, 
2H), 2.70–2.59 (m, 2H), 2.17 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz) δ 201.6, 
168.1, 143.3, 112.0, 90.2, 68.4, 61.9, 32.7, 30.8, 25.4, 13.9. HRMS (ESI) m/z calcd for C10H14O4 
([M+Na]+) 221.0790; found 221.0784. 
 
1,1'-(3-Methylenetetrahydrofuran-2,2-diyl)bis(ethan-1-one) (5h). Prepared from 3-
diazopentane-2,4-dione and 3-butynol using general procedure EI. Orange oil (52 mg, 
78%). 1H NMR (400 MHz) δ 5.34 (t, J = 2.2 Hz, 1H), 5.30 (t, J = 2.4 Hz, 1H), 4.08 (t, J = 7.1 Hz, 
2H), 2.67 (ddd, J = 7.1, 4.9, 2.3 Hz, 2H), 2.23 (s, 6H).13C-NMR (101 MHz) δ 198.8, 178.9, 
144.7, 112.9, 95.5, 42.3, 25.9.  Compound matched literature known values. 
 
1,1'-(4,4-Dimethyl-3-methylene-5-oxotetrahydrofuran-2,2-diyl)bis(ethan-1-one) (5i). 
Prepared from 3-diazopentane-2,4-dione and 2,2-dimethylbut-3-ynoic acid using general 
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procedure EI. Yellow oil (45 mg, 91%). TLC: Rf 0.71 (7:3 hexanes/EtOAc). IR (NaCl): 2977, 
2932, 2874, 2853, 1798, 1740, 1720, 1644, 1582. 1H NMR (400 MHz) δ 5.53 (d, J = 1.5 Hz, 
1H), 5.34 (d, J = 1.5 Hz, 1H), 2.28 (s, 6H), 1.29 (s, 6H). 13C-NMR (101 MHz) δ 198.8, 178.9, 
144.7, 112.9, 95.5, 42.3, 25.9. HRMS (ESI) m/z calcd for C11H14O4 ([M+Na]+) 233.0790; 
233.0787 found. 
 
1,1'-(4,4-Dimethyl-3-methylenetetrahydrofuran-2,2-diyl)bis(ethan-1-one) (5j). Prepared 
from 3-diazopentane-2,4-dione and 2,2-dimethylbut-3-yn-1-ol using general procedure EI.  
Pale yellow oil (51 mg, 87%). TLC: Rf 0.57 (4:1 hexanes/EtOAc). IR (NaCl): 2966, 2931, 2871, 
1736, 1714, 1660, 1583. 1H NMR (400 MHz) δ 5.28 (t, J = 0.8 Hz, 1H), 5.18 (t, J = 0.8 Hz, 1H), 
3.78 (s, 2H), 2.25 (s, 6H), 1.12 (s, 6H). 13C NMR (101 MHz) δ 203.0, 152.0, 109.3, 98.5, 80.5, 
26.4, 25.7. HRMS (ESI) m/z calcd for C11H16O3 ([M+Na]+) 219.0997; found 219.0997. 
 
1,1'-(3-Methylene-4-phenyltetrahydrofuran-2,2-diyl)bis(ethan-1-one) (5k).  Prepared 
from ethyl 2-diazo-3-oxobutanoate and 2-phenylbut-3-yn-1-ol using general procedure EI. 
Yellow oil (81 mg, 86%). TLC: Rf 0.60 (4:1 hexanes/EtOAc). 1H NMR (400 MHz) δ 7.36–7.27 
(m, 3H), 7.18 (dd, J = 6.9, 1.6 Hz, 2H), 5.46–5.39 (m, 1H), 5.07–5.00 (m, 1H), 4.55–4.44 (m, 
1H), 3.96–3.91 (m, 2H), 2.30 (d, J = 4.9 Hz, 6H). 13C NMR (101 MHz) δ 203.1, 202.6, 147.0, 
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138.7, 128.8, 128.5, 127.4, 113.7, 75.3, 50.4, 26.2, 25.8. HRMS (ESI) m/z calcd for C15H16O3 
([M+Na]+) 267.0997; found 267.0995. 
 
1,1'-(3-Methylene-5-phenyltetrahydrofuran-2,2-diyl)bis(ethan-1-one) (5l). Prepared 
from 3-diazopentane-2,4-dione and 1-phenylbut-3-yn-1-ol using general procedure EI. 
Yellow oil (72mg, 72%). TLC: Rf 0.63 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 7.46–7.30 
(m, 5H), 5.37 (dd, J = 2.8, 1.6 Hz, 1H), 5.34 (dd, J = 3.0, 1.6 Hz, 1H), 5.07 (dd, J = 10.3, 6.1 Hz, 
1H), 3.03 (ddt, J = 15.7, 6.1, 1.6 Hz, 1H), 2.65 (ddt, J = 15.8, 10.3, 2.9 Hz, 1H), 2.31 (d, J = 5.4 
Hz, 6H). 13C NMR (101 MHz) δ 203.3, 202.6, 142.6, 139.9, 128.7, 128.3, 126.1, 111.9, 81.4, 
41.2, 26.3, 26.0. HRMS (ESI) m/z calcd for C15H16O3 ([M+Na]+) 267.0997; found 267.0993. 
 
 
Methyl-2-benzoyl-3-methylene-4-phenyltetrahydrofuran-2-carboxylate (5m).  Prepared 
from methyl 2-diazo-3-oxo-3-phenylpropanoate and 2-phenylbut-3-yn-1-ol using general 
procedure EI. Clear oil (47 mg, 77%). TLC: Rf 0.65 (4:1 hexanes/EtOAc). 1H NMR (400 MHz) 
δ 8.14–8.02 (m, 2H), 7.63–7.53 (m, 1H), 7.52–7.37 (m, 2H), 7.40–7.15 (m, 5H), 5.55 (d, J = 
3.0 Hz, 1H), 5.13 (d, J = 2.7 Hz, 1H), 4.47 (t, J = 8.2 Hz, 1H), 4.27 (dd, J = 10.1, 8.3 Hz, 1H), 
3.97 (ddt, J = 10.7, 8.1, 2.8 Hz, 1H), 3.80 (s, 3H). 13C NMR (101 MHz) δ 190.6, 170.2, 148.7, 
O
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138.5, 134.2, 133.4, 129.8, 128.9, 128.7, 128.5, 127.3, 114.4, 91.4, 76.1, 53.1, 50.6. 
Compound matched literature known values 
 
Methyl-2-benzoyl-3-methylene-5-phenyltetrahydrofuran-2-carboxylate (5n).  Prepared 
from methyl 2-diazo-3-oxo-3-phenylpropanoate and 1-phenylbut-3-yn-1-ol using general 
procedure EI. Clear oil (52 mg, 77%). TLC: Rf 0.64 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) 
δ 8.16–8.03 (m, 4H), 7.60–7.50 (m, 1H), 7.48–7.39 (m, 1H), 7.37–7.19 (m, 4H), 5.53 (dd, J = 
2.8, 1.3 Hz, 1H), 5.46 (dd, J = 3.1, 1.2 Hz, 1H), 5.42 (dd, J = 10.8, 5.6 Hz, 1H), 3.77 (s, 3H), 
3.04 (ddt, J = 15.2, 5.7, 1.3 Hz, 1H), 2.67 (ddt, J = 15.1, 10.8, 2.9 Hz, 1H). 13C NMR (101 MHz) 
δ 190.8, 170.3, 144.2, 140.0, 134.4, 133.2, 129.9, 128.4, 128.4, 128.3, 127.9, 125.9, 112.6, 
82.2, 52.9, 41.9. HRMS (ESI) m/z calcd for C20H18O4 ([M+Na]+) 345.1095; found 345.1102. 
 
Methyl (5R)-2-benzoyl-5-((benzyloxy)methyl)-3-methylenetetrahydrofuran-2-
carboxylate (4o).  Prepared from methyl 2-diazo-3-oxo-3-phenylpropanoate and (R)-1-
(benzyloxy)pent-4-yn-2-ol using general procedure EI. Clear oil (62 mg, 64%): [α]21D +22.8 
(c = 1, CHCl3). TLC: Rf 0.52 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 8.13–8.00 (m, 2H), 
7.40 (t, J = 7.8 Hz, 3H), 7.23 (dd, J = 5.2, 1.7 Hz, 3H), 7.16 (dd, J = 6.9, 2.8 Hz, 2H), 5.48 (dd, 
J = 2.7, 1.6 Hz, 1H), 5.40 (dd, J = 2.9, 1.6 Hz, 1H), 4.43 (s, 2H), 3.75 (s, 3H), 3.66 (ddd, J = 
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14.6, 4.8, 2.4 Hz, 1H), 3.53 (t, J = 4.3 Hz, 2H), 2.84 – 2.72 (m, 1H), 2.68 (ddt, J = 8.9, 5.9, 2.7 
Hz, 1H). 13C NMR (101 MHz) δ 191.3, 170.2, 143.8, 138.0, 134.4, 133.1, 129.9, 129.3, 128.6, 
128.3, 128.3, 128.2, 127.5, 127.4, 112.8, 90.9, 79.9, 77.3, 73.2, 71.1, 53.0, 35.2. HRMS (ESI) 
m/z calcd for C22H22O5 ([M+Na]+) 389.1357; found 389.1365. 
 
Methyl (5S)-2-benzoyl-5-((benzyloxy)methyl)-3-methylenetetrahydrofuran-2-
carboxylate (4p). Prepared from methyl 2-diazo-3-oxo-3-phenylpropanoate and (S)-1-
(benzyloxy)pent-4-yn-2-ol using general procedure EI. Clear oil (47 mg, 75%): [α]21D –22.8 
(c = 1, CHCl3). TLC: Rf 0.52 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 8.13–8.00 (m, 2H), 
7.40 (t, J = 7.8 Hz, 3H), 7.23 (dd, J = 5.2, 1.7 Hz, 3H), 7.16 (dd, J = 6.9, 2.8 Hz, 2H), 5.48 (dd, 
J = 2.7, 1.6 Hz, 1H), 5.40 (dd, J = 2.9, 1.6 Hz, 1H), 4.43 (s, 2H), 3.75 (s, 3H), 3.66 (ddd, J = 
14.6, 4.8, 2.4 Hz, 1H), 3.53 (t, J = 4.3 Hz, 2H), 2.84 – 2.72 (m, 1H), 2.68 (ddt, J = 8.9, 5.9, 2.7 
Hz, 1H). 13C NMR (101 MHz) δ 191.3, 170.2, 143.8, 138.0, 134.4, 133.1, 129.9, 129.3, 128.6, 
128.3, 128.2, 127.5, 127.4, 112.8, 90.9, 79.9, 77.3, 73.2, 71.1, 53.0, 35.2. HRMS (ESI) m/z 
calcd for C22H22O5 ([M+Na]+) 389.1357; found 389.1365. 
 
5-Benzoyl-4-methylene-5-phenyldihydrofuran-2(3H)-one (5q). Prepared from 2-diazo-
1,2-diphenylethan-1-one and but-3-ynoic acid using general procedure EI. Clear oil (19 mg, 
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87%).   TLC: Rf 0.54 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 7.56–7.29 (m, 10H), 5.45 (d, 
J = 2.5 Hz, 1H), 5.28 (t, J = 2.8 Hz, 1H), 3.50 – 3.22 (m, 2H). 13C NMR (101 MHz) δ 194.5, 
172.9, 134.9, 133.3, 132.9, 130.7, 129.9, 129.0, 128.9, 128.8, 128.7, 128.3, 124.9, 115.2, 
34.7, 29.7. HRMS (ESI) m/z calcd for C18H14O3 ([M+H]+) 279.1002; found 279.1003.  
 
(3-Methylene-2-phenyltetrahydrofuran-2-yl)(phenyl)methanone (5r). Prepared from 2-
diazo-1,2-diphenylethan-1-one and but-3-yn-1-ol using general procedure EI. Clear oil (70 
mg, 86%).   TLC: Rf 0.85 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 7.71–7.62 (m, 1H), 7.56–
7.41 (m, 5H), 7.40–7.24 (m, 4H), 5.36 (t, J = 2.1 Hz, 1H), 5.05 (t, J = 2.3 Hz, 1H), 4.22–4.08 
(m, 1H), 3.98 (td, J = 8.2, 6.8 Hz, 1H), 2.93–2.58 (m, 2H). 13C NMR (101 MHz) δ 198.4, 148.6, 
140.3, 135.2, 134.9, 130.5, 129.9, 129.0, 128.5, 128.4, 128.3, 127.8, 127.7, 125.4, 111.5, 
92.6, 66.7, 32.7. HRMS (ESI) m/z calcd for C15H16O3 ([M+Na]+) 287.1048; found 287.1038. 
 
(3-Methylene-2,4-diphenyltetrahydrofuran-2-yl)(phenyl)methanone (5s). Prepared from 
2-diazo-1,2-diphenylethan-1-one and 2-phenylbut-3-yn-1-ol using general procedure EI. 
Clear oil (19 mg, 82%). TLC: Rf 0.84 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 7.71–7.62 
(m, 1H), 7.57–7.21 (m, 11H), 7.24–7.12 (m, 3H), 5.11 (d, J = 2.7 Hz, 1H), 5.03 (d, J = 2.4 Hz, 
1H), 4.40 (t, J = 8.1 Hz, 1H), 4.13 (t, J = 8.1 Hz, 1H), 4.07 (tt, J = 7.8, 2.5 Hz, 1H). 13C NMR 
(101 MHz) δ 197.8, 153.2, 140.0, 134.9, 132.6, 130.6, 129.9, 129.0, 128.7, 128.6, 128.5, 
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127.9, 127.8, 126.9, 125.4, 113.9, 109.9, 77.3, 74.5, 50.3, 29.7. HRMS (ESI) m/z calcd for 
C24H20O2 ([M+Na]+) 363,1360; found 363.1350. 
 
3-Methylene-3',4,4',5-tetrahydro-2'H,3H-spiro[furan-2,1'-naphthalen]-2'-one (5t). 
Prepared from 1-diazo-3,4-dihydronaphthalen-2(1H)-one and but-3-yn-1-ol using general 
procedure EI. Clear oil (28 mg, 71%).   TLC: Rf 0.52 (8:2 hexanes/EtOAc). 1H NMR (400 MHz) 
δ 7.41–7.11 (m, 4H), 5.19 (d, J = 2.2 Hz, 1H), 4.67 (d, J = 2.2 Hz, 1H), 4.42 (td, J = 8.3, 5.6 Hz, 
1H), 4.23 (q, J = 7.6 Hz, 1H), 3.16 (qd, J = 16.1, 7.9 Hz, 2H), 3.01 – 2.91 (m, 1H), 2.92 – 2.83 
(m, 1H), 2.78 (ddd, J = 15.2, 7.7, 5.7 Hz, 1H), 2.64 (dt, J = 15.4, 6.5 Hz, 1H). 13C NMR (101 
MHz) δ 208.1, 151.1, 138.9, 136.4, 128.1, 128.0, 127.6, 127.2, 110.8, 67.9, 35.9, 32.6, 28.7. 
HRMS (ESI) m/z calcd for C14H14O2 ([M+Na]+) 237.0892; found 237.0896. 
 
Ethyl 6-acetyl-1-methyl-3-oxo-2-oxabicyclo[3.1.0]hexane-6-carboxylate (7). Prepared 
from ethyl 2-diazo-3-oxobutanoate and pent-3-ynoic acid using general procedure 3. Clear 
thick oil (17 mg, 64%). TLC: Rf 0.47 (7:3 hexanes/EtOAc). 1H NMR (400 MHz) δ 4.26 – 4.15 
(m, 2H), 3.63 – 3.57 (m, 1H), 2.95 (d, J = 8.7 Hz, 1H), 2.91 (d, J = 8.7 Hz, 1H), 2.86 (d, J = 2.5 
Hz, 1H), 2.81 (d, J = 2.5 Hz, 1H), 2.23 (d, J = 1.7 Hz, 3H), 1.75 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz) δ 173.8, 166.6, 164.3, 134.3, 134.1, 129.3, 129.2, 115.1, 109.9, 105.9, 
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77.3, 77.0, 76.7, 60.1, 47.1, 34.4, 23.7, 14.3, 14.2, 14.0. ESI-MS m/z calcd for C11H14O5 
([M+Na]+) 249.6; found 249.1. 
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CHAPTER 3 
 
Rh(II)/Au(I) Catalyzed Synthesis of  
Spiroethers and Azaspiro-Ring Systems 
 
 
3.1  INTRODUCTION 
 
  The stereoselective synthesis of spiroethers, which are found in a wide range of 
bioactive natural products and drug molecules (Figure 3.1), is of great importance to the 
field of synthetic chemistry.[1] Examples of naturally occurring spiroethers include the 
pseurotins and spirooxindoles. Due to the biological importance of spiroethers, the 
synthesis of this scaffold remains an area of current interest to the chemical community. 
 
Figure 3.1. Representative examples of biologically active spiroethers as natural products 
and synthetically derived drug molecules. 
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Most existing methods to access spiroethers rely heavily on intramolecular 
cyclization/rearrangement reactions of appropriate linear precursors which require 
multiple synthetic steps for preparation. For example, in 2012 Jiao et al. identified a direct 
C(sp3)–H functionalization of tetrahydrofurans to access spiroethers (Scheme 3.1).[2] In this 
work it was necessary to start with a tetrahydrofuran that contained both an a,b-
unsaturated aldehyde and a diethylmalonate moiety. When this highly functionalized 
substrate was placed in the presence of a strong Lewis acid and organocatalyst, an iminium 
ion mediated C–H functionalization occurred. Although this method provided access to a 
variety of spiroethers with differing substituents and ring sizes, the method is not ideal 
because of the four synthetic steps needed to access the linear precursor for intramolecular 
cyclization. 
 
Scheme 3.1. Previous approach to spiroethers showing the general need to synthesize a 
complex linear precursor prior to setting spirocenter. 
 
H O
i.	Cat.	1	(30	mol%)
AgSbF6	(30	mol%) O
EtO2C
EtO2C
O
EtO2C
EtO2C
CO2Et
N
H2
H
NO
Ph Cl	–
Cat.	1
ii.	PPh3=CHCO2Et
Jiao,	2012
EtO2C CO2Et
+
O
Br
4	steps	to	
starting	material
CH. 3 – Rh(II)/Au(I) Catalyzed Synthesis of Spiroethers and Azaspiro-Ring Systems 118 
Also of great value are azaspiro-ring systems which uniquely possess an aza-
substituted quaternary center.[3] This motif is frequently found in many biologically active 
natural alkaloids such as cylindricine A, lepadeformine A, TAN1251A, and FR901483 (Figure 
3.2).[3a] Azaspiro-ring systems are also found in a variety of highly valuable ligand scaffolds. 
These types of ligands have been proven to be especially powerful due to their ability to 
induce impeccable stereocontrol because of the proximity of the spiro-backbone to the 
nitrogen center which coordinates catalysts. Although azaspiro-ring systems such as 
spiropyrollidines are of great value, their associated synthetic challenges cause syntheses 
for accessing them to be limited, similar to spiroethers. 
 
Figure 3.2. Biologically active azaspiro-ring systems found in natural products 
 
In 2015 Zhang et al. designed a spiropyrollidine organocatalyst and applied it to a 
catalytic asymmetric Michael addition for the construction of all-carbon quaternary centers 
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synthetic steps from a complex linear precursor to obtain their spiropyrollidine ligand 
scaffolds for screening. This eight-step sequence had to be repeated for each different 
ligand scaffold for screening.  
 
Scheme 3.2. Biologically active azaspiro-ring systems found in natural products 
 
 When analyzing the structures of spiroethers and spiropyrollidines, one’s attention 
is immediately drawn to the daunting task of forming the quaternary stereocenter 
stereoselectively, and this feat is increasingly difficult because the quaternary stereocenter 
is incorporated into a spirocycle. Despite this obvious challenge, we were intrigued by the 
uniqueness, usefulness, and lack of representation of these scaffolds. Therefore, to 
overcome the aforementioned challenge and avoid the application of complex linear 
precursors, we decided to dissect the molecule in a simple yet unique manner: by splitting 
it down the middle. This disconnection would provide convergent access to spiroethers and 
azaspiro-ring systems. After splitting this scaffold down the middle, we see that it is 
necessary to have two substrates that possess both nucleophilic and electrophilic 
reactivity, which is better known as “ambiphilic reactivity” (Figure 3.3). This ambiphilicity 
can be found within a tethered molecule having both an electrophile and nucleophile and 
also within a singlet carbene that can be directly accessed through diazo compounds.[4] 
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Figure 3.3. Novel disconnection to spirocycles developed by Sharma Lab 
 
3.2 STEREOSELECTIVE TRAPPING OF Rh(II) CARBENES WITH Au(I) 
ACTIVATED ALKYNOLS FOR THE SYNTHESIS OF SPIROETHERS  
In the preceding chapter, we reported the identification and application of 
Rh2(esp)2 and PPh3AuOTf as a synergistic catalytic cocktail to access g-butyrolactones and 
tetrahydrofurans.[5] Within this work, our diazocarbonyls were often linear substrates. 
However, there was one example where we implemented a cyclic diazocarbonyl derived 
from 2-tetralone (Scheme 3.3). When diazo 1a was exposed to our catalytic conditions in 
the presence of 3-butynol, we were able to obtain the corresponding spiroether 3a in 71% 
yield.  
 
Scheme 3.3. Preliminary results to help justify synthetic approach. 
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With this preliminary result in hand, we hypothesized that we could split 
spiroethers “down the middle” into a corresponding cyclic diazocarbonyl and alkynol 
derivative, the hydroxyl group being our nucleophile and the alkyne being our electrophile. 
When these two substrates are exposed to our Rh2(esp)2/PPh3AuOTf catalytic cocktail, the 
desired spiroether would be rapidly and efficiently obtained. This approach would 
eliminate the need to synthesize highly functionalized linear precursors, thereby making 
our method highly convergent. 
 
3.2.1  INITIAL SCREENING OF CATALYTIC CONDITIONS 
Inspired by the initial synthesis of spiroether 3a using our Rh2(esp)2/PPh3AuOTf 
catalytic conditions, we decided to focus our attention on optimizing this transformation 
using N-methyl isatin diazo 1b. This diazo would provide highly relevant spirooxindole 
scaffolds which are privileged skeletons due to their broad and promising biological 
activities and prevalence in naturally occurring molecules.[6] 
 
Scheme 3.4.  Preliminary results for cascade spirocyclization 
N
O
N2
HO
+
O
	Rh2(esp)2	(1	mol%)
PPh3AuOTf	(10	mol%)
CH2Cl2,	rt,	instantly
N
O
O
O
+
N
O
O
O
100%	conv.0%	conv.
N
O
N2
HO
+
	Rh2(esp)2	(1	mol%)
PPh3AuOTf	(10	mol%)
CH2Cl2,	rt,	instantly N
O
O
+
N
O
O
75%	conv.25%	conv.
a)
b)
1b 2b 3b 4b
1b 2a
3c 4c
CH. 3 – Rh(II)/Au(I) Catalyzed Synthesis of Spiroethers and Azaspiro-Ring Systems 122 
 We initiated our work by attempting the carboxylic acid O–H insertion/Conia-ene 
cyclization using diazo 1b and 3-butynoic acid (Scheme 3.4a). Surprisingly, this reaction 
yielded only the corresponding insertion product 4b and no trace of the cyclized product 
3b was detected. The incompatibility of the carboxylic acid in this cascade reaction may be 
attributed to the low pKa value of the protonated carboxylic acid in the zwitterionic 
intermediate (approximated –7.4).[7] This low pKa value would thereby favor a higher rate 
of proton transfer over the trapping of the activated alkyne. Undeterred by this failed 
reaction, we next decided to screen the reaction with 3-butynol, as it was just as efficient 
as 3-butynoic acid in our O–H insertion/Conia-ene cyclization methodology (Scheme 3.4b). 
Upon completion of this reaction we observed a 25:75 ratio of the desired spiroether 3c to 
the competing insertion product 4c. Encouraged by the results in hand, we began to 
optimize the reaction in order to obtain a higher conversion to spiroether 3c (Table 3.1). 
When examining the mechanism of this transformation it is understood that in 
order to have a higher probability of the active Rh(II)-bound zwitterionic intermediate 
being trapped by the Au(I)-activated alkynol, the lifetime of the Rh(II)–bound zwitterionic 
intermediate must be increased.[8] One obvious way to increase the lifetime is to limit the 
amount of diazocarbonyl present in the reaction mixture, consequently the Rh(II) will not 
be influenced to leave the zwitterionic intermediate to go decompose another 
diazocarbonyl. To test this hypothesis, we added a solution of 1b in dichloromethane via 
syringe pump to a mixture of the catalytic solution and 3-butynol. When this reaction was 
complete, we observed a significant increase in conversion to a 40:60 ratio of the desired 
spiroether 3c to the competing insertion product 4c (Table 3.1, entry 2). Next, we decided 
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to test the influence of a decreased temperature, however, when the reaction was 
conducted at 0 ºC with a syringe pump addition of 1b no significant change in conversion 
was observed (Table 3.1, entry 3). Lastly, we hypothesized that an increase in Lewis-acidity 
of the Rh(II) catalyst could extend the lifetime of the Rh(II)-bound zwitterionic 
intermediate.[8a, 9] To test this hypothesis, we conducted the reaction in the presence of 
highly electrophilic Rh2(TFA)4 instead of Rh2(esp)2. This change proved to be exceedingly 
successful, providing almost exclusively the desired spiroether in an 80% conversion (Table 
3.1, entry 4). 
 
Table 3.1. Optimization of O–H Insertion/Conia-ene Cascade for Spiroether Synthesis 
 
entry Rh(II)/Lewis acid timeb(temp) 3c:4cc 
1 Rh2(esp)2/AgOTf/PPh3AuCl Instant(rt) 25:75 
2 Rh2(esp)2/AgOTf/PPh3AuCld 1hr addition(rt) 40:60 
3 Rh2(esp)2/AgOTf/PPh3AuCld 1hr addition(0 ºC) 40:60 
4 Rh2(TFA)4e/AgOTf/PPh3AuCld 1hr addition(0 ºC) 80:20 
aAll optimization reactions were performed in 0.1 M CH2Cl2 with 1b (1.20 equiv.), 2a (1 equiv.), Rh2L4 
(1 mol%), and Lewis acids (10 mol%) along with 4 Å molecular sieves; btime required for the 
complete consumption of 1b; cConversion (%) was determined from the crude 1H NMR 
spectrum;d1b was added via syringe pump addition as a solution in CH2Cl2; eTFA = trifluoroacetate. 
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3.2.2  APPLICATION TO SUBSTRATE SCOPE 
 
Scheme 3.5. Representative substrate scope of oxindole spiroethers accessed through O–H 
Insertion/Conia-ene cyclization with Rh2(TFA)4/PPh3AuOTf 
 
With optimized conditions in hand, we undertook a thorough study of the substrate 
scope of this transformation in hopes of accessing a variety of functionalized spiroethers 
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oxindole core, and this perturbation in electronics also did not have an effect on the 
transformation (3i). 
 
Scheme 3.6. Representative substrate scope of spiroethers accessed through O–H 
Insertion/Conia-ene cyclization with Rh2(esp)2/PPh3AuSbF6 
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a mild source of triflic acid which could cause decomposition of the desired spiroether 
product.[10] With this problem in hand, we thought to screen a more stable silver salt with 
a less active counter ion and our silver salt of choice was AgSbF6. Delightfully, this change 
increased the yield of the desired product 3j to 42%. 
 With our newly modified conditions, we expanded the substrate scope of this 
reaction to A/A cyclic diazocarbonyls (Scheme 3.6). The Meldrum’s acid diazo was 
compatible with substituted primary and secondary alcohols giving the desired substrates 
3k and 3l in 40% yield and 32% yield, respectively. We believe the moderate yields observed 
in these transformations with Meldrum’s acid diazocarbonyl can be attributed to molecular 
instability of the corresponding spiroether in the presence of Lewis acids.[11] These 
substrates have a high level of entropic driving force for fragmentation. Next, we decided 
to screen the diazocarbonyl derived from barbituric acid which would not have the entropic 
driving force for fragmentation. When this diazo was reacted with 3-butynol under the 
optimized conditions the desired compound 3m was produced in a 62% yield, validating 
our hypothesis. As expected, this diazo also accommodated primary and secondary alcohol 
substituents (3n–3o). 
 
3.2.3  MECHNISTIC INSIGHTS 
 To probe the reaction mechanism, deuterium labeling experiments were conducted 
with both the donor/acceptor and acceptor/acceptor cyclic diazocarbonyls. To conduct this 
study, it was necessary to synthesize a deuterated 3-butynol derivative (Scheme 3.5). 
Initially, we explored a kinetic deprotonation and exposed our parent 3-butynol to 2.5 
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equivalents of n-butyllithium and proceeded to quench the reaction with D2O, however, 
this was proven to be unsuccessful. Next, we decided to exploit the relative acidity of the 
alkyne proton and explored thermodynamic deprotonation conditions. We exposed a TBS-
protected 3-butynol derivative to 1.2 equivalents of trithethylamine in a 1:1 mixture of D2O 
and THF, hoping to facilitate a proton/deuterium exchange within the reaction. This 
solution was stirred overnight and the next morning the desired compound was isolated 
with 95% deuterium incorporation. To complete the synthesis of the desired deuterated 
alkynol, a TBS-deprotection was needed, however when this compound was exposed tetra-
butylammonium fluoride (TBAF) and isolation was attempted, the desired compound was 
 
Scheme 3.7. Insights into the synthesis of deuterated 3-butynol derivative 
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point of the desired compound. However, when the deuterated derivative was synthesized 
and exposed to TBAF, 1H NMR showed reincorporation of the proton at the alkyne. This 
caused us to explore an alternative method of TBS-deprotection, HF-pyridine which was 
quenched with methoxytrimethylsilane instead of water upon completion of the reaction. 
This method produced the desired substrate 2c[D] in a 33% yield. 
 Once our deuterated alkynol was obtained, it was exposed to both the 
donor/acceptor and acceptor/acceptor cyclic diazocarbonyls under their respective 
optimized reaction conditions (Scheme 3.8). In both cases, no deuterium scrambling was 
observed, and the deuterium was found to be syn to the carbonyl functionality using 1D 
nOe experiments. This observation was in accordance with results published by Toste et al. 
in his previous Au(I)-catalyzed Conie-ene cyclization.[12] These results suggest a mechanism 
involving the trapping of an enol-intermediate with a gold-alkyne p-coordinated complex, 
ruling out the formation of a gold acetylide.[13] 
 
Scheme 3.8. Deuterium labeling studies using deueterated alkynol 
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 For further insights we conducted the reaction with isatin diazo 1b and 3-butynol in 
the presence of D2O in order to determine a possible mode of proto-demetalation for this 
transformation (Scheme 3.9). Upon completion of the reaction a 47:53 ratio of spirother 
3c/3c[D] to insertion byproduct 4c/4c[D] was observed. For the spiroether, there was a 
38% deuterium incorporation at the alkene and for the insertion compound there was a 
55% deuterium incorporation at the a-center of the isatin and no deuterium incorporation 
at the alkyne. These observations suggest that there is a high likelihood the proto-
demetalation step for this transformation occurs intermoleculary through trace amount of 
water present in the reaction. 
  
 
Scheme 3.9. Deuterium labeling studies using D2O as an additive 
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donor/acceptor and acceptor/acceptor cyclic diazocarbonyls using Rh2(TFA)4 and Rh2(esp)2 
as catalysts, respectively. When the insertion compounds were subjected to the Au(I) 
catalyzed Conia-ene cyclizatin condition, we did not observe any cyclized products even 
 
Scheme 3.10. Probing stepwise transformation for validation of synergy 
 
after 12 hours in refluxing dichloromethane (Scheme 3.8). We also exposed the insertion 
products to a mixture of Rh(II) and cationic Au(I), in order to probe whether the catalyst 
mixture is able to induce the stepwise transformation. However, no cyclized products were 
observed under these conditions also, even after 12 hours in refluxing dichloromethane. 
This study supports the complete synergy of Rh(II) and Au(I) in this catalytic cascade. 
As a final effort to obtain mechanistic understanding, we conducted studies to 
probe whether this transformation could be conducted asymmetrically (Table 3.2). Initially, 
we attempted the cascade reaction with chiral Rh(II) catalysts, Rh2(S-DOSP)4 and Rh2(S-
PTAD)4 with isatin diazo 1b. We also screened the optimized reaction with the 
incorporation of R-BINAP(AuCl)2. Nevertheless, after screening these conditions no 
enantiomeric excess (ee) was observed. This observation was in accordance with literature 
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Table 3.2. Optimization of Asymmetric Transformation with Isatin Diazo 
 
entry Condition timeb(temp) %ee(yield%) 
1 Rh2(S-DOSP)4/AgOTf/PPh3AuCl 1hr addition(0 ºC) 0 (52) 
2 Rh2(S-PTAD)4/AgOTf/PPh3AuCl 1hr addition(0 ºC)) 0 (43) 
3 Rh2(TFA)4c/AgOTf/R-BINAP(AuCl)2 1hr addition(0 ºC) 0 (61) 
aAll optimization reactions were performed in 0.1 M CH2Cl2 with 1b (1.20 equiv.), 2a (1 equiv.), Rh2L4 
(1 mol%), and Lewis acids (10 mol%) along with 4 Å molecular sieves; btime required for the 
complete consumption of 1b; cTFA = trifluoroacetate. 
 
reports of inducing negligible enantioselectivity with chiral Rh(II) catalysts when the 
reaction centralized around the trapping of electrophiles with oxonium and ammonium 
zwitterionic intermediates that are formed in situ. Subsequently, we probed whether we 
could induce asymmetry using a chiral Au(I) catalyst. After completing the reaction with 
Rh2(TFA)4/R-BINAP(AuCl)2/AgOTf the desired compound 3c was isolated in a 53% yield, but 
no enantiomeric excess was induced.  
Next, we decided to change the diazocarbonyl for optimization to the 2-tetralone 
diazocarbonyl due to a hypothesis that the reactivity of an a-ketone diazocarbonyl would 
differ from the amide of isatin diazocarbonyl (Table 3.3). Whenever we exposed 1a to 3-
butynol in the presence of Rh2(esp)2/R-BINAP(AuCl)2/AgOTf we obtained the desired 
spiroether 3a in a 73% yield with 33% ee. Subsequently we replaced Rh2(esp)2 with 
Rh2(OAc)4 and the ee dropped to 28%. However, when Rh2(TFA)4 was used the yield 
increased to 96% and the ee also increased to 39%. It is well known that decreasing the 
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temperature of the reaction can increase the corresponding ee, therefore we lowered the 
temperature to 0 ºC and the ee increased to 42%. A further drop to -40 ºC increased the 
ee to 66%, however, conducting the reaction at -78 ºC was ineffective due to the inability 
of the diazocarbonyl to be decomposed.  
 
Table 3.3. Optimization of Asymmetric Transformation with 2-Tetralone Diazo 
 
entry Condition timeb(temp) %ee(yield%) 
1 Rh2(S-DOSP)4/AgOTf/PPh3AuCl 1hr addition(rt) 0 (65) 
2 Rh2(S-PTAD)4/AgOTf/PPh3AuCl 1hr addition(rt) 0 (63) 
3 Rh2(esp)2/AgOTf/R-BINAP(AuCl)2 1hr addition(rt) 33 (73) 
4 Rh2(OAc)4/AgOTf/R-BINAP(AuCl)2 1hr addition(rt) 28 (62) 
5 Rh2(TFA)4/AgOTf/R-BINAP(AuCl)2 1hr addition(rt) 39 (96) 
6 Rh2(TFA)4/AgOTf/R-BINAP(AuCl)2 1hr addition(0 ºC) 42 (95) 
7 Rh2(TFA)4/AgOTf/R-BINAP(AuCl)2 1hr addition(-40 ºC) 66 (96) 
8 Rh2(TFA)4/AgOTf/R-BINAP(AuCl)2 1hr addition(-78 ºC) – d 
aAll optimization reactions were performed in 0.1 M CH2Cl2 with 1b (1.20 equiv.), 2a (1 equiv.), Rh2L4 
(1 mol%), and Lewis acids (10 mol%) along with 4 Å molecular sieves; btime required for the 
complete consumption of 1a; cTFA = trifluoroacetate; dDiazo 1a did not decompose at -78 ºC. 
 
With these mechanistic insights we were able to propose a mechanism for this 
transformation (Scheme 3.11). When added in a stepwise fashion, Rh(II)/Au(I) work 
independently without exerting any synergistic effect on each other. Specifically, Rh(II) 
decomposes the diazocarbonyl compound to form a Rh(II)-carbene 5 that undergoes 
O
O
3a
HO
+
O
N2
1a 2a
conditions	a
CH2Cl2
CH. 3 – Rh(II)/Au(I) Catalyzed Synthesis of Spiroethers and Azaspiro-Ring Systems 133 
oxygen insertion to provide a zwitterionic intermediate 6 which undergoes keto–enol 
tautomerism to provide a reactive, dually activated intermediate 7. The reactive enol form 
enables the Conia-ene cyclization with the cyclic diazocarbonyl compound. The enol-
intermediate also explains the lack of enantioinduction with chiral Rh(II) salts. The 
stereoselectivity of the Conia-ene cyclization is influenced by the steric bulk as well as the 
Au(I)-coordinated alkynol substrate, where the enol form approaches the Au(I)-activated 
alkyne from the opposite face of the steric bulk. 
 
 
Scheme 3.11. Probing stepwise transformation for validation of synergy 
 
 The newly identified conditions for the synthesis of spiroethers are mild, selective, 
and provide a general and convergent route to diverse spiroethers. An important feature 
of this transformation is the high stereoselectivity and success of new Conia-ene 
cyclizations that are inaccessible using traditional mono-catalytic systems. The next goal 
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for our Rh(II)/Au(I) synergistic catalytic cocktail was its application to a corresponding N–H 
insertion/Conia-ene cascade to access various azaspiro-ring systems such as 
spiropyrollidines.  
 
3.3 STEREOSELECTIVE TRAPPING OF Rh(II) CARBENES WITH Au(I) 
ACTIVATED AMINOALKYNES FOR THE SYNTHESIS OF 
SPIROPYROLLIDINES 
 As one has seen thus far, diazocarbonyl derived rhodium carbenes are versatile 
synthetic intermediates that offer sequential reactions with a nucleophile and electrophile. 
In continuation with our interest in accessing diverse spirocyclic scaffolds, we focused our 
efforts on the development of a synergistic cascade reaction that would provide direct 
access to five membered azaspiro heterocycles which are common structural motifs in 
bioactive natural products and pharmaceuticals. Inspired by our previous work[14], in which 
we efficiently trapped rhodium carbenes with a variety of Au(I)-activated alkynoic acids and 
alkynols, we envisioned trapping rhodium carbenes with aminoalkynes using the same 
Rh(II)/Au(I) catalytic cocktail. 
 
3.3.1  INITIAL SCREENING OF CATALYTIC CONDITIONS 
To initiate our study, aminoalkyne 5a and 2-tetralone diazo 1a were selected as 
model substrates. The addition of 2-tetralone diazo 1a to aminoalkyne 5a in the presence 
of our previously optimized Rh2(esp)2/PPh3AuCl/AgSbF6 catalyst cocktail in 
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dichloromethane at room temperature provided the major spiropyrollidine product 6a in 
75% conversion with an isolated 60% yield (Table 3.4, entry 1). Encouraged by the initial 
results of this cascade reaction, we examined the effect of different Lewis acids known for 
synthesizing N-heterocycles through alkyne cyclization.[15] We screened ZnCl2, In(OTf)3, 
PPh3AuCl (alone), AgSbF6 (alone) and no conversion to the desired spiro compound was 
observed (Table 3.4, entry 2–5). Next, we decided to examine the effect of different 
dirhodium carboxylates known to decompose diazocarbonyls. Surprisingly, a mixture of 
Rh2(OAc)4/PPh3AuSbF6 was completely ineffective and produced none of the desired 
 
Table 3.4. Optimization of N–H insertion/Conia-ene Cascade 
 
entry Rh(II) Lewis Acid 6a:7a 
1 Rh2(esp)2 PPh3AuSbF6 75:25 
2 Rh2(esp)2 ZnCl2 0:100 
3 Rh2(esp)2 In(OTf)3 0:100 
4 Rh2(esp)2 PPh3AuCl 0:100 
5 Rh2(esp)2 AgSbF6 0:100 
6 Rh2(OAc)4 PPh3AuSbF6 0:100 
7 Rh2(TFA)4 PPh3AuSbF6 40:60 
aAll optimization reactions were performed by adding diazo 1a (1 equiv.) dropwise via syringe to a 
solution of 5a (1 equiv.), Rh2L4 (1 mol%), and Lewis acids (10 mol%) along with 4 Å molecular sieves 
in 0.3 M CH2Cl2. 
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spiropyrollidine (Table 3.4, entry 6). Subsequently we screened a mixture of 
Rh2(TFA)4/PPh3AuSbF6, which were the optimal conditions for the O–H insertion/Conia-ene 
cyclization of donor/acceptor cyclic diazocarbonyls, but only 40% conversion to the desired 
spiroether was observed (Table 3.4, entry 7). 
 
3.3.2  APPLICATION TO SUBSTRATE SCOPE 
 With the optimized conditions in hand, we investigated the applicability of this 
cascade reaction to a wide variety of substrates (Scheme 3.12). The fused aromatic 
phenanthrenone diazocarbonyl also participated in the cascade under the optimized 
conditions to provide spiropyrollidine 6b in a 62% yield. To demonstrate the utility of the 
transformation, it was necessary to identify a removable protecting group that would 
provide access to the free N–H spiropyrollidine, a functionality necessary for many ligand 
scaffolds. Using an aminoalkyne that was synthesized from para-anisidine, we were able to 
obtain the PMP (para-methoxy phenyl) protected spiropyrollidine 6c in 65% yield. This 
substrate was then taken forward and exposed to CAN (ceric ammonium nitrate) to give 
the free spiropyrollidine 8 in 83% yield. 
 Next, we hoped to apply these conditions to the more stable acceptor/acceptor 
diazocarbonyls. To initiate these efforts, methyl-benzoylacetate diazocarbonyl was 
exposed to aminoalkyne 5a in the presence of our optimized catalytic cocktail. At room 
temperature this electron deficient A/A diazocarbonyl did not decompose because of 
preferred complexation of Rh2(esp)2 with the Lewis-basic aminoalkyne. Due to the 
ineffectiveness of the catalyst at room temperature the reaction was refluxed in order to 
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initiate the desired transformation. However, 6d was obtained in a very low yield because 
the aminoalkyne 5a favored the 5-endo-dig self-cyclization when heated in the presence of 
PPh3AuSbF6. To optimize the yield of 6d, the A/A diazocarbonyl was added to the 
aminoalkyne in the presence of Rh2(esp)2 alone in refluxing dichloromethane. After the 
desired insertion product was visualized via thin layer chromatography PPh3AuCl and 
AgSbF6 were added to the same reaction vial and provided 6d in 92% yield. This modified 
protocol was also used to synthesize pyrollidine 6e in 90% yield and 6f in 94% yield.  
 
Scheme 3.12. Substrate scope of Rh2(esp)2/PPh3AuSbF6 catalyzed N–H insertion/Conia-ene 
cascade reaction to access spiropyrollidines/pyrollidines 
 
As seen in the synthesis of spiroethers, A/A cyclic diazocarbonyls are extremely 
stable substrates and required modified conditions to obtain their corresponding 
O
NPh O
NPh
NPMP
O
Ph
O
MeO
NPh
O
Me
O
EtO
O
O
O
O
NPh
N
O
N
O
NPh
O
Rh2(esp)2	(1	mol	%)
PPh3AuSbF6	(10	mol	%)
1 5 6
O
N2 + O
N
CH2Cl2
R
6a,	60%
6f,	94%6e,	90% 6g,	41% 6h,	52%
6b,	62%
HN
R
O
NPMP
6c,	65%
NPh
O
Ph
O
MeO
6d,	92%
O
HN
8,	83%
CAN
CH. 3 – Rh(II)/Au(I) Catalyzed Synthesis of Spiroethers and Azaspiro-Ring Systems 138 
spiroether products. This observation persisted with the aminoalkynes, also. When 
attempting to extend the aforementioned modified protocol to A/A cyclic diazocarbonyls 
such as Meldrum’s acid and barbituric acid diazos, it was observed that the stepwise Conia-
ene reaction was unsuccessful. Therefore, to synthesize substrates 6g–6h, the cyclic 
diazocarbonyl was added to the aminoalkyne and Rh2(esp)2/PPh3AuSbF6 then refluxed until 
complete. The method produced 6g and 6h in lower yields due to the competing self-
cyclization of the aminoalkyne 5a. 
 
Scheme 3.13. Applicaton of 2-ethynlaniline to access spiro-indoles 
 
 Next, we desired to expand our system to accommodate other aminoalkynes. Easily 
accessible 2-ethynylaniline was synthesized and exposed to Meldrum’s acid diazocarbonyl. 
In the presence of our catalytic cocktail the desired product 6i was produced in a mediocre 
yield. However, the self-cyclization of 2-ethynylaniline under Au(I) catalysis cannot occur  
due to geometrical restraints. Therefore, the decreased yield in this transformation is 
presumable attributed to the thermal decomposition of the desired product in the 
presence of Lewis acids. Nevertheless, we hypothesized that aromatic constraint found 
within 2-ethynylaniline could facilitate the Conia-ene cyclization step with Rh2(esp)2 alone, 
exploiting the inherent reactivity of the zwitterionic intermediate. Our hypothesis was 
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proven correct and spiro-indoline 6i was produced in 65% yield. The benzyl protected 
compound 6j was also successfully synthesized using this modified method (Scheme 3.13). 
 
3.3.3  MECHANISTIC INSIGHTS 
 To gain further insight into the mechanism of this transformation insertion products 
were synthesized with both the donor/acceptor 2-tetralone diazocarbonyl (7a) and the 
acceptor/acceptor methylbenzoylacetate diazocarbonyl (7b) using Rh2(esp)2 as a catalyst 
(Scheme 3.14a). When the insertion products were subjected to the Au(I)-catalyzed Conia-
ene cyclization we did not observe any cyclization for the 2-tetralone insertion compound 
7a even after refluxing for 12 hours in dichloromethane. However, for the 
methylbenzoylacetate insertion product 7b, cyclization occurred with equal efficiency as 
observed in our one pot, tandem cyclization protocol. 
Next, we examined if non-terminal alkynes were tolerated in this transformation 
(Scheme 3.14b). When insertion product 7c was exposed to PPh3AuSbF6 no cyclization 
occurred even after the reaction was refluxed for 12 hours. Lastly in an attempt to access 
piperidines, insertion product 7d was synthesized and exposed to PPh3AuSbF6, however no 
cyclization occurred with this substrate either (Scheme 3.14b).  
Given the results from the control experiments, we decided to probe the reaction 
mechanism using deuterium labeling experiments with 2-tetralone diazocarbonyl 1a and 
methylbenzoylacetate diazocarbonyl 1c (Scheme 3.15). When the deuterium labeling 
experiment was completed with 2-tetralone diazocarbonyl and the deuterated 
aminoalkyne, the desired product 3k was obtained in 62% yield, proving there was no effect 
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of deuterium on the overall reaction efficiency. However, deuterium scrambling was 
observed with only 67% deuterium incorporation in the final product 3k. This observation 
 
Scheme 3.14. a) Insertion products exposed to Conia-ene cyclization conditions; b) 
Attempted cyclizations for non-terminal and 6-membered alkynes. 
 
was inconsistent with studies in our synthesis of spiroethers conducted earlier within this 
chapter and also studies completed by Toste et al. in their original identification of cationic 
Au(I) catalysis for Conia-ene cyclizations.[12b] When the experiment was conducted using 
diazocarbonyl 1c, deuterium scrambling was also observed, although in a lessened manner 
with 80% deuterium incorporation in the final product 3l. The results of these experiments 
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suggest the possibility of a Au(I)-acetylide as a reactive intermediate that is in equilibrium 
with an alkyne-p-complex with Au(I), and the equilibrium prefers the alkyne-p-complex 
with Au(I). 
 
Scheme 3.15. Deuterium labeling studies. 
 
 These findings allow us to propose a reaction mechanism that is similar to the 
mechanism observed with spiroethers (Scheme 3.16). Specifically, Rh(II) decomposes the 
diazocarbonyls to form a Rh(II)-carbene 1 that undergoes nitrogen addition to provide a 
zwitterionic intermediate 9, which proceeds to undergo keto–enol tautomerism to provide 
a reactive dually activated zwitterionic intermediate 11. This active zwitterionic 
intermediate proceeds to undertake a Conia-ene cyclization with the diazocarbonyl 
compounds when in the presence of a Au(I)-activated alkyne. In the stepwise mechanism, 
the zwitterionic intermediate undergoes 1,2-proton transfer to provide the insertion 
product 7 and only when this insertion product is derived from an A/A diazo will a stepwise 
Conia-ene cyclization ensue in the presence of cationic Au(I). 
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Scheme 3.16. Plausible mechanism for the stepwise and synergistic Rh(II)/Au() catalyzed 
diazo N–H insertion/Conia-ene cascade. 
 
This new method for trapping rhodium carbenes with aminoalkynes is convergent 
in nature and uses readily available starting materials for the synthesis of a variety of N-
heterocycles. An important feature of this transformation is its high chemo- and regio-
selectivity. Upon completion of this work we were able to fulfill our goal of developing a 
general method to access azaspiro-ring systems using our Rh(II)/Au(I) synergistic catalytic 
cocktail. 
 
3.4  STEPWISE ASYMMETRIC CONIA-ENE CYCLIZATION 
 A pronounced challenge during the development of the previously mentioned 
methodologies was their respective applications to an asymmetric transformation. During 
a literature survey it was realized that there were no reports of enantioselective Conia-ene 
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cyclizations for the synthess of tetrahydrofurans and pyrrolidines, although there have 
been several reports of enantioselective Conia-ene cyclizations for the synthesis of 
cyclopentanes.[16]  
 Due to the fact that the asymmetric Conia-ene cyclization has been employed in the 
synthesis of a variety of complex molecules[17], we believed the development of an 
asymmetric Conia-ene oxo- (to access tetrahydrofurans) and aza- (to access pyrrolidines) 
cyclization would be of great value to the chemical community, even if it could not be 
accessed through a derivative of our synergistic Rh(II)/Au(I) synergistic catalytic cocktail. 
Our synergistic cocktail is dependent on an expeditious activation of our corresponding 
reactive intermediates; consequentially, this method of reactivity is not conducive to an 
enantioselective transformation. Also, non-asymmetric Conia-ene cyclizations that are 
catalyzed by metal-based Lewis acids are efficient because they proceed through pure 
alkyne activation and when asymmetric variants of these known transformations were 
investigated, it was realized that a lack of enantioselectivity is achieved due to the poor 
transmission of ligand chirality as a consequence of the linear geometry of the alkyne-metal 
complex.[16c] Therefore, to induce adequate levels of enatioselectivity in the Conia-ene 
cyclization of carbonyl and dicarbonyl compounds, it is necessary to create a chiral enolate 
that would attack the alkyne.[16b]  
 
3.4.1  OPTIMIZATION OF ASYMMETRIC CATALYTIC CONDITIONS 
 Although there are many non-enantioselective protocols for the Conia-ene carbo-
cyclization which use a wide range of Lewis acid metal complexes, asymmetric methods are 
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scarce and typically rely on the activation of a metallic complex with a chiral ligand. The 
first report of a transformation of this kind came from Toste et al. in which they developed 
an asymmetric Pd(II) DTBM-SegPhos complex with Yb(OTf)3 as a co-catalyst.[16c] 
Subsequently, a system using La(OiPr)3/AgOAc and a peptide-based ligand was developed 
by Shibasaki et al.[16e] Next, Enders et al. identified a AgNTf2/quinidine combination and a 
(CuOTf)2-tol/cinchona complex that both enabled the enantioselective Conia-ene 
cyclization, respectively.[16b] Lastly White et al. obtained excellent results with their 
application of an iron-salene complex to achieve the desired transformation.[16a] 
 
Table 3.5. Optimizatin of Asymmetric Stepwise Conia-ene Cyclization 
 
entry Lewis Acid/Chiral Ligand solvent Yield (% ee) 
1 R-BINAP(AuOTf)2 CH2Cl2 48 (24) 
2 (CuOTf)2-tol/cinchona ligand CH2Cl2 76 (33) 
3 R-DTBM-SegPhos[Pd(OTf)2] ether 95 (83) 
All optimization reactions were performed by adding 8a (1 equiv.) to a solution of the Lewis Acid 
(10 mol%) in 0.1 M of the appropriate solvent. The reaction was then stirred overnight until 
visualized as complete by thin layer chromatography. 
 
 Inspired by the reports in the literature, we set out determine the applicability of a 
select number of these systems with our insertion substrate 8a, that was accessed through 
the Rh2(esp)2 catalyzed O–H insertion of 3-butynol into methylbenzoylacetate 
diazocarbonyl (Table 3.5). As a means of setting a proper basis for our initial studies, we 
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examined chiral Au(I) catalysis through the use of R-BINAP(AuOTf)2. This chiral Au(I) 
complex gave us the desired cyclization in a 48% yield and a mediocre 24% ee (Table 3.5, 
entry 1). Next, we applied the (CuOTf)2-tol/cinchona complex reported by Enders et al., 
these conditions increased the yield to 77% but the ee remained mediocre at 33% (Table 
3.5, entry 2). Lastly, we applied the Pd(II) DTBM-SegPhos complex with Yb(OTf)3 in ether 
that was developed by Toste et al. (Table 3.5, entry 3). This system provided great results 
with a 95% yield and 83% ee. When this system was applied to the corresponding N–H 
insertion product, the desired compound was isolated in a 64% yield and 81% ee (Scheme 
3.17). 
 
Scheme 3.17. Asymmetric synthesis of pyrollidine 6c using chiral Pd(II) catalysis. 
 
 Excited by these results and the ability to induce ee in our system, we desired to 
design a new asymmetric catalytic system that was cheaper, easier to access, and was not 
known for any prior Conia-ene type cyclizations. Although Toste’s conditions were effective 
they required a palladium complex that necessitated 5 synthetic steps to obtain. Inspired 
by the development of an asymmetric cross-dehydrogenative coupling reaction that was 
dependent on the formation of a chrial enolate and developed by the Schiedt group, we 
decided to investigate Cu(I) catalysis with readily available bisoxazoline (BOX) ligands that 
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Schiedt applied in their system.[18] BOX ligands are ideal ligands for asymmetric catalysis 
because they are accessed through a chiral amino acids, allowing them to be readily 
accessible. 
 
Table 3.6. Optimization of Cu(I)/BOX Ligand Catalyzed Conia-ene Cyclization 
 
entry BOX Ligand solvent Yield (% ee) 
1 Ligand 1 (L1) CH2Cl2 84 (47) 
2 Ligand 2 (L2) CH2Cl2 81 (83) 
3 Ligand 3 (L4) CH2Cl2 44 (34) 
4 Ligand 4 (L4) CH2Cl2 86 (91) 
5 Ligand 4 (L4) toluene 47 (28) 
6 Ligand 4 (L4) ether 25 (43) 
7 Ligand 4 (L4) CHCl3 87 (93) 
All optimization reactions were performed by adding 8a (1 equiv.) to a solution of the (CuOTf)2-tol 
(10 mol%) and Ligand (12 mol%) in 0.1 M of the appropriate solvent. The reaction was then stirred 
overnight until visualized as complete by thin layer chromatography. 
 
To initiate our studies we synthesized a variety of BOX ligands using known 
synthetic protocols.[18-19] First, we complexed ligand L1 with (CuOTf)2-tol in 
dicholoromethane and allowed that solution to stir for 15 minutes before adding our 
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insertion compound 8a. After stirring overnight, the desired compound 9a was obtained in 
87% yield but only 47% ee. Next, we used the same conditions with ligand L2 that has more 
steric bulk, this ligand increased the ee to 83%. Inspired by previous works showing the 
impeccable stereo-induction of spiro-BOX ligands such as L3[19b, 19c], we applied this ligand 
to our system. However, the reaction was extremely sluggish and provided the desired 
product in a mediocre 34% ee. Lastly, we were curious about the impact of a cyclopropane 
backbone on our optimal ligand. The inclusion of this scaffold would decrease the “bite-
angle” of our catalyst/ligand complex and thereby increase the steric crowding of the 
system. Gratifyingly, when ligand L4 was applied in our system the ee increased to 91%. 
Next, we screened the effect of different solvents and chloroform increased the ee to 93%. 
When this system was applied to the corresponding N–H insertion product 7b, the desired 
compound was isolated in 81% yield and 94% ee (Scheme 3.18).  
 
Scheme 3.18. Asymmetric synthesis of pyrollidine 6c using chiral Cu(I) catalysis. 
 
 In conclusion, we have identified a (CuOTf)2/BOX ligand complex that effectively 
induces asymmetry in the Conia-ene oxo- and aza-cyclizations to provide chiral 
tetrahydrofurans and pyrollidines. This catalytic system allows for the asymmetric 
installation of quaternary centers and generates an alkene that can be further manipulated 
O
OMe
O
Ph
N
O
OMe
O
Ph
N
7b 6c,	81%
94%	ee
Ph
Ph(CuOTf)2-tol/Ligand	4
CHCl3,	rt
CH. 3 – Rh(II)/Au(I) Catalyzed Synthesis of Spiroethers and Azaspiro-Ring Systems 148 
for valuable transformations. Further applications of this system will be reported in due 
course. 
 
3.5  SUMMARY 
 After completion of the work within this chapter, we developed strategies to 
prepare spiroethers[14] and azaspiro-ring systems[20] from readily available starting 
materials and easily accessible diazocarbonyl compounds. Difficulties in preparing certain 
substrates led us to explore different catalytic conditions, temperatures, and reagent 
addition methods. Prompted by several mechanistic probing experiments, we were able to 
identify a differing mode of reactivity for O–H insertion/Conia-ene cyclizations as compared 
to N–H insertion/Conia-ene cyclizations. Enantioselective variants of this transformation 
were also explored. Results from the asymmetric experiments for the synthesis of 
spiroethers provided insight into the difficulty of inducing ee using chiral Rh(II) salts, 
however, the use of chiral Au(I) complexes provided preliminary ee data and valuable 
understanding of the transition state involved in this transformation. Due to our desire to 
synthesize chiral tetrahydrofurans and pyrrolidines, we were able to identify a Cu(I)/chiral 
bisoxazoline catalytic combination that enabled the stepwise enantioselective Conia-ene 
cyclization in ee’s as high as 93%. 
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3.7  EXPERIMENTAL SECTION 
3.7.1  GENERAL PRODCEDURE OF O–H INSERTION/CONIA ENE FOR A/D DIAZOS 
In a 15 mL round bottom flask, powdered 4Å molecular sieves (100 mg/mmol of diazo) 
were activated via heat and cooled to room temperature under vacuum.  Rh2(TFA)4 (1 
mol%), AgOTf (5 mol%), and PPh3AuCl (5 mol%) were added, and dissolved in a solution of 
dry dichloromethane (0.2M).  The flask was sealed and cooled to 0 ºC in an ice water bath.  
In a separate 4 mL vial, alkynol (1 equiv.) and N-methylisatin diazo (1.2 equiv.) were 
dissolved together in dry dichloromethane (0.1M) and taken into a syringe.  The 
diazo/alkynol solution was then added to the catalytic mixture dropwise via syringe pump 
at a rate of 1 mL/hr.  Once addition was complete, the reaction was diluted with 
dichloromethane (20 mL) and quenched with a saturated solution of sodium bicarbonate.  
The aqueous layer was extracted, and combined organics were dried over sodium sulfate, 
filtered, and concentrated.  Crude NMR was analyzed, and the mixture was purified by flash 
chromatography with the designated solvent system as listed below. 
 
1'-methyl-3-methylene-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-one (3c). Prepared 
from 3-diazo-1-methylindolin-2-one and but-3-yn-1-ol using general procedure G.  orange 
oil (30 mg, 79%). TLC: Rf  0.38 (20% EtOAc in hexanes).  IR (NaCl): 3059.10, 2922.16, 
2362.80, 2339.65, 1724.36, 1614.42.  1H NMR (400 MHz) δ 7.34 – 7.32 (td, J = 7.7, 1.3 Hz, 
1H), 7.21 – 7.18 (dd, J = 7.5, 1.3 Hz, 1H), 7.09 – 7.05 (t, J = 7.5 Hz, 1H), 6.82 – 6.80 (d, J = 7.8 
N
O
O
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Hz, 1H), 5.11 – 5.10 (t, J = 2.2 Hz, 1H), 4.58 – 4.57 (t, J = 2.4 Hz, 1H), 4.53 – 4.49 (td, J = 8.1, 
6.7 Hz, 1H), 4.28 – 4.23 (td, J = 7.9, 5.9 Hz, 1H), 3.16 (s, 3H), 3.13 – 3.07 (m, 1H), 2.93 – 2.85 
(m, 1H). 13C NMR (101 MHz) δ 169.5, 149.4, 144.6, 129.9, 129.5, 125.3, 124.8, 123.2, 123.0, 
108.6, 108.2, 68.1, 32.9, 26.2 HRMS (ESI) m/z calcd for C13H13NO2Na ([M+Na]+) 238.0844; 
found 238.0835. 
 
1'-methyl-3-methylene-5-phenyl-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-one (3d). 
Prepared from 3-diazo-1-methylindolin-2-one and 1-phenylbut-3-yn-1-ol using general 
procedure G.  Orange oil (55 mg, 70%). TLC: Rf  0.59 (20% EtOAc in hexanes). IR (NaCl): 
3062, 2953, 2926, 2854, 2594, 2358, 2341, 1728, 1614, 1558, 1494, 1571, 1373, 1255, 1097, 
1026, 1004, 937, 777, 754, 698.  1H NMR (500 MHz) δ 7.67 – 7.66 (m, 1H), 7.42 – 7.35 (m, 
2H), 7.13 – 7.10  (t, J = 7.5 Hz, 0H), 6.85 – 6.83 (d, J = 7.8 Hz, 1H), 5.33 – 5.30 (dd, J = 11.0, 
5.3 Hz, 1H), 5.15 – 5.14 (d, J = 2.7 Hz, 1H), 4.58 – 4.57 (d, J = 2.9 Hz, 1H), 3.33 –3.27 (ddt, J 
= 14.2, 11.0, 2.9 Hz, 1H), 3.21 (s) 3.13 – 3.07 (dd, J = 14.7, 5.3 Hz, 1H). 13C NMR (126 MHz) 
δ 168.5, 145.6, 134.8, 129.9, 128.1, 126.9, 125.0, 123.2, 108.9, 108.1, 82.2, 42.5, 26.4. LRMS 
(ESI) m/z calcd for C19H17NO2Na ([M+Na]+) 314.1157; found 314.1151. 
 
N
O
O
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1'-methyl-3-methylene-4-phenyl-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-one (3e). 
Prepared from 3-diazo-1-methylindolin-2-one and 2-phenylbut-3-yn-1-ol using general 
procedure G.  Orange oil (25 mg, 68%). TLC: Rf  0.41 (20% EtOAc in hexanes). IR (NaCl): 
3057, 3028, 2920, 2893, 2850, 2360, 2343, 1722, 1614, 1492, 1469, 1369, 1348, 1246, 1095, 
1039, 1018, 906, 754, 700.  1H NMR (500 MHz) δ 7.41 – 7.30 (m, 7H), 7.12 – 7.08 (td, J = 
7.5, 1.0 Hz, 1H), 6.85 – 6.83 (dt, J = 7.7, 0.7 Hz, 1H), 4.87 – 4.84 (t, J = 8.4 Hz, 1H), 4.77 – 
4.76  (d, J = 2.5 Hz, 1H), 4.66 – 4.65 (d, J = 2.8 Hz, 1H), 4.51 – 4.47 (tt, J = 8.2, 2.7 Hz, 1H), 
4.27 – 4.25 (t, J = 8.1 Hz, 1H), 3.19 (s, 3H). 13C NMR (126 MHz) δ 167.2, 153.7, 144.6, 140.0, 
130.1, 128.8, 128.6, 127.9, 127.1, 125.2, 123.3, 110.6, 108.3, 77.3, 75.4, 49.9, 26.3. HRMS 
(ESI) m/z calcd for C19H17NO2Na ([M+Na]+) 314.1157; found 314.1152. 
 
 
 
5'-chloro-1'-methyl-3-methylene-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-one (3f). 
Prepared from 5-chloro-3-diazo-1-methylindolin-2-one and 3-butyn-1-ol using general 
procedure G. Orange oil (27 mg, 90%). TLC: Rf  0.25 (30% EtOAc in hexanes).  IR (NaCl): 2958, 
N
O
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2920, 2891, 2358, 2331, 1780, 1610, 1489, 1429, 1359, 1342, 1263, 1195, 1103, 1033, 981, 
900, 812, 742.  1H NMR (500 MHz) δ 7.31 (dd, J = 8.3, 2.1 Hz, 1H), 7.19 (dd, J = 2.1, 0.4 Hz, 
1H), 6.75 (d, J = 8.3 Hz, 1H), 5.15 (t, J = 2.2 Hz, 1H), 4.60 (t, J = 2.3 Hz, 1H), 4.51 (td, J = 8.1, 
6.6 Hz, 1H), 4.26 (td, J = 7.9, 5.9 Hz, 1H), 3.16 (s, 3H), 3.11 (dddt, J = 15.5, 8.3, 6.0, 2.4 Hz, 
1H), 2.89 (dddt, J = 15.4, 7.7, 6.6, 2.1 Hz, 1H).13C NMR (126 MHz) δ 176.3, 148.9, 143.1, 
134.2, 134.1, 131.1, 129.8, 129.3, 129.2, 128.5, 125.3, 109.2, 109.0, 68.4, 32.8, 26.3. HRMS 
(ESI) m/z calcd for C13H12ClNNaO2 ([M+Na]+) 272.0454; found . 
 
5'-chloro-1'-methyl-3-methylene-5-phenyl-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-
one (3g). Prepared from 5-chloro-3-diazo-1-methylindolin-2-one and 1-phenylbut-3-yn-1-
ol using general procedure G.  Orange oil (18 mg, 66%). TLC: Rf  0.71 (30% EtOAc in 
hexanes).  IR (NaCl): 3427.5, 3298.3, 3049.5, 2926.01, 2353.2, 1728.2, 1612.5.  1H NMR (500 
MHz) δ 7.66 – 7.63 (m, 2H), 7.42 – 7.36 (m, 4H), 7.34 – 7.33 (p, J = 1.5 Hz, 3H), 6.78 – 6.76 
(d, J = 8.2 Hz, 1H), 5.32 – 5.29 (dd, J = 11.0, 5.3 Hz, 1H), 5.18 – 5.17 (dd, J = 2.9, 1.1 Hz, 1H), 
4.60 (dd, J = 3.0, 0.8 Hz, 1H), 3.32 – 3.25 (ddt, J = 14.1, 11.0, 2.9 Hz, 1H), 3.20 (s, 3H), 3.12 
– 3.07 (ddt, J = 14.7, 5.4, 1.0 Hz, 1H). 13C NMR (126 MHz) δ 171.8, 149.1, 143.2, 140.6, 131.3, 
129.9, 128.5, 128.3, 128.2, 128.0, 126.9, 125.7, 125.5, 109.9, 109.3, 109.2, 82.4, 72.3, 70.9, 
42.4, 29.5, 26.5. HRMS (ESI) m/z calcd for C19H16ClNO2Na ([M]+) 325.0870; found 326.0949. 
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5'-chloro-1'-methyl-3-methylene-4-phenyl-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-
one (3h). Prepared from 5-chloro-3-diazo-1-methylindolin-2-one and 2-phenylbut-3-yn-1-
ol using general procedure G.  Orange oil (14 mg, 60%). TLC: Rf  0.52 (20% EtOAc in 
hexanes).  IR (NaCl): 2931.8, 2858.5, 2362.8, 2349.3, 1728.2.  1H NMR (500 MHz) δ 7.44 – 
7.30 (m, 5H), 7.25 (d, J = 2.1 Hz, 1H), 6,80 – 6.78 (d, J = 8.3 Hz, 1H), 4.88 – 4.84 (t, J = 8.4 Hz, 
1H), 4.80 – 4.79 (d, J = 2.5 Hz, 1H), 4.69 – 4.68 (d, J = 2.8 Hz, 1H), 4.52 – 4.49 (tt, J = 8.3, 2.7 
Hz, 1H), 4.27 – 4.24 (t, J = 8.2 Hz, 1H), 3.19 (s, 3H). 13C NMR (126 MHz) δ 175.8, 153.2, 143.1, 
139.4, 130.9, 130.0, 128.8, 128.6, 128.5, 127.2, 125.6, 110.9, 109.2, 75.5, 49.8, 29.7, 26.4.  
HRMS (ESI) m/z calcd for C19H16ClNO2Na ([M+Na]+) 348.0767; found 348.0753. 
 
 
 
5'-methoxy-1'-methyl-3-methylene-4-phenyl-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-
2'-one (3i). Prepared from 3-diazo-5-methoxy-1-methylindolin-2-one and 2-phenylbut-3-
yn-1-ol using general procedure G.  Orange oil (5 mg, 63%). TLC: Rf  0.42 (20% EtOAc in 
hexanes).  IR (NaCl): 3429.4, 3400.5, 2922.2, 2856.6, 2366.6, 2341.6, 1724.4.  1H NMR (500 
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MHz) δ 7.44 – 7.26 (m, 5H), 6.89 – 6.87 (m, 2H), 6.79 – 6.73 (m, 1H), 4.88 – 4.86 (t, J = 8.4 
Hz, 1H), 4.79 – 4.78 (d, J = 2.5 Hz, 1H), 4.69 – 4.68 (d, J = 2.8 Hz, 1H), 4.52 – 4.48 (tt, J = 8.3, 
2.7 Hz, 1H), 4.28 – 4.25 (t, J = 8.0 Hz, 1H), 3.81 (s, 3H), 3.18 (s, 2H).   13C NMR (126 MHz) δ 
176.1, 156.4, 139.8, 134.0, 114.3, 112.3, 109.9, 108.6, 75.3, 65.8, 55.8, 49.8, 29.7, 26.3, 
15.2. HRMS (ESI) m/z calcd for C23H19NO3Na ([M+Na]+) 344.1263; found 344.1246. 
 
1'-methyl-3-(methylene-d)-5-phenyl-4,5-dihydro-3H-spiro[furan-2,3'-indolin]-2'-one 
(3p). Prepared from 3-diazo-1-methylindolin-2-one and 1-phenylbut-3-yn-4-d-1-ol using 
general procedure H.  Orange oil (14 mg, 70%). TLC: Rf  0.59 (20% EtOAc in hexanes).  IR 
(NaCl): 3057, 3028, 2924, 2981, 2854, 2358, 2339, 1722, 1614, 1558, 1539, 1494, 1469, 
1369, 1346, 1240, 1093, 1035, 958, 848, 754, 698.  1H NMR (500 MHz) δ 7.67 – 7.66 (m, 
1H), 7.42 – 7.35 (m, 2H), 7.13 – 7.10  (t, J = 7.5 Hz, 0H), 6.85 – 6.83 (d, J = 7.8 Hz, 1H), 5.33 
– 5.30 (dd, J = 11.0, 5.3 Hz, 1H), 5.15 – 5.14 (d, J = 2.7 Hz, 1H), 4.58 – 4.57 (d, J = 2.9 Hz, 0.06 
H), 3.33 –3.27 (ddt, J = 14.2, 11.0, 2.9 Hz, 1H), 3.21 (s) 3.13 – 3.07 (dd, J = 14.7, 5.3 Hz, 1H). 
13C NMR (126 MHz) δ 168.5, 145.6, 134.8, 129.9, 128.1, 126.9, 125.0, 123.2, 108.9, 108.1, 
82.2, 42.5, 26.4. HRMS (ESI) m/z calcd for C19H16DNO2Na ([M+Na]+) 315.1220; found 
314.1219. 
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3.7.2  GENERAL PRODCEDURE OF O–H INSERTION/CONIA ENE FOR A/A DIAZOS 
To a 4.0 mL vial equipped with a magnetic stir bar was added powdered 4Å molecular sieves 
(70 mg/ mL solvent).  The molecular sieves were activated via heat and allowed to cool to 
room temperature under vacuum.  Rh2(esp)2 (1 mol %), AuClPPh3 (10 mol %), and AgSbF6 
(10 mol %) were then measured directly into the reaction vessel.  A solution of alkynol (1.2 
equiv.) and diazo (1.0 equiv.)  in dichloromethane (0.3M)  was added, and the mixture was 
sonicated for 30 seconds.   The reaction vessel was sealed, and heated to 60 ºC.   The 
reaction was monitored by TLC until complete consumption of diazo was observed 
(between 30 minutes – 5 h).  The crude reaction mixture was then cooled to room 
temperature, filtered through a pad of celite, concentrated, and analyzed via 1H NMR. The 
crude mixture was then purified via flash chromatography to furnish spirocyclic 
compounds.  
 
 
 
8,8-dimethyl-4-methylene-1,7,9-trioxaspiro[4.5]decane-6,10-dione (3j). Prepared from 5-
diazo-2,2-dimethyl-1,3-dioxane-4,6-dione and but-3-yn-1-ol using general procedure F 
(Conversion of Diazo observed in 30 minutes).  Clear oil (20 mg, 42%). TLC: Rf  0.6 (20% 
EtOAc in hexanes). IR (NaCl): 2957, 2918, 2850, 2359, 2340, 1732, 1714, 1633, 1608, 1558, 
1539, 1489, 1456, 1384, 1211, 1097, 1010, 939.  1H NMR (500 MHz) δ 5.37 – 5.35 (q, J = 2.0 
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Hz, 1H), 5.27 – 5.26 (q, J = 2.1 Hz, 1H), 4.44 – 4.41 (t, J = 7.1 Hz, 2H), 2.92 – 2.89 (tt, J = 7.1, 
2.2 Hz, 2H), 1.83 – 1.82 (d, J = 4.5 Hz, 6H). 13C NMR (126 MHz) δ 167.3, 149.5,  109.9, 106.0, 
71.4, 32.6, 30.5, 27.3. HRMS (ESI) m/z calcd for C10H12O5Na ([M+Na]+) 235.0582; found 
235.0578. 
 
8,8-dimethyl-4-methylene-3-phenyl-1,7,9-trioxaspiro[4.5]decane-6,10-dione (3k). 
Prepared from 5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dione and 2-phenylbut-3-yn-1-ol 
using general procedure F (Conversion of Diazo observed in 30 minutes).  Clear oil (12 mg, 
40%). TLC: Rf  0.75 (20% EtOAc in hexanes). IR (NaCl): 3004, 2980, 2918, 2950, 2359, 2341, 
1791, 1761, 1683, 1558, 1494, 1394, 1292, 1199, 1118, 1029, 999, 914, 700.  1H NMR (500 
MHz) δ 7.39 – 7.30 (m, 5H), 5.36 – 5.35 (ddd, J = 3.1, 1.9, 0.6 Hz, 1H), 4.96 – 4.95 (dd, J = 
2.8, 1.9 Hz, 1H), 4.76 – 4.74 (td, J = 8.3, 0.5 Hz, 1H), 4.43 – 4.42 (dd, J = 10.4, 8.2 Hz, 1H), 
4.27 – 4.22 (ddt, J = 10.6, 8.5, 2.9 Hz, 1H), 1.87 – 1.85 (m, 6H). 13C NMR (126 MHz) δ 167.6, 
166.9, 154.2, 129.1, 128.9, 127.7, 111.4, 106.2, 78.2, 50.4, 30.6, 27.3. HRMS (ESI) m/z calcd 
for C16H16O5Na ([M+Na]+) 311.0895; found 311.0894. 
 
 
8,8-dimethyl-4-methylene-2-phenyl-1,7,9-trioxaspiro[4.5]decane-6,10-dione (3l). 
Prepared from 5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dione and 1-phenylbut-3-yn-1-ol 
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using general procedure F (Conversion of Diazo observed in 30 minutes).  Clear oil (24 mg, 
32%). TLC: Rf  0.80 (20% EtOAc in hexanes). IR (NaCl): 3052, 2920, 2850, 2358, 2341, 1791, 
1759, 1683, 1558, 1456, 1394, 1386, 1284, 1197, 1118, 1012, 916, 700.  1H NMR (500 MHz) 
δ 7.57 – 7.55 (m, 2H), 7.42 – 7.33 (m, 3H), 5.55 – 5.52 (dd, J = 10.5, 5.8 Hz, 1H), 5.38 – 5.37 
(dt, J = 2.9, 1.5 Hz, 1H), 5.30 – 5.29 (dt, J = 3.1, 1.5 Hz, 1H), 3.18 – 3.13 (ddt, J = 15.5, 5.7, 
1.4 Hz, 1H), 2.99 – 2.93 (ddt, J = 15.4, 10.5, 2.9 Hz, 1H), 1.85 – 1.83 (d, J = 9.9 Hz, 6H). 13C 
NMR (126 MHz) δ 167.8, 167.0, 149.5, 139.3, 128.6, 128.6, 126.7, 109.9, 109.9, 106.1, 84.6, 
82.1, 41.5, 30.6, 27.4. HRMS (ESI) m/z calcd for C16H16O5Na ([M+Na]+) 311.0895; found 
311.0895. 
 
7,9-dimethyl-4-methylene-1-oxa-7,9-diazaspiro[4.5]decane-6,8,10-trione (3m). Prepared 
from 5-diazo-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and 3-butyn-1-ol using 
general procedure F (Conversion of Diazo observed in 40 minutes). cloudy oil (40 mg, 55%). 
TLC: Rf  0.43 (30% EtOAc in hexanes). IR (NaCl): 2858.5, 2358.9, 2339.7, 1670.6.  1H NMR 
(400 MHz) δ 5.25 – 5.24 (q, J = 2.1, 1.5 Hz, 1H), 5.00 – 4.99 (q, J = 2.2 Hz, 1H), 4.47 – 4.43 
(td, J = 7.1, 1.2 Hz, 2H), 3.47 – 3.40 (d, J = 1.0 Hz, 6H), 2.86 – 2.81 (tdd, J = 6.9, 2.5, 1.6 Hz, 
2H). 13C NMR (101 MHz) δ 168.1, 159.4, 155.0, 149.0, 108.3, 78.9, 70.9, 32.4, 31.5, 29.4, 
29.2. HRMS (ESI) m/z calcd for C16H16N2O4Na ([M+Na]+) 247.0695; found 247.0698. 
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7,9-dimethyl-4-methylene-3-phenyl-1-oxa-7,9-diazaspiro[4.5]decane-6,8,10-trione (3n). 
Prepared from 5-diazo-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and 2-phenylbut-3-
yn-1-ol using general procedure F (Conversion of Diazo observed in 40 minutes).  Cloudy oil 
(75 mg, 62%). TLC: Rf  0.63 (30% EtOAc in hexanes). IR (NaCl): 3061, 3030, 2958, 2899, 2852, 
2361, 2342, 1759, 1693, 1681, 1602, 1446, 1377, 1280, 1163, 1068, 908, 7541H NMR (500 
MHz) δ 7.35– 7.17 (m, 5H), 5.11 – 5.10 (ddd, J = 2.9, 2.1, 0.5 Hz, 1H), 4.85 – 4.84 (dd, J = 2.8, 
2.1 Hz, 1H), 4.81 – 4.78 (t, J = 8.4 Hz, 1H), 4.51 – 4.47 (dd, J = 10.3, 8.2 Hz, 1H), 4.21 – 4.16 
(m, 1H), 3.39 (s 3H), 3.37 (s 3H). 13C NMR (126 MHz) δ 168.5, 167.4, 153.8, 150.9, 137.1, 
128.9, 128.9, 128.3, 127.6, 109.7, 84.2, 77.7, 72.6, 67.5, 50.2, 29.4, 29.1. HRMS (ESI) m/z 
calcd for C16H16N2O4Na ([M+Na]+) 323.1008; found 323.1013. 
 
7,9-dimethyl-4-methylene-2-phenyl-1-oxa-7,9-diazaspiro[4.5]decane-6,8,10-trione (3o).  
Prepared from 5-diazo-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and (S)-1-
phenylbut-3-yn-1-ol using  general procedure F (Conversion of Diazo observed in 1 hour).  
Faint yellow oil (21 mg, 60%).  [α]21D –2.4 (c = 0.005, CHCl3).  TLC : Rf 0.73 (50% Ethyl acetate 
in hexanes).  IR (NaCl): 3056, 2920, 2850, 2360, 2330, 1732, 1693, 1681, 1558, 1435, 1375, 
1281, 1068, 985, 754, 700.  1H NMR (500 MHz) δ 7.65 – 7.61 (m, 2H), 7.42 – 7.31 (m, 3H), 
5.57 (dd, J = 10.5, 5.7 Hz, 1H), 5.26 (m, 1H), 5.02 (m, 1H), 3.38 (d, J = 2.7 Hz, 6H), 3.12 – 3.05 
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(m, 1H), 2.88 (ddt, J = 15.4, 10.5, 2.9 Hz, 1H).  13C NMR (126 MHz) δ 168.7, 149.3, 139.9, 
128.6, 128.4, 126.6, 108.3, 83.9, 41.5, 29.4, 29.2.  HRMS (ESI) m/z calcd for C16H16N2O4Na 
([M+Na]+) 323.1008; found 323.1014. 
 
7,9-dimethyl-4-methylene-2-phenyl-1-oxa-7,9-diazaspiro[4.5]decane-6,8,10-trione (3q).  
Prepared from 5-diazo-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and (R)-1-
phenylbut-3-yn-1-ol using general procedure F (Conversion of Diazo observed in 1 hour).  
Faint yellow oil (22 mg, 61%).  [α]21D –2.3 (c = 0.007, CHCl3).  TLC : Rf 0.73 (50% Ethyl acetate 
in hexanes).  IR (NaCl): 3042, 2956, 2922, 2852, 2358, 2339, 1693, 1579, 1454, 1438, 1375, 
1280, 1134, 1068, 985, 754, 731, 700.  1H NMR (400 MHz) δ 7.63 (d, J = 7.4 Hz, 2H), 7.44 – 
7.24 (m, 3H), 5.58 (d, J = 12.4 Hz, 1H), 5.26 (s, 1H), 5.03 (s, 1H), 3.38 (d, J = 2.2 Hz, 6H), 3.10 
(dd, J = 15.3, 5.7 Hz, 1H), 2.94 – 2.83 (m, 1H).  13C NMR (126 MHz) δ 168.7, 167.7, 151.0, 
149.3, 139.9, 128.6, 128.4, 128.3, 126.6, 108.3, 83.9, 41.5, 29.4, 29.2.  HRMS (ESI) m/z calcd 
for C16H16N2O4Na ([M+Na]+) 323.1008; found 323.0992. 
 
3.7.3  GENERAL PRODCEDURE FOR PYRROLIDINES 6a–6c, 6k 
To a 4.0 mL vial equipped with a magnetic stir bar was added Rh2(esp)2 (1 mol %), PPh3AuCl 
(10 mol %), and AgSbF6 (10 mol %) directly into the reaction vessel.  A solution of (but-3-
yn-1-yl)-aniline (1.1 equiv.) was then added.  Lastly, the diazo (1.0 equiv.) in 
dichloromethane (0.3M)  was added. The reaction vessel was sealed, and allowed to stir at 
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room temperature until bubbling ceased and the diazo was consumed via TLC 
(approximately 30 minutes). Once the reaction was complete, the crude reaction mixture 
was filtered through a slurry of celite/silica gel, concentrated, and analyzed via crude 1H 
NMR. The crude mixture was then purified via flash chromatography to furnish 
functionalized spiropyrrolidines. 
 
3'-methylene-1'-phenyl-3,4-dihydro-2H-spiro[naphthalene-1,2'-pyrrolidin]-2-one (6a). 
Prepared from 1-diazo-3,4-dihydronaphthalen-2(1H)-one and N-(but-3-yn-1-yl)aniline 
(Reaction time = 10 minutes) Yellow oil (32 mg, 60%). TLC :  Rf 0.52 (20% ethyl acetate in 
hexanes). IR (NaCl): 3289, 3065, 2922, 2859, 2367, 2320, 1719. 1H NMR (500 MHz, CDCl3) δ 
7.23 (td, J = 7.3, 1.5 Hz, 1H), 7.18 – 7.12 (m, 1H), 7.10 (dd, J = 7.9, 1.5 Hz, 1H), 7.06 – 6.99 
(m, 2H), 6.59 (tt, J = 7.3, 1.0 Hz, 1H), 6.29 (dt, J = 7.8, 1.0 Hz, 2H), 5.15 (dd, J = 2.6, 1.3 Hz, 
1H), 4.61 (dd, J = 2.9, 1.2 Hz, 1H), 3.95 – 3.85 (m, 2H), 3.49 – 3.16 (m, 4H), 3.03 – 2.88 (m, 
1H), 2.84 – 2.75 (m, 1H), 2.74 – 2.62 (m, 1H).  13C NMR (151 MHz, CDCl3) δ 207.6, 152.9, 
145.1, 140.0, 135.6, 128.6 (2C), 128.1, 127.8, 127.7, 127.3 (2C), 116.7, 113.7 (2C), 111.6, 
49.02, 36.73, 29.89, 28.62. LRMS (ESI) m/z calcd for C20H19NONa ([M+Na]+) 312.13; found 
312.14. 
 
O
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3'-methylene-1'-phenyl-10H-spiro[phenanthrene-9,2'-pyrrolidin]-10-one (6b). Prepared 
from 10-diazophenanthren-9(10H)-one and N-(but-3-yn-1-yl)aniline (Reaction time = 10 
minutes). Yellow oil (33 mg, 62%). TLC : Rf 0.55 (20% ethyl acetate in hexanes).  IR (NaCl): 
3065, 3036, 2959, 2926, 2363, 2350, 1684. 1H NMR (600 MHz, CDCl3) δ 8.13 (d, J = 8.1 Hz, 
1H), 8.10 – 8.05 (m, 2H), 7.73 (td, J = 7.7, 1.5 Hz, 1H), 7.46 – 7.40 (m, 1H), 7.37 (td, J = 8.0, 
7.6, 1.4 Hz, 1H), 7.31 (dd, J = 7.9, 1.3 Hz, 1H), 7.23 (d, J = 7.0 Hz, 1H), 7.00 (dd, J = 8.5, 7.2 
Hz, 2H), 6.61 – 6.53 (m, 1H), 6.26 (d, J = 8.1 Hz, 2H), 4.86 (t, J = 2.1 Hz, 1H), 4.54 (t, J = 2.1 
Hz, 1H), 4.03 (td, J = 8.2, 6.8 Hz, 1H), 3.99 (td, J = 8.9, 4.9 Hz, 1H), 3.06 – 2.97 (m, 1H), 2.89 
– 2.82 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 197.1, 150.1, 145.2, 141.4, 137.4, 134.8 (2C), 
129.9, 129.8, 128.7, 128.5 (2C), 128.2, 127.9, 127.0, 124.0, 123.1, 116.7, 114.4 (2C), 109.8, 
76.6, 49.0, 29.5.  LRMS (ESI) m/z calcd for C24H19NONa ([M+Na]+) 360.13; found 360.14. 
 
1'-(4-methoxyphenyl)-3'-methylene-3,4-dihydro-2H-spiro[naphthalene-1,2'-pyrrolidin]-
2-one (6c). Prepared from 1-diazo-3,4-dihydronaphthalen-2(1H)-one and N-(but-3-yn-1-
yl)-4-methoxyaniline (Reaction time = 10 minute). Yellow oil (70 mg, 65%). TLC : Rf 0.60 
(30% ethyl acetate in hexanes). IR (NaCl): 2926, 2859, 2359, 2324, 2124, 1792, 1753. 1H 
NMR (500 MHz, CDCl3) δ 7.29 – 7.21 (m, 2H), 7.17 – 7.15 (m, 2H), 6.70 – 6.61 (m, 2H), 6.31 
O
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– 6.19 (m, 2H), 5.13 (dd, J = 2.6, 1.4 Hz, 1H), 4.60 (dd, J = 2.9, 1.3 Hz, 1H), 3.90 – 3.84 (m, 
2H), 3.66 (s, 3H), 3.39 – 3.30 (m, 1H), 3.27 – 3.14 (m, 2H), 2.93 (dddt, J = 15.0, 10.1, 7.6, 2.7 
Hz, 1H), 2.82 – 2.74 (m, 1H), 2.69 – 2.61 (m, 1H).  13C NMR (126 MHz, CDCl3) δ 208.4, 153.2, 
151.3, 140.3, 139.8, 135.7, 128.3, 128.1, 128.0, 127.7, 127.3, 114.7 (2C), 114.4 (2C), 111.4, 
55.6, 49.4, 37.1, 30.0, 28.6.  LRMS (ESI) m/z calcd for C21H21NO2Na ([M+Na]+]) 342.14; found 
342.16. 
 
3'-(methylene-d)-1'-phenyl-3,4-dihydro-2H-spiro[naphthalene-1,2'-pyrrolidin]-2-one 
(6k). Prepared from 1-diazo-3,4-dihydronaphthalen-2(1H)-one and N-(but-3-yn-1-yl-4-
d)aniline (Reaction time = 10 minutes). Faint yellow oil (43 mg, 67%). TLC: Rf  0.77 (30% 
ethyl acetate in hexanes). IR (NaCl): 3032, 2922, 2849, 1719, 1600. 1H NMR (600 MHz, 
CDCl3) δ 7.26 (t, J = 6.7 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 7.08 (d, J = 
7.9 Hz, 1H), 7.02 (t, J = 7.9 Hz, 2H), 6.58 (t, J = 7.3 Hz, 1H), 6.27 (d, J = 8.0 Hz, 2H), 5.15 – 
5.10 (m, 1H), 4.59 (t, J = 1.8 Hz, 0.44H), 3.91 – 3.84 (m, 2H), 3.35 (dt, J = 13.8, 6.7 Hz, 1H), 
3.29 – 3.15 (m, 2H), 2.97 – 2.87 (m, 1H), 2.76 (dt, J = 15.2, 5.6 Hz, 1H), 2.72 – 2.63 (m, 1H).  
13C NMR (151 MHz, CDCl3) δ 207.6, 152.8, 152.7, 145.1, 140.0, 135.6, 135.6, 128.6, 128.3, 
128.0, 127.7, 127.7, 127.4, 116.7, 113.7, 111.6, 111.37, 111.2, 49.4, 36.7, 29.9. LRMS (ESI) 
m/z calcd for C21H21NONa ([M+Na]+) 313.14; found 313.06. 
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3.7.4  GENERAL PRODCEDURE FOR PYRROLIDINES 6d–6f, 6l 
To a 4.0 mL vial equipped with a magnetic stir bar was added Rh2(esp)2 (1 mol %) and a 
solution of (but-3-yn-1-yl)-aniline (1.1 equiv.).  The diazo (1.0 equiv.)  in dichloromethane 
(0.3M)  was added and the reaction vessel was sealed, and allowed to stir at reflux until 
bubbling ceased and the diazo was consumed via TLC (approximately 5 minutes). Once the 
insertion product had formed PPh3AuCl (10 mol %), and AgSbF6 (10 mol %) were added 
directly into the reaction vessel and this solution was allowed to stir an additional 30 
minutes until the insertion product was no longer visible on TLC and a new, more polar spot 
had formed (the cyclization product).  Once the reaction was complete, the crude reaction 
mixture was filtered through a slurry of celite/silica gel, concentrated, and analyzed via 
crude 1H NMR. The crude mixture was then purified via flash chromatography to furnish 
functionalized pyrrolidines 
 
methyl-2-benzoyl-3-methylene-1-phenylpyrrolidine-2-carboxylate (6d).  Prepared from 
methyl 2-diazo-3-oxo-3-phenylpropanoate and N-(but-3-yn-1-yl)aniline (Reaction time = 20 
minutes). Yellow oil (54 mg, 92%). TLC :  Rf 0.41 (20% ethyl acetate in hexanes). IR (NaCl): 
3059, 2949, 2916, 2849, 2320, 1740, 1678. 1H NMR (600 MHz, CDCl3) δ 7.68 (dd, J = 8.4, 1.4 
Hz, 2H), 7.35 (ddt, J = 8.8, 7.3, 1.3 Hz, 1H), 7.24 – 7.19 (m, 2H), 7.11 – 7.05 (m, 2H), 6.67 (td, 
J = 7.3, 1.0 Hz, 1H), 6.61 (dq, J = 7.3, 1.5, 1.0 Hz, 2H), 5.31 – 5.24 (m, 2H), 3.87 (dt, J = 8.9, 
7.5 Hz, 1H), 3.73 (s, 3H), 3.64 (dt, J = 8.7, 7.2 Hz, 1H), 2.98 (tt, J = 7.3, 2.3 Hz, 2H). 13C NMR 
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(151 MHz, CDCl3) δ 197.2, 169.2, 146.4, 145.1, 136.0, 132.2, 128.8 (2C), 128.7 (2C), 127.9 
(2C), 118.2, 113.7, 112.8, 80.3, 74.8, 52.7, 47.8, 30.0. LRMS (ESI) m/z calcd for C20H19NO3Na 
([M+Na]+) 344.12; found 344.15. 
 
ethyl-2-acetyl-3-methylene-1-phenylpyrrolidine-2-carboxylate (6e).  Prepared from ethyl 
2-diazo-3-oxobutanoate and N-(but-3-yn-1-yl)aniline (Reaction time = 20 minutes).  Faint 
yellow oil (50 mg, 90%). TLC :  Rf 0.44 (20% ethyl acetate in hexanes).  IR (NaCl): 2978, 2926, 
2855, 2363, 2324, 1751, 1734, 1601.  1H NMR (500 MHz, CDCl3) δ 7.25 – 7.14 (m, 2H), 6.78 
(tt, J = 7.3, 1.0 Hz, 1H), 6.56 (dt, J = 7.9, 1.0 Hz, 2H), 5.34 (td, J = 2.3, 0.7 Hz, 1H), 5.27 (td, J 
= 2.2, 0.7 Hz, 1H), 4.19 – 4.01 (m, 2H), 3.80 (ddd, J = 8.6, 7.3, 6.0 Hz, 1H), 3.64 (dt, J = 8.6, 
7.5 Hz, 1H), 2.93 – 2.83 (m, 2H), 2.13 (s, 3H), 1.07 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 202.8, 168.5, 145.4, 129.1 (2C), 118.2, 113.2 (2C), 111.4, 80.3, 61.4, 48.1, 30.6, 
26.1, 13.8. LRMS (ESI) m/z calcd for C16H19NO3Na ([M+Na]+) 296.12; found 296.14. 
 
methyl-2-benzoyl-1-(4-methoxyphenyl)-3-methylenepyrrolidine-2-carboxylate (6f). 
Prepared from methyl 2-diazo-3-oxo-3-phenylpropanoate and N-(but-3-yn-1-yl)-4-
methoxyaniline (Reaction time = 20 minutes).  Vibrant yellow oil (80 mg, 94%). TLC: Rf  0.47 
(30% ethyl acetate in hexanes). IR (NaCl): 2955, 2835, 1740, 1682. 1H NMR (600 MHz, CDCl3) 
δ 7.78 – 7.71 (m, 2H), 7.41 – 7.33 (m, 1H), 7.25 – 7.22 (m, 2H), 6.71 – 6.62 (m, 2H), 6.61 – 
NPh
O
Me
O
EtO
NPMP
O
Ph
O
MeO
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6.53 (m, 2H), 5.25 (qd, J = 2.3, 0.8 Hz, 2H), 3.82 (ddd, J = 8.7, 7.9, 6.2 Hz, 1H), 3.71 (s, 3H), 
3.66 (s, 3H), 3.58 (td, J = 8.5, 6.6 Hz, 1H), 2.99 – 2.91 (m, 2H).  13C NMR (151 MHz, CDCl3) δ 
197.3, 169.3, 152.3, 146.7, 139.3, 136.1, 132.2, 128.9 (2C), 127.9 (2C), 115.0 (2C), 114.3 
(2C), 112.8, 80.8, 55.5, 52.6, 48.2, 30.1. LRMS (ESI) m/z calcd for C21H21NO4Na ([M+Na]+) 
374.13; found 374.52. 
 
methyl-2-benzoyl-3-(methylene-d)-1-phenylpyrrolidine-2-carboxylate (6l). Prepared 
from methyl 2-diazo-3-oxo-3-phenylpropanoate and N-(but-3-yn-1-yl-4-d)aniline (Reaction 
time = 20 minutes). Yellow oil (50 mg, 95%). TLC: Rf  0.59 (30% ethyl acetate in hexanes). IR 
(NaCl): 3059, 2949, 2855, 2363, 1748, 1680. 1H NMR (500 MHz, benzene d6) δ 7.85 – 7.74 
(m, 2H), 7.06 – 6.99 (m, 2H), 6.94 – 6.84 (m, 3H), 6.83 – 6.77 (m, 2H), 6.61 (ddt, J = 8.4, 7.4, 
1.1 Hz, 1H), 5.34 (t, J = 2.2 Hz, 0H), 4.93 – 4.88 (m, 1H), 3.44 (dq, J = 11.4, 4.3, 2.4 Hz, 1H), 
3.37 (s, 3H), 3.29 (td, J = 9.0, 5.3 Hz, 1H), 2.54 (ddt, J = 10.9, 8.6, 4.3 Hz, 1H), 2.46 – 2.36 (m, 
1H). 13C NMR (151 MHz, CDCl3) δ 197.2, 169.2, 146.3, 145.1, 136.0, 132.2, 128.8, 128.7, 
127.9, 118.2, 113.7, 112.7, 112.6, 112.4, 80.3, 53.4, 52.7, 47.8, 30.1, 30.0. LRMS (ESI) m/z 
calcd for C20H18DNO3Na ([M+Na]+) 345.13; found 345.61. 
 
3.7.5  GENERAL PRODCEDURE FOR PYRROLIDINES 6g–6h 
To a 4.0 mL vial equipped with a magnetic stir bar was added Rh2(esp)2 (1 mol %), PPh3AuCl 
(10 mol %), and AgSbF6 (10 mol %) directly into the reaction vessel.  A solution of (but-3-
NPh
O
Ph
O
MeO D
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yn-1-yl)-aniline (1.1 equiv.) was then added.  Lastly, the diazo (1.0 equiv.) was added. The 
reaction vessel was sealed and allowed to stir at reflux for 16 hours. After this time, the 
crude reaction mixture was filtered through a slurry of celite/silica gel, concentrated, and 
analyzed via crude 1H NMR. The crude mixture was then purified via flash chromatography 
to furnish functionalized spiropyrrolidines. 
 
8,8-dimethyl-4-methylene-1-phenyl-7,9-dioxa-1-azaspiro[4.5]decane-6,10-dione (6g).  
Prepared from 5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dione and N-(but-3-yn-1-yl)aniline 
(Reaction time = 16 hours).  Yellow oil (24 mg, 41%).  TLC : Rf 0.26 (20% ethyl acetate in 
hexanes). IR (NaCl): 2926, 2845, 2359, 2162, 1684.  1H NMR (600 MHz, CDCl3) δ 7.23 (d, J = 
8.0 Hz, 2H), 6.85 (t, J = 7.3 Hz, 1H), 6.61 (d, J = 8.1 Hz, 2H), 5.37 (t, J = 2.1 Hz, 2H), 3.79 (t, J 
= 6.9 Hz, 2H), 2.96 (tt, J = 6.9, 2.0 Hz, 2H), 1.91 (s, 6H).  13C NMR (151 MHz, CDCl3) δ 165.6, 
148.8, 144.3, 134.2, 132.0, 129.3, 129.2, 119.9, 114.6, 111.1, 107.1, 72.1, 48.8, 31.3, 30.5, 
29.2.  LRMS (ESI) m/z calcd for C16H17NO4Na ([M+Na]+) 310.10; found 310.12. 
 
7,9-dimethyl-4-methylene-1-phenyl-1,7,9-triazaspiro[4.5]decane-6,8,10-trione (6h). 
Prepared from 5-diazo-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and N-(but-3-yn-1-
yl)aniline (Reaction time = 16 hours).  Yellow oil (33 mg, 52%)  TLC : Rf 0.22 (20% ethyl 
O
O
O
O
NPh
N
O
N
O
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acetate in hexanes). 1H NMR (600 MHz, CDCl3) δ 7.19 (dd, J = 8.7, 7.4 Hz, 2H), 6.79 – 6.75 
(m, 1H), 6.32 (dt, J = 7.7, 1.0 Hz, 2H), 5.20 (q, J = 2.1 Hz, 1H), 5.01 (q, J = 2.2 Hz, 1H), 3.86 (t, 
J = 7.0 Hz, 2H), 3.40 (s, 6H), 2.96 (tt, J = 6.9, 2.2 Hz, 2H).  13C NMR (151 MHz, CDCl3) δ 168.4 
(2C), 149.3, 144.3, 129.5 (2C), 118.7 (2C), 112.9 (2C), 108.5, 90.0, 48.5, 31.0, 29.7, 29.5.  
LRMS (ESI) m/z calcd for C16H17N3O3Na ([M+Na]+); 322.11; found 322.12. 
 
3.7.6  GENERAL PRODCEDURE FOR PYRROLIDINES 6i–6j 
To a 4.0 mL vial equipped with a magnetic stir bar was added Rh2(esp)2 (1 mol %) directly 
into the reaction vessel.  A solution of 2-ethynylaniline (1.1 equiv.) was then added.  Lastly, 
the diazo (1.0 equiv.) was added. The reaction vessel was sealed and allowed to stir at reflux 
for 16 hours. After this time, the crude reaction mixture was filtered through a slurry of 
celite/silica gel, concentrated, and analyzed via crude 1H NMR. The crude mixture was then 
purified via flash chromatography to furnish functionalized spiropyrrolidines 
 
 
2',2'-dimethyl-3-methylenespiro[indoline-2,5'-[1,3]dioxane]-4',6'-dione (6i). prepared 
from 2,2-dimethyl-1,3-dioxane-4,6-dione and 2-ethynylaniline (Reaction time = 16 hours).  
Faint yellow oil (50 mg, 65%).  TLC : Rf 0.14 (20% ethyl acetate in hexanes).  IR (NaCl): 3327, 
2922, 2855, 2363, 2324, 1790, 1740. 1H NMR (600 MHz, CDCl3) δ 7.35 – 7.32 (m, 1H), 7.25 
– 7.22 (m, 1H), 6.91 (t, J = 7.3 Hz, 2H), 5.65 (d, J = 2.3 Hz, 1H), 5.37 (d, J = 2.4 Hz, 1H), 4.66 
O
O
O
O
N
H
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(s, 1H), 1.90 (s, 3H), 1.78 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.7 (2C), 152.3, 147.8, 131.4 
(2C), 123.5, 121.6, 112.8, 106.1, 104.2, 71.6, 31.1, 27.3.  LRMS (ESI) m/z calcd for 
C14H13NO4Na ([M+Na]+) 282.07; found 282.11. 
 
1-benzyl-2',2'-dimethyl-3-methylenespiro[indoline-2,5'-[1,3]dioxane]-4',6'-dione (6j). 
Prepared from 5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dione and N-benzyl-2-ethynylaniline 
(Reaction time = 16 hours).  Faint yellow oil (30 mg, 73%). TLC : Rf 0.38 (20% ethyl acetate 
in hexanes).  IR (NaCl): 2926, 2855, 2359, 2324, 2124, 1792, 1753. 1H NMR (600 MHz, CDCl3) 
δ 7.55 – 7.51 (m, 2H), 7.37 – 7.33 (m, 2H), 7.29 (t, J = 6.7 Hz, 2H), 7.12 – 7.08 (m, 1H), 6.76 
(td, J = 7.5, 0.9 Hz, 1H), 6.40 (d, J = 8.1 Hz, 1H), 5.62 (d, J = 2.3 Hz, 1H), 5.34 (d, J = 2.3 Hz, 
1H), 4.47 (s, 2H), 1.85 (s, 3H), 1.52 (s, 3H).  13C NMR (151 MHz, CDCl3) δ 164.8 (2C), 153.5, 
147.0, 136.2, 131.4, 128.7, 128.2 (2C), 127.8 (2C), 123.2, 121.2, 119.4, 109.0, 106.2, 103.4, 
51.6, 31.1, 29.7, 28.0. LRMS (ESI) m/z calcd for C21H19NO4Na ([M+Na]+]) 372.12; found 
372.13. 
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CHAPTER 4 
 
 Metal Carbene Initiated Synthesis of 
 5-, 6-, and 7-membered Spirocarbocycles  
  
 
 
4.1  INTRODUCTION 
 
 Research groups throughout the field of synthetic chemistry have focused great 
efforts on the stereoselective synthesis of spirocarbocycles with multiple stereocenters.[1] 
In particular, their focus has been centralized around the synthesis of six-membered 
spirocarbocycles, which are found in many biologically active natural and synthetic 
compounds, with one of the most well-known examples being gelsemine (Figure 4.1).  
A common strategy for synthesizing all carbon spirocycles, such as the one found in 
gelsemine, involves the cyclization of the ends of two substituents on a fully-substituted 
carbon center that was previously installed on a pre-formed ring system (Figure 4.2).[1] In 
very few cases are the both rings on the spirocarbocycle formed in the same step, thereby  
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Figure 4.1. Biologically active natural products and drug molecules containing 5-, 6-, and 
7-membered spirocarbocycle core 
 
 
Figure 4.2. Current synthetic challenges in synthesis all-carbon spirocycles 
 
making it extremely difficult to maintain stereocontrol in the desired product. With this 
challenge in mind, it was of great interest to our research group to induce de novo 
formation of both ring systems of the spirocarbocycle in a single step in hopes of 
maintaining control of the stereochemistry in the spirocenter bond forming process. 
 As previously mentioned, dual catalysis is a powerful way to assemble molecular 
complexity, such as the spirocarbocyclic motif, from readily available starting materials due 
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to the fact that multiple bonds, that are often difficult to install, are formed in one pot by 
simultaneous yet discrete catalytic events.[2] Other than being synthetically appealing, this 
approach allows for price efficiency in terms of reagents, solvents, and waste management 
as well as in time and effort.[3] Recently, significant efforts have been devoted to developing 
one-pot dual catalytic methods to achieve carbon-carbon bond formations[4], and we 
believed that dual catalysis would enable us to complete the task of forming both rings of 
the spirocarbocycle in one pot.  
 Given the success of our Rh(II)/Au(I) synergistic catalytic cocktail for the synthesis 
of g-butyrolactones, tetrahydrofurans, spiroethers, and azaspiro-ring systems[5] we 
envisioned the possibility of using this catalytic system to synthesize oxindole hybridized 
spirocarbocycles, which are found in a wide range of bioactive natural products and 
pharmaceuticals such as sclerotiamide, gelsemine, chitosenine, and ubrogepant (Figure 
4.1).[6] Spriocyclic hybrids containing oxindole units exhibit higher interaction with 
biological receptors by protein inhibition or ezymatic pathways.[6j] These hybrids have been 
recognized as having promising anticancer activity.[6j]  
 Our proposed retrosynthetic design for the synthesis of oxindole hybridized 
spirocarbocycles involved an intramolecular carbene sp2 C–H functionalization/Conia-ene 
cascade as visualized in Scheme 4.1b. As seen in previous chapters, we have had great 
success with the Conia-ene cyclization, however, the generation of a masked “carbon 
nucleophile” that would insert into an active Rh(II) carbene and create our desired 
zwitterionic intermediate was a new challenge. Within the literature there are various 
types of C–H insertion reactions in which diazocarbonyl compounds participate, however,  
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Scheme 4.1. a) Initial development of sp2 C–H functionalization by Doyle et al. 
 b) Our retrosynthetic design using sp2 C–H functionalization/Conia-ene cascade. 
 
in 1998 Doyle et al. proposed the formation of a zwitterionic intermediate during the 
aromatic C–H insertion of N-aryl diazoamide into a Rh(II)-carbene (Scheme 4.1a).[7] This 
zwitterionic intermediate is electronically favorable because the positive charge of the 
intermediate is stabilized by the electron-rich oxindole resonance stabilization. This 
zwitterionic intermediate typically undergoes rapid proton transfer to generate C–H 
functionalized products, conversely, we desired to trap this intermediate with an alkyne.  
With these insights from the literature in mind, we decided to design a substrate 
that linked an alkyne substituted acceptor/acceptor diazocarbonyl to an electron rich 
aniline to access a derivative of the N-aryl diazoamide that Doyle used in his initial 1988 
study.[7] It is important to note that there were no previous reports of an intramolecular 
cascade reaction utilizing both sp2 C–H functionalization[8] and a Conia-ene cascade[9]. This 
may be attributed to selectivity issues caused by the alkyne functionality in the carbene sp2 
C–H functionalization step, such as cyclopropenation[10] or carbene/alkyne metathesis.[11] 
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 For the initial investigation, we took our newly synthesized diazo-acetoacetamide 
1a as a model substrate and exposed it to our previously developed Rh(II)/Au(I) synergistic 
catalytic cocktail that was used for our carbene heteroatom insertion/Conia-ene 
cyclizations. This reaction proceeded very cleanly, however, it provided a major product in 
which the characteristic ketone peak (~200 ppm) in 13C NMR spectrum was missing. Further 
structural analysis revealed the formation of an unexpected exo-glycal product in 67% yield 
(Scheme 4.2). With this finding we quickly realized that application of our prolific 
Rh(II)/Au(I) synergistic catalytic cocktail would not be as direct when applying it to the 
synthesis of spirocarbocycles.  
 
Scheme 4.2. Unexpected results that provided an undesired exo-glycal via O-alkylation of 
alkyne instead of C-alkylation. 
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4.2 Rh(II)/Au(I) DUAL CATALYSIS IN CARBENE sp2 C–H 
FUNCTIONALIZATION/CONIA-ENE CASCADE 
 
Figure 4.3. a) Baldwin rules for enol-endo cyclizations; b) Visualization of two different 
modes of attack possible within our designed system 
 
Given the results from our initial experiment with 1a in Scheme 4.2, we looked into 
the literature to examine enolendo intramolecular ring cyclizations.[12] After a survey of 
literature, we observed that while there were indeed few reports of 5–enolendo–exo dig 
cyclizations known in literature, it was only obtained in a trace amount as a byproduct with 
the more favorable 6-enolendo-endo dig cyclization.[12a–c] Next, we looked into Sir Jack E. 
Baldwin’s original work in which he derived a different set of rules for enolendo cyclizations 
(Figure 4.3a).[12d–f] In these studies, Baldwin investigated the ring closure reactions of 
enolendo-exo-tet/trig systems; however, there was no report of enolendo-exo-dig 
cyclizations in his work.[10f] Keeping in mind the Baldwin rules for enolendo-exo-tet/trig 
systems and examples from literature of 6-enolendo-exo dig cyclizations, we hypothesized 
that through extension of the hydrocarbon chain length we would create a substrate with 
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a better trajectory to favor C-alkylation over O-alkylation to provide the desired 
spirocarbocycle (Figure 4.3b).[13] 
 
4.2.1  INITIAL SCREENING OF CATALYTIC CONDITIONS 
 For the initial optimization, diazo-acetoacetamide 1b was selected as the model 
substrate. The addition of 1b to our previously optimized synergistic 
Rh2(esp)2/AgOTf/PPh3AuCl and Rh2(esp)2/AgSbF6/PPh3AuCl catalytic conditions for carbene 
heteroatom insertion/Conia-ene cascades provided the sp2 C–H functionalization product 
with instantaneous alkyne hydration to give a 1,5-dione 4b at room temperature (Table 
4.1, entry 1–2). This Markovnikov addition of water across a triple bond to generate 
ketones is a well-known practice and is generally initiated by strong Brønsted and Lewis 
acids.[12j–12l] In particular, the generation of the 1,5-dione is highly favorable due to the 
stabilized 6-membered transition state found in intermediate-A that promotes 
hydration.[12l] It is important to note this is the same type of intermediate that led to the 
formation of the undesired exo-glycal in our initial studies in Scheme 4.2. 
 As we have seen in previous chapters, Au(I)-catalyzed reactions involve [LAu][Y] as 
an active species, where L = any type of phosphine ligand and Y = TfO–, SbF6– or a variety of 
other counter anions.[14] These electrophilic species are generated by the metal–ion 
exchange between PPh3AuCl and AgY (Y = TfO–  or SbF6–) and are typically not isolated after 
formation due to their highly active nature, even though there is a risk of interference of 
silver with the catalytic process.[14] Assuming the highly cationic nature of a Ag(I) activated 
Au(I) salt was not ideal for this transformation, we decided to examine other Lewis acids  
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Table 4.1. Optimization for the Synthesis of 6-Membered Spirocarbocycle 
 
entry catalysts temp, t yield (%)b 
1 Rh2(esp)2/AgOTf/PPh3AuCl rt, 30 min 0c 
2 Rh2(esp)2/AgSbF6/PPh3AuCl rt, 30 min 0c 
3 Rh2(esp)2/PPh3AuCl/(CuOTf)2-tol reflux, 3 h 57 
4 Rh2(esp)2/(CuOTf)2-tol reflux, 12 h 45 
5 Rh2(esp)2/PPh3AuCl reflux, 12 h 32 
6 Rh2(esp)2/ZnCl2 reflux, 12 h 43 
7 Rh2(OAc)4/PPh3AuCl/(CuOTf)2-tol reflux, 3 h 31 
8 Rh2(HFB)4d/PPh3AuCl/(CuOTf)2-tol reflux, 3 h 63 
9 Rh2(HFB)4d/PPh3AuCl/(CuOTf)2-tol reflux, 3 h 68e 
10 PPh3AuCl/ (CuOTf)2-tol reflux, 12h 0f 
a All optimization reactions were performed by adding a 0.5 M solution of 1b (1.0 equiv.) into a 0.2 
M solution of Rh(II) (1 mol %) and Lewis acid(s) (10 mol %) via syringe, unless otherwise noted all 
reactions were refluxed until starting material diazo was consumed. b Isolated yields after column 
chromatography. c Reaction conditions instantaneously hydrated the alkene to provide the 1,5-
dione alkyne hydration product derived from 4a. d HFB = heptafluorobutyrate. e Reaction ran with 
the addition of heat activated 4 Å MS (100 mg/1 mmol of 1b).fReaction conditions did not 
decompose 1b, starting material remained. 
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known to promote Conia-ene cyclizations[9] in hopes of attenuating the level of activation 
of our active intermediate (Table 4.1). Recently hit has been shown that Cu(I) triflate can 
activate Au(I) salts to form stable cationic Au(I) complexes at elevated temperatures.[14] In 
2013 Guérinot et al. hypothesized that a gradual, and possibly reversible, delivery of 
cationic Au(I) from a reservoir of stable PPh3AuCl would create a more controlled reaction 
environment for their respective transformation.[14] The authors stated that the quick 
precipitation of AgCl makes any source of silver salt undesirable for this catalytic method, 
however within their study they. showed that Cu(I) triflate provided the desired attenuated 
reactivity. [14] With these insights in mind, we exposed diazo 1b to a catalytic cocktail of 
Rh2(esp)2/PPh3AuCl/(CuOTf)2-tol at room temperature and only obtained the C–H 
functionalization product 3b and no spirocarbocycle 2b. However, in refluxing 
dichloromethane, the desired product 2b was obtained in 57% yield after 3 hours (Table 
4.1, entry 3). 
 Next, we wanted to determine if this reactivity was due to the Au(I)/Cu(I) Lewis 
acids acting in synergism, therefore we screened Au(I) and Cu(I) salts individually (Table 
4.1, entry 4–5). When diazo 1b was exposed to Rh2(esp)2/(CuOTf)2-tol in refluxing 
dichloromethane, the reaction was found to be sluggish and spirocarbocycle 2b was 
formed in 45% yield after refluxing for 12 hours. We also observed a sluggish reaction with 
the Rh2(esp)2/PPh3AuCl combination. It is well known that ZnCl2 can efficiently catalyze 
Conia-ene cyclizations[15], therefore we screened a mixture of Rh2(esp)2/ZnCl2 but did not 
achieve any significant improvement, only a 43% of the desired spirocarbocycle formed 
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after 12h refluxing in dichloromethane with a mixture of the undesired endo-alkene 
rearrangement product (Table 4.1, entry 6).  
 With our best Au(I)/Cu(I) Lewis acid combination, we then examined different 
dirhodium carboxylates known to decompose diazocarbonyls in our attempt to increase 
the yield of 2b (Table 4.1, entry 7–9).[16] In a thorough study by Doyle et al. in 1998, he 
proposed that the process of aromatic C–H functionalization is more accurately described 
mechanistically as electrophilic aromatic substitution[7], therefore a more electrophilic 
Rh(II)-carbene would be most ideal for this transformation. With this insight in mind, we 
first screened Rh2(OAc)4, which creates a less electrophilic carbene as compared to 
Rh2(esp)2.[16] This Rh(II) salt decreased the yield of the desired transformation to 31%, 
providing solid evidence for validation of our hypothesis. Next, we screened the highly 
electrophilic Rh2(HFB)4 catalyst and the yield of the desired product increased to 63%, 
thereby validating the hypothesis of the need for an electrophilic carbene. Subsequently, 
we repeated these conditions in the presence of heat activated 4Å molecular sieves and 
the reaction yield was increased to 68%. Lastly, to ensure the necessity of Rh(II) in the 
system, we exposed 1b to the Au(I)/Cu(I) catalytic conditions (Table 4.1, entry 10). 
However, under these conditions 1b did not undergo decomposition to initiate the desired 
sp2 C–H functionalization. 
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4.2.2  SYNTHESIS OF 5/6 OXINDOLE HYBRIDIZED SPIROCARBOCYCLES 
With optimized conditions in hand, we then investigated the scope of this cascade 
sequence (Scheme 4.3). For our initial studies, we decided to probe the diastereoselectivity 
of the transformation. A phenyl substituted diazo was exposed to the optimized conditions  
 
Scheme  4.3. Scope of Rh(II)/Au(I)/Cu(I) catalyzed cascade for the synthesis of 
functionalized 6-membered oxindole hybridized spirocarbocycles. 
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oxindole ring is trans to the side chain substituent on the ring formed during the Conia-ene 
cyclization. The stereochemical arrangement of the substituents was determined based on 
the coupling constants of the protons of interest (Figure 4.4). The coupling constant for the 
benzylic proton to the neighboring diastereotopic protons was J = 12.8 Hz for the axial-axial 
interaction and J = 6.4 Hz for the axial-equatorial interaction. This high diastereoselectivity 
was also maintained for the less bulky methyl substituted spirocarbocycle 2d.  
  
 
Figure  4.4. Stereochemical analysis of 2c via calculated coupling constants. 
 
Next, we looked into the electronic effects of the cascade transformation. Electron 
rich substrates were equally efficient as the non-electronically perturbed substrates, 
-2.00.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
f1 (ppm)
1
.7
5
0
.8
4
0
.8
9
2
.7
7
0
.8
6
0
.8
6
0
.8
7
0
.8
6
0
.8
6
1
.7
4
1
.0
4
2
.7
8
1
.0
0
2
.3
9
2
.4
0
2
.4
0
2
.4
1
2
.4
1
2
.4
2
2
.4
3
2
.4
5
2
.4
5
2
.4
6
2
.4
7
2
.4
7
2
.4
8
2
.9
5
2
.9
5
2
.9
6
2
.9
7
2
.9
7
2
.9
8
2
.9
9
3
.0
4
3
.0
5
3
.0
6
3
.0
6
3
.0
7
3
.0
8
3
.2
2
4
.0
1
4
.0
2
4
.0
3
4
.0
4
4
.7
9
5
.1
2
6
.8
6
6
.8
7
7
.0
7
7
.0
8
7
.1
0
7
.1
5
7
.1
7
7
.2
3
7
.2
4
7
.2
5
7
.2
5
7
.2
9
7
.3
0
7
.3
1
7
.3
3
7
.3
6
 b
e
n
z
e
n
e
 d
6
7
.4
0
7
.4
2
Ha
N
O
O Ph
Hb
Hb’
Stereochemistry Analysis
Jab = 12.8 Hz (ax–ax)
Jab’ = 6.4 Hz (ax–eq)
Ch. 4 – Metal Carbene Initiated Synthesis of 5-, 6-, and 7-membered Spirocarbocycles 211 
producing the desired compounds 2e and 2f in 70% and 65% yields. Next, an electron poor 
diazo-acetoacetamide was synthesized and exposed to the optimized conditions. This 
substrate underwent the desired transformation to provide 2g, albeit in a significantly 
lower 32% yield showing that electron withdrawing substituents on the aromatic ring have 
a substantial effect on the efficiency of the reaction. An extended reaction time of 14 hours 
was necessary for this substrate and caused alkene isomerization to the more 
thermodynamically favored product. which also contributed to the decreased yield of 2g. 
Next, diazo-acetoacetamide derived from the corresponding naphthalenamine was 
examined and it gave the desired product 2h in 71% yield with high regioselectivity for C–
H functionalization. Subsequently, we synthesized a benzopyran substituted diazo-
acetoacetamide and exposed it to our optimized reaction conditions. The desired 
spirocarbocycle 2i was synthesized in 87% yield and afforded a scaffold which is found in 
many biologically active oxindole hybridized spirocarbocycles. [6e]  
 Lastly, we hypothesized our optimized conditions could be extended to the 
synthesis of spirobenzofuranones, a scaffold that is found in the biologically active natural 
product rosmadial (Figure 4.1). A phenol substituted diazo-acetoacetate was synthesized 
and exposed to the Rh2(HFB)4/PPh3AuCl/(CuOTf)2-tol catalytic cocktail and a complex 
mixture was obtained. Upon a literature survey, it was discovered that sp2 C–H 
functionalization of phenol substituted diazo-acetates is highly dependent on the nature of 
the ligand (therefore the corresponding electronics) of the Rh(II) catalyst.[17] In literature, 
Rh(II) perfluorobutyrate catalysts provide a cycloheptatrienyl ring expanded product over 
sp2 C–H functionalization.[17] Therefore, Rh2(OAc)4 was used instead of Rh2(HFB)4 to obtain 
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the desired sp2 C–H functionalization and intramolecular Conia-ene cyclization to provide 
2j in 72% yield (Scheme 4.4).  
 
Scheme 4.4. Syntheis of spriobenzofuranone through modified conditions using Rh2(OAc)4. 
 
4.2.3  SYNTHESIS OF 5/7 OXINDOLE HYBRIDIZED SPIROCARBOCYCLES 
 In order to expand the applicability of this methodology to larger ring cyclizations, 
we decided to synthesize a diazo-acetoacetamide with an extended carbon chain which 
would provide a seven-membered spirocarbocyle. Carbocyclic seven-membered rings are 
common structural units that can be found in a variety of polycyclic natural products that 
are of considerable medicinal interest. [6j] However, unlike smaller ring sizes, the 
construction of seven-membered rings is more challenging, and their syntheses are limited 
in literature. [6j] 
 We hypothesized that the application to seven-membered scaffolds would not be 
simple, typically seven-membered rings are much more difficult to form than the 
corresponding five- and six-membered rings. This is due to two factors: entropy and 
enthalpy. Entropy favors the formation of smaller rings; however, our model substrate 
would only give access to either a seven-membered (7-exo-dig) cyclization or an eight-
membered (8-endo-dig) cyclization. Therefore, we knew entropic barriers would not be an 
O O
O
2j,	72%b
O
O O
N2
Rh2(OAc)4	(1	mol%)
PPh3AuCl	(10	mol%)
(CuOTf)2-tol	(10	mol%)
4	Å	MS
CH2Cl2,	reflux
H
Ch. 4 – Metal Carbene Initiated Synthesis of 5-, 6-, and 7-membered Spirocarbocycles 213 
issue. Nevertheless, overcoming enthalpic barriers would play a major role. When we 
consider the strain in the transition state leading to our desired ring cyclization, we see that 
transannular repulsion through the unfavorable “flagpole” interactions becomes an issue. 
With these thermodynamic insights in mind, we set out to apply our methodology to the 
synthesis of seven-membered spirocarbocycles. 
 When the extended diazo-acetoacetamide was exposed to the optimized reaction 
conditions identified in Table 4.1, the reaction stalled at the C–H functionalization step to 
provide the corresponding insertion compound, proving that the seven-membered ring 
formation needed more energy to proceed. Therefore, we increased the catalytic loading 
of PPh3AuCl and (CuOTf)2-tol to 20 mol% and allowed a longer reaction time and the 
desired product 2k was isolated in a 49% yield. Next, we looked into the diastereoselectivity 
of this reaction with a phenyl-substituted seven-membered diazo-acetoacetamide. The 
desired product 2l was isolated in 54% yield as a single diastereomer. The relative 
stereochemistry of the phenyl substituent and spiro-junction in 2l was determined based 
on the nuclear Overhauser effect (nOe) correlations and was further confirmed by the 
single crystal structure using X-Ray crystallography (Figure 4.5). Similar to the six-
membered spirocarbocycle, the aryl component of the oxindole is trans to the stereo-
center substituent on the ring formed during the Conia-ene cyclization. Lastly, 2m was 
synthesized in a 47% yield and the high stereoselectivity was also maintained with the less 
bulky methyl substituent on the side chain.  
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Scheme 4.5. Synthesis of 7-membered spirocarbocycle oxindole hybrids 
 
Figure  4.5. Cyrstal structure of 2l; 
 C–H bond lengths in resulting alkene functionality = 0.95 Å. 
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4.2.4  SYNTHESIS OF 5/5 OXINDOLE HYBRIDIZED SPIROCARBOCYCLES 
 After the successful formation of the 6- and 7-membered oxindole hybridized 
spirocarbocycles, we turned our attention to the synthesis of 5-membered hybrids. 
Scaffolds of this type are found in a variety of biologically active natural products. [6a, 6e, 6f] 
Due to the prevalence of this core in nature, it was a great desire of ours to access the 
corresponding spirocyclization through our optimized methodology. Because of our failed 
attempt at a 5-membered spirocyclization with diazo 1a in Scheme 4.2, we hypothesized 
that by synthesizing mono-carbonyl diazo 1n we would create a substrate that has a more 
favorable trajectory to prefer C-alkylation over the undesired O-alkylation. We would also 
avoid the possibility of forming intermediate-A as seen in Table 4.1 that promotes the 
undesired O-alkylation by excluding the additional carbonyl ketone. Our newly designed 
substrate would proceed through a well-known 5-exo-dig cyclization that is similar to work 
published by the Toste group.[18] Furthermore, all enolexo cyclizations for the tet/trig/dig 
systems follow the original Baldwin rules as seen in our previous work[5, 19] with Rh(II)-
carbene initiated heteroatom insertion/Conia-ene cascade cyclizations, therefore this 
substrate possessed the ideal design to achieve a successful reaction. 
 For the initial optimization we exposed 1n to our optimized conditions that 
provided the 6- and 7-membered spirocarbocycles. After refluxing in dichloromethane for 
three hours, this catalytic combination of Rh2(HFB)4/PPh3AuCl/(CuOTf)2-tol provided the 
sp2 C–H functionalization product 3n only (Table 4.2, entry 1). We hypothesized that the 
mild activation of PPh3AuCl with (CuOTf)2-tol was not enough to catalyze this reaction, 
therefore we decided to attempt this transformation with our previously developed 
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Table 4.2. Optimization for the Synthesis of 5-Membered Spirocarbocycle 
 
entry catalysts temp, t yield (%)b 
1 Rh2(HFB)4/PPh3AuCl/(CuOTf)2-tol reflux, 3 h 0c 
2 Rh2(HFB)4/PPh3AuCl/AgSbF6 rt, 2 h 53 
3d PPh3AuCl/AgSbF6 rt, 12 h 67 
a For entries 1 and 2: reactions were performed by adding a 0.5 M solution of 1n (1.0 equiv) into a 
0.2 M solution of Rh(II) (1 mol %) and Lewis acid(s) (10 mol %), and heat activated 4 Å MS (100 
mg/mmol) via syringe; Reactions were stirred at the designated temperature until 1n was 
consumed. b Isolated yields. c Reaction provided only the sp2 C–H activation product. d For entry 3: 
reaction was performed by adding a 0.5 M solution of 1n (1.0 equiv.) into a 0.2 M solution of 
PPh3AuCl (20 mol %) and AgSbF6 (20 mol %) via syringe, and was stirred at rt until desired product 
formed. 
 
Rh(II)/Au(I)/Ag(I) conditions (Table 4.2, entry 2). This combination provided the desired 
compound 2n in a 53% isolated yield after reacting for two hours. Interestingly, we did not 
observe any hydration product of the alkyne functionality as previously observed for the 
corresponding six-membered Conia-ene cyclization.  
 In an attempt to increase the yield of 2n we conducted a literature survey and found 
that mono-carbonyl diazos such as 1n can readily decompose under gold-catalyzed 
conditions to generate a gold-carbenoid.[20] With this insight, we hypothesized that the 
entire transformation of 1n to 2n could be catalyzed with Au(I) alone. When 1n was added 
to a solution of PPh3AuCl/AgSbF6 and stirred at room temperature for 12 hours, the 
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diazocarbonyl was consumed to provide complete conversion to 2n without any uncyclized 
sp2 C–H functionalization product 3n present.  
 
Scheme 4.6. Scope of Au(I)/Ag(I) catalyzed cascade for the synthesis of functionalized 5-
membered oxindole hybridized spirocarbocycles. 
 
 With these newly optimized conditions in hand we decided to look into the 
electronic effects for this transformation (Scheme 4.6). Electron rich aromatics were 
accommodated with equal efficiency as the parent compound (2o). Furthermore, the 
benzopyran fused spirocarbocycle 2p was also obtained in a moderate 54% yield under 
these reaction conditions. The core of 2p can be found in the natural product, 
sclerotiamide, which has recently been identified by Duerfeldt et al. as the first non-
peptide-based natural product activator of bacterial caseinolytic protease P (ClpP) (Figure 
4.1).[6a] It is important to note that the electron deficient substrate could not be accessed 
with this methodology. The reaction stalled at the sp2 C–H functionalization presumably 
due to the decreased nucleophilicity of the oxindole in the intramolecular Conia-ene 
cyclization. 
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4.2.5  MECHANISTIC INSIGHTS 
 To probe the mechanism of this transformation and determine if synergy was 
necessary to obtain the desired oxindole hybridized spirocarbocycles, we synthesized 
insertion compound 3b and isolated it as the enol tautomer of the b-keto amide. We 
exposed this substrate to PPh3AuCl/(CuOTf)2-tol in refluxing dichloromethane and 2b was 
isolated in 84% yield. This suggests the possibility of a non-synergistic stepwise 
transformation involving a carbene sp2 C–H functionalization and subsequent Conia-ene 
cyclization (Scheme 4.7). 
 
Scheme 4.7. Synthesis of 2b from isolated insertion compound. 
 
 To further probe the mechanism, we synthesized a variety of deuterium labeled 
diazo compounds. Diazo acetoacetamide 1q was synthesized to examine the kinetic 
isotope effect of the reaction and validate whether the transformation was through a 
cyclopropanation or electrophilic aromatic substitution mechanism (Scheme 4.8). In the 
literature, it has been stated that typical kH/kD values for electrophilic aromatic substitution 
mechanisms are less than 1.3 unless the formation of the initial sigma-complex from 
nucleophilic attack of the aromatic ring onto the electrophile is reversible. [17] Therefore, 
when we observed a kH/kD = 1 in this experiment we were able to conclude that the 
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Scheme 4.8. Deuterium labeling experiment probing kinetic isotope effect for C–H 
functionalization. 
 
mechanism is proceeding through electrophilic aromatic substitution as originally 
proposed by Doyle in 1998 and also Hu et al. in their work featuring a similar sp2 C–H 
functionalization intermediate.  
 Next, the penta-deuterated diazo 1r was synthesized and exposed to the optimized 
reaction conditions to provide 2r (Scheme 4.9). Interestingly no deuterium incorporation 
was observed in the resulting alkene functionality of 2r, suggesting the possibility of an 
intermolecular 1,2-proton transfer. As seen in Scheme 4.7, the transformation has a high 
likelihood of proceeding through an enol-intermediate where the corresponding 
deuterium transferred during the C–H functionalization can now be exchanged at a high  
 
Scheme 4.9. Deuterium labeling experiment probing inter- vs intra- molecular deuterium 
transfer. 
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rate as a deuterated enol. This exchange is likely occurring with the minimal moisture 
present in the reaction medium. Therefore, in the resultant Conia-ene cyclization we are 
not observing any deuterium incorporation on the alkene. This experiment provided 
additional conclusive evidence of the stepwise transformation.  
  
 
Scheme 4.10. Deuterium labeling experiment giving insight into gold complexation. 
 
Figure 4.6. Crystal structure of 2s; C–D bond length = 0.87 Å; C–H bond length = 1.02 Å. 
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Lastly diazo-acetoacetamide 1s was synthesized with a deuterium incorporated on 
the alkyne. When this substrate was exposed to the optimized conditions, the desired 
product 2s was obtained in good yield with 86% deuterium incorporation at the resulting 
alkene functionality (Scheme 4.10). The deuterium was found to be syn to the carbonyl 
functionality as observed in our previous spiroether work and by the Toste group. [9a] The 
deuterium orientation was further confirmed by the single crystal structure using X-ray 
crystallography (Figure 4.6). Upon analysis, the C–D bond length, which was 0.87 Å, was 
found to be significantly shorter than the C–H bond length, which was 1.02 Å. [21] The results 
from this deuterium labeling experiment suggest the possibility of an equilibrium between 
an alkyne-p complex with gold and a gold acetylide.[22]  
Table 4.3. Attempted Optimization of Asymmetric Spirocyclization 
 
Entry Catalystsa Ligand Yield (%) % ee 
1 Rh2(R-DOSP)4 /PPh3AuCl/(CuOTf)2 tol – 52 0 
2 Rh2(HFB)4/L1(AuCl)2/(CuOTf)2 tol L1  44 0 
3 Rh2(HFB)4/PPh3AuCl/(CuOTf)2 tol/L2 L2 < 5 0 
a
 Catalyst loading: 1 mol% of Rh(II), 10 mol % of Au(I), 10 mol % of Cu(I), 11 mol% ligand 
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In an attempt to induce asymmetry in our methodology (Table 4.3), we attempted 
the cascade reaction with chiral rhodium salt Rh2(S-DOSP)4, PPh3AuCl, (CuOTf)2-tol, and our 
model six-membered diazo-acetoacetamide. Unfortunately no enantiomeric excess (ee) 
was observed using chiral Rh(II) salts. We also attempted the cascade reaction with gold 
and copper bearing chrial ligands but did not induce ee in the resulting spirocarbocycle. 
The findings identified by our mechanistic probing experiments in combination with 
evidence found during the development of our substrate scope allowed us to propose a 
mechanism depicted in Scheme 4.11. First the diazo is decomposed by the metal catalyst  
 
Scheme 4.11. Proposed mechanism through a stepwise C–H functionalization and Conia-
ene cascade cyclization.  
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to form a metal carbene that undergoes a sp2 C–H functionalization to provide an alkyne-
gold activated oxindole zwitterionic intermediate. This substrate then undergoes a gold(I) 
activated Conia-ene cyclization to provide the desired spirocarbocycle. As seen through the 
deuterium loss in Scheme 4.10, gold activation of the alkyne is in equilibrium between the 
gold-acetylide and gold-p complex, with the equilibrium favoring the p-complex.  
 
4.3  SUMMARY 
 Upon completion of this work, a general approach to the stereoselective synthesis 
of 5-, 6-, and 7-memebered oxindole hybridized spirocarbocycles was developed. Extension 
of our previously identified Rh(II)/Au(I) catalytic cocktail was proven to be successful, 
although a modification to the activation of Au(I) by Cu(I) was needed to obtain the desired 
reactivity. The experimental findings within this work led to the development of a novel 
bond disconnection in the synthesis of a variety of spirocarbocycles. The next logical step 
in building upon this methodology is to complete computational analyses to provide insight 
into how one could effectively induce asymmetry in the system. 
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4.5  EXPERIMENTAL SECTION 
4.5.1  MATERIALS AND METHODS 
Reagents: Reagents and solvents were obtained from Sigma-Aldrich (www.sigma-
aldrich.com), Chem-Impex (www.chemimpex.com) or Acros Organics (www.fishersci.com) 
and used without further purification unless otherwise indicated. Dry solvents 
(acetonitrile) were obtained from Acros Organics (www.fishersci.com), and 
dichloromethane was distilled over CaH under N2 unless otherwise indicated. THF 
purchased from Sigma-Aldrich was distilled over Na metal with benzophenone indicator. 
Toluene was obtained from Sigma-Aldrich. Reactions: All reactions were performed in 
flame-dried glassware under positive N2 pressure with magnetic stirring unless otherwise 
noted. Liquid reagents and solutions were transferred through rubber septa via syringes 
flushed with N2 prior to use. Cold baths were generated as follows: 0 °C with wet ice/water 
and -78 °C with dry ice/acetone. Chromatography: TLC was performed on 0.25 mm 
E. Merck silica gel 60 F254 plates and visualized under UV light (254 nm) or by staining with 
potassium permanganate (KMnO4), cerium ammonium molybdenate (CAM), 
phosphomolybdic acid (PMA), and ninhydrin. Silica flash chromatography was performed 
on Sorbtech 230–400 mesh silica gel 60. Analytical Instrumentation: IR spectra were 
recorded on a Thermo Scientific Nicolet 6700 FTIR spectrometer with peaks reported in 
cm–1. NMR spectra were recorded on a Varian VNMRS 400, 500 and 600 MHz NMR 
spectrometer in CDCl3 unless otherwise indicated. Chemical shifts are expressed in ppm 
relative to solvent signals: CDCl3 (1H, 7.26 ppm, 13C, 77.0 ppm); coupling constants are 
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expressed in Hz. NMR spectra were processed using Mnova 
(www.mestrelab.com/software/mnova-nmr). Mass spectra were obtained on an Advion 
ExpressionL CMS Mass Spectrometer or at the OU Analytical Core Facility on an Agilent 6538 
High-Mass-Resolution QTOF Mass Spectrometer and an Agilent 1290 UPLC. X-ray 
crystallography analysis was carried out at the University of Oklahoma using a Bruker APEX 
ccd area detector (1) and graphite-monochromated Mo Ka radiation (l = 0.71073 Å) 
source. Crystal structures were visualized using CCDC Mercury software 
(http://www.ccdc.cam.ac.uk/products/mercury/). Nomenclature: N.B.: Atom numbers 
shown in chemical structures herein correspond to IUPAC nomenclature, which was used 
to name each compound. 
 
4.5.2  GENERAL PROCEDURE FOR 6-MEMBERED SPIROCARBOCYCLES 
 
To a teflon coated 20 mL vial was added heat activated 4 Å molecular sieves (100 
mg/mmol of starting material), Rh2(HFB)4 (1 mol %), PPh3AuCl (10 mol %), and 
(CuOTf)2-toluene (10 mol %). This mixture was dissolved in 0.2 M dichloromethane 
and allowed to stir for 5 minutes at room temperature. The corresponding diazo 
compound 1 (0.55 mmol) was dissolved in 0.5 M dicholoromethane and then added 
to the catalyst solution stirring at room temperature. The 20 mL vial was sealed and 
X
O O
N2 X
O
O
Rh2L4 (1 mol%)
1b – 1j and 1q – 1s 2b – 2j and 2q – 2s
R1 R2
R1
R2
PPh3AuCl (10 mol%)
(CuOTf)2-tol (10 mol%)
4 Å MS
CH2Cl2, reflux
H
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placed on a heating mantle and allowed to stir at reflux for 5 hours. Once the 
reaction was completed, the crude mixture was filtered over a celite pad to remove 
the 4 Å molecular sieves.  The filtrate was directly loaded to a silica gel column and 
purified using flash column chromatography eluting with 10% EtOAc in Hex to afford 
spirocarbocycle product 2b–2j and 2q–2s. 
 
1'-methyl-2-methylenespiro[cyclohexane-1,3'-indoline]-2',6-dione (2b). White solid (39 
mg, 68%, mp 141-142 °C). TLC: Rf 0.71 (40% EtOAc in Hex). IR (NaCl): 3055, 2941, 2644, 
2367, 1730. 1H NMR (500 MHz, , Chloroform-d) δ 7.36 (t, J = 5.0, 1H), 7.19 (t, J = 5.0, 1H), 
7.15 (t, J = 5.0, 1H), 6.88 (d, J = 7.8 Hz, 1H), 4.88 (s, 1H), 4.51 (s, 1H), 3.35 – 3.24 (m, 2H), 
3.18 (s, 3H), 2.66–2.55 (m, 2H), 2.26–2.20 (m, 1H), 1.86 (qt, J = 13.2, 4.2 Hz, 1H). 13C NMR 
(126 MHz, Chloroform-d) δ 203.0, 171.2, 145.7, 143.7, 128.8, 127.1, 126.4, 122.6, 111.6, 
108.5, 72.3, 39.1, 30.9, 26.6, 24.6. HRMS (ESI) m/z calcd for C15H16NO2 ([M+H]+) 242.1181; 
found 242.1184. 
 
N
O
O
2b, 68%
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1'-methyl-6-methylene-3-phenylspiro[cyclohexane-1,3'-indoline]-2,2'-dione (2c). Orange 
solid (31.0 mg, 65%, mp 155-156 °C). TLC: Rf 0.54 (20% EtOAc in Hex). IR (NaCl): 2934, 2113, 
1729, 1697. 1H NMR (600 MHz, Chloroform-d) δ 7.41 (d, J = 7.5 Hz, 1H), 7.31 (q, J = 7.4 Hz, 
3H), 7.25–7.23 (m, 1H), 7.16 (d, J = 7.5 Hz, 2H), 7.08 (t, J = 7.6 Hz, 1H), 6.86 (d, J = 7.8 Hz, 
1H), 5.12 (s, 1H), 4.79 (s, 1H), 4.02 (dd, J = 12.8, 6.4 Hz, 1H), 3.22 (s, 3H), 3.08–3.04 (m, 1H), 
2.99–2.93 (m, 1H), 2.51–2.38 (m, 2H). 13C NMR (151 MHz, Chloroform-d) δ 203.5, 173.3, 
144.1, 143.7, 137.7, 129.3, 129.0, 128.8 (2C), 128.3 (2C), 127.2, 123.4, 122.6, 113.9, 108.9, 
77.1, 70.6, 54.6, 31.1, 29.6. HRMS (ESI) m/z calcd for C21H21NO3Na ([M+Na+H2O]+) 
336.1600; found 336.1598. 
 
1',3-dimethyl-6-methylenespiro[cyclohexane-1,3'-indoline]-2,2'-dione (2d). White solid 
(98 mg, 64%, mp 139-138 °C). TLC: Rf 0.84 (40% EtOAc in Hex). IR (NaCl): 3069, 2936, 1732, 
1657. 1H NMR (600 MHz, , Chloroform-d) δ 7.32–7.28 (m, 2H), 7.04 (t, J = 7.8 Hz, 1H), 6.86 
(d, J = 7.8 Hz, 1H), 5.01 (s, 1H), 4.70 (s, 1H), 3.25 (s, 3H), 2.91–2.81 (m, 3H), 2.23–2.18 (m, 
Ha
2c, 65% 
(dr > 98:2)
N
O
O
Ph
H
N
O
O Me
Hb
Hb’
Stereochemistry Analysis5 
Jab = 12.8 Hz (ax–ax)
Jab’ = 6.4 Hz (ax–eq)
N
O
O
2d, 64% 
(dr > 98:2)
Me
H
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1H), 1.85–1.78 (m, 1H), 1.13 (d, J = 6.5 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 206.1, 
173.5, 144.4, 143.9, 134.1, 128.8, 123.3, 122.4, 113.1, 108.9, 70.5, 42.6, 30.9, 30.3, 26.5, 
14.9. HRMS (ESI) m/z calcd for C16H17NO2Na ([M+Na]+) 278.1157; found 278.1163. 
 
5'-methoxy-1'-methyl-2-methylenespiro[cyclohexane-1,3'-indoline]-2',6-dione (2e). 
Yellow oil (30 mg, 70%). TLC: Rf 0.68 (40% EtOAc in Hex). IR (NaCl): 2367, 1701, 1638, 1603. 
1H NMR (600 MHz, Chloroform-d) δ 6.86 (dd, J = 8.5, 2.6 Hz, 1H), 6.79–6.73 (m, 2H), 4.86 
(s, 1H), 4.51 (s, 1H), 3.79 (s, 3H), 3.33–3.23 (m, 2H), 3.13 (s, 3H), 2.63–2.51 (m, 2H), 2.23–
2.18 (m, 1H), 1.86–1.77 (m, 1H). 13C NMR (151 MHz, Chloroform-d) δ 203.1, 170.9, 155.7, 
145.7, 137.2, 131.9, 127.6, 114.2, 113.5, 111.6, 108.8, 72.7, 55.8, 39.2, 26.8, 24.5. HRMS 
(ESI) m/z calcd for C16H17NO3Na ([M+Na]+) 294.1106; found 294.1113. 
 
4',6'-dimethoxy-1'-methyl-2-methylenespiro[cyclohexane-1,3'-indoline]-2',6-dione (2f). 
Yellow oil (33 mg, 65%). TLC: Rf 0.61 (40% EtOAc in Hex). IR (NaCl): 3007, 2945, 2363, 1703, 
1620. 1H NMR (600 MHz, Chloroform-d) δ 6.22 (d, J = 2.0 Hz, 1H), 6.10 (d, J = 2.0 Hz, 1H), 
4.80 (d, J = 1.9 Hz, 1H), 4.42 (s, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 3.22–3.14 (m, 1H), 3.10 (s, 
3H), 3.03 (ddd, J = 15.2, 13.3, 6.1 Hz, 1H), 2.66–2.55 (m, 2H), 2.18–2.13 (m, 1H), 1.81 (qt, J 
N
O
O
2e, 70%
MeO
N
O
OMeO
MeO
2f, 65%
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= 13.2, 4.0 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 202.5, 172.2, 162.3, 156.3, 145.8, 
143.5, 110.3, 106.6, 93.1, 88.7, 70.5, 55.6, 55.5, 39.6, 31.0, 26.8, 23.3. HRMS (ESI) m/z calcd 
for C17H19NO4Na ([M+Na]+) 324.1212; found 324.1209. 
 
 
1'-methyl-2-methylene-2',6-dioxospiro[cyclohexane-1,3'-indoline]-6'-carbonitrile (2g). 
Yellow oil (17 mg, 32% combined yield). TLC: Rf 0.52 (40% EtOAc in Hex). IR (NaCl): 3075, 
2926, 2324, 2224, 1699. 1H NMR (600 MHz, Chloroform-d) [external alkene] δ 7.45 (t, J = 
7.9 Hz, 1H), 7.34 (dd, J = 7.8, 1.1 Hz, 1H), 6.98 (dd, J = 7.9, 1.1 Hz, 1H), 5.08 (d, J = 4.5 Hz, 
1H), 3.55 (t, J = 7.1 Hz, 3H), 3.27 (s, 5H), 2.26 – 2.17 (m, 6H), 2.16 (q, J = 1.6 Hz, 4H).1',2-
dimethyl-2',6-dioxospiro[cyclohexane-1,3'-indolin]-2-ene-6'-carbonitrile (S1) (600 MHz, 
Chloroform-d) [internal alkene] (600 MHz, Chloroform-d) [internal alkene] δ 7.39 (dd, J = 
7.9, 1.0 Hz, 1H), 7.26–7.24 (m, 1H), 7.05 (dd, J = 7.9, 1.0 Hz, 1H), 4.96 (d, J = 2.0 Hz, 1H), 
4.33 (d, J = 1.8 Hz, 1H), 3.17 (s, 3H), 3.17–3.11 (m, 2H), 2.75–2.60 (m, 2H), 2.26–2.17 (m, 
1H), 1.95 (qt, J = 13.7, 3.9 Hz, 1H). 13C NMR (101 MHz) (151 MHz, Chloroform-d) δ 200.7, 
169.8, 149.7, 143.2, 141.0, 129.7, 127.9, 126.5, 126.3, 126.1, 123.4, 123.3, 119.7, 116.3, 
112.2, 111.8, 111.1, 110.7, 109.5, 106.3, 101.9, 101.4, 71.9, 39.3, 31.0, 29.7, 26.9, 26.0, 
23.3, 22.4, 19.1, 16.8. HRMS (ESI) m/z calcd for C16H15N2O2 ([M+H]+) 267.1133; found 
267.1137. 
N
O
O
NC
2g (2:1)
N
O
NC
S1 (2:1)
O
+
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1-methyl-2'-methylenespiro[benzo[f]indole-3,1'-cyclohexane]-2,6'(1H)-dione (2h). Clear 
oil (25 mg, 71%). TLC: Rf 0.79 (40% EtOAc in Hex). IR (NaCl): 3055, 2941, 1707, 1639. 1H 
NMR (600 MHz, Chloroform-d) δ 7.81 (dd, J = 17.8, 8.1 Hz, 2H), 7.62 (s, 1H), 7.49 (ddd, J = 
8.1, 6.9, 1.2 Hz, 1H), 7.40 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.15 (s, 1H), 4.91 (d, J = 1.8 Hz, 1H), 
4.57 (s, 1H), 3.37–3.29 (m, 2H), 3.28 (s, 3H), 2.71–2.59 (m, 2H), 2.29–2.24 (m, 1H), 1.95–
1.87 (m, 1H). 13C NMR (151 MHz, Chloroform-d) δ 203.0, 171.1, 145.9, 141.8, 133.9, 130.2, 
128.5, 127.0, 126.9, 126.8, 126.7, 124.3, 112.0, 104.2, 71.7, 39.4, 31.2, 26.9, 24.6. HRMS 
(ESI) m/z calcd for C19H18NO2 ([M+H]+) 292.1337; found 292.1344. 
 
1'-(2,4-dimethoxybenzyl)-7',7'-dimethyl-2-methylene-1',7'-dihydro-2'H-
spiro[cyclohexane-1,3'-pyrano[2,3-g]indole]-2',6-dione (2i). Bright yellow oil (92 mg, 
87%). TLC: Rf 0.74 (40% EtOAc in Hex). IR (NaCl): 2968, 2941, 2868, 1699. 1H NMR (500 
MHz, Chloroform-d) δ 6.93 (d, J = 8.1 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 8.2 Hz, 
1H), 6.48 (d, J = 2.4 Hz, 1H), 6.35 (dd, J = 8.4, 2.4 Hz, 1H), 6.27 (d, J = 10.1 Hz, 1H), 5.45 (d, J 
= 10.1 Hz, 1H), 5.01–4.89 (m, 3H), 4.65 (s, 1H), 3.86 (s, 3H), 3.76 (s, 3H), 3.34–3.24 (m, 2H), 
N
O
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2.69–2.57 (m, 2H), 2.25–2.19 (m, 1H), 1.91–1.81 (m, 1H), 1.38 (s, 3H), 1.34 (s, 3H). 13C NMR 
(101 MHz, Chloroform-d) δ 203.8, 172.9, 160.2, 157.2, 153.9, 138.9, 134.1, 130.5, 126.9, 
126.3, 119.2, 117.1, 116.4, 110.9, 107.3, 104.1, 98.6, 74.9, 71.3, 60.4, 55.4, 40.9, 39.3, 31.1, 
27.5, 27.1, 24.4, 14.2. HRMS (ESI) m/z calcd for C28H29NO5Na ([M+Na]+) 482.1944; found. 
482.1945. 
 
2'-methylene-2H-spiro[benzofuran-3,1'-cyclohexane]-2,6'-dione (2j). Clear oil (32 mg, 
72%). TLC: Rf 0.60 (20% EtOAc in Hex). IR (NaCl): 2924, 2852, 1712, 1608. 1H NMR (600 
MHz, Chloroform-d) δ 7.39 (ddd, J = 8.1, 5.7, 3.4 Hz, 1H), 7.28–7.23 (m, 2H), 7.15 (dt, J = 
8.1, 0.8 Hz, 1H), 5.00 (d, J = 1.8 Hz, 1H), 4.60 (d, J = 1.4 Hz, 1H), 3.27–3.18 (m, 2H), 2.70–
2.58 (m, 2H), 2.28–2.23 (m, 1H), 1.87 (qt, J = 13.1, 4.2 Hz, 1H). 13C NMR (151 MHz, 
Chloroform-d) δ 200.4, 170.4, 153.4, 144.3, 129.8, 127.5, 124.5, 124.2, 113.4, 110.8, 70.5, 
38.4, 30.3, 24.7. HRMS (ESI) m/z calcd for C14H13O3 ([M+H]+) 229.0864; found 229.0876. 
 
 
O
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 1'-methyl-2-methylenespiro[cyclohexane-1,3'-indoline]-2',6-dione-7'-d (2q). White solid 
(15 mg, 60%, mp 140-141 °C). TLC: Rf 0.71 (40% EtOAc in Hex). IR (NaCl): 3059, 2941, 2320, 
1699.  1H NMR (500 MHz, Chloroform-d δ 7.38 – 7.34 (m, 1H), 7.21 – 7.14 (m, 2H), 6.88 (dt, 
J = 7.8, 0.8 Hz, 0.47H), 4.88 (d, J = 2.1 Hz, 1H), 4.51 (d, J = 1.6, 1H), 3.36 – 3.25 (m, 2H), 3.18 
(s, 3H), 2.66 – 2.55 (m, 2H), 2.27 – 2.21 (m, 1H), 1.86 (qt, J = 13.1, 4.1 Hz, 1H).  13C NMR 
(101 MHz, Chloroform-d) δ 203.1, 171.2, 145.7, 128.7, 127.1, 126.4, 122.6, 121.2, 111.6, 
108.5, 72.3, 39.2, 30.9, 26.7, 24.6. HRMS (ESI) m/z calcd for C15H14DNO2Na ([M+Na]+) 
265.1064; found 265.1060. 
 
1'-methyl-2-methylenespiro[cyclohexane-1,3'-indoline]-2',6-dione-4',5',6',7'-d4 (2r). 
White solid (23 mg, 63%, mp 141-142 °C). TLC: Rf 0.71 (40% EtOAc in Hex). IR (NaCl): 3059, 
2936, 1703, 1600. 1H NMR (400 MHz, Chloroform-d) δ 4.86 (s, 1H), 4.49 (s, 1H), 3.34–3.22 
(m, 2H), 3.16 (s, 3H), 2.64–2.53 (m, 2H), 2.25–2.21 (m, 1H), 1.89–1.82 (m, 1H). 13C NMR 
(101 MHz) (101 MHz, Chloroform-d) δ 203.1, 171.2, 145.7, 143.6, 126.9, 126.7, 126.3, 
N
O
O
D
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111.6, 109.9, 108.2, 72.3, 39.2, 30.9, 26.7, 24.6. HRMS (ESI) m/z calcd for C15H11D4NO2 
([M+H]+) 246.1432; found 246.1437. 
 
 
1'-methyl-2-(methylene-d)spiro[cyclohexane-1,3'-indoline]-2',6-dione (2s). White solid 
(80 mg, 63%). Recrystallization from 1:1 dichloromethane/hexanes (slow evaporation 
method) yielded colorless block crystals (mp 140-141 °C).  TLC: Rf 0.71 (40% EtOAc in Hex). 
IR (NaCl): 3052, 2939, 1696, 1610. 1H NMR (600 MHz, Chloroform-d) δ 7.33 (td, J = 7.6, 1.3 
Hz, 1H), 7.17 (dd, J = 7.5, 1.4 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 7.8 Hz, 1H), 4.84 (d, 
J = 1.9 Hz, 1H), 4.49 (d, J = 1.5 Hz, 0.16H), 3.32–3.23 (m, 2H), 3.15 (s, 3H), 2.63–2.52 (m, 
2H), 2.23–2.18 (m, 1H), 1.83 (qt, J = 13.1, 4.1 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 
203.1, 171.2, 145.6, 143.7, 128.8, 127.1, 126.4, 122.6, 111.4 (t, J = 24.17 Hz, 1C), 108.5, 
72.3, 39.2, 30.9, 26.7, 24.6. HRMS (ESI) m/z calcd for C15H14DNO2Na ([M+Na]+) 265.0987; 
found 265.0984. 
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4.5.3  GENERAL PROCEDURE FOR 7-MEMBERED SPIROCARBOCYCLES 
 
 
To a teflon coated 20 mL vial was added heat activated 4 Å molecular sieves (100 mg/mmol 
of starting material), Rh2(HFB)4 (1 mol %), PPh3AuCl (20 mol %), and (CuOTf)2-toluene (20 
mol %). This mixture was dissolved in 0.2 M dichloromethane and allowed to stir for 5 
minutes at room temperature.  The corresponding diazo compound 1 (0.55 mmol) was 
dissolved in 0.5 M CH2Cl2 and then added to the catalyst solution stirring at room 
temperature. The 20 mL vial was sealed and placed on a heating mantle and allowed to stir 
at reflux for 5 hours. Once the reaction was completed, the crude mixture was filtered over 
a celite pad to remove the 4 Å molecular sieves.  The filtrate was directly loaded to a silica 
gel column and purified using flash column chromatography eluting with 10% EtOAc in Hex 
to afford spirocarbocycle product 2k–2m. 
 
1'-methyl-2-methylenespiro[cycloheptane-1,3'-indoline]-2',7-dione (2k). White sticky oil 
(30.5 mg, 49%). TLC: Rf 0.74 (40% EtOAc in Hex). IR (NaCl): 3059, 2932, 1734, 1632. 1H NMR 
(600 MHz, Chloroform-d) δ 7.32 (td, J = 7.7, 1.3 Hz, 1H), 7.23 (dd, J = 7.5, 1.2 Hz, 1H), 7.07 
N
O O
N2
Rh2(HFB)4 (1 mol%)
4 Å MS 
CH2Cl2, reflux
1k – 1m
R2 PPh3AuCl (20 mol%)(CuOTf)2-tol (20 mol%)
N
O
O
2k – 2m
R2
R1
H
R1
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(td, J = 7.6, 1.1 Hz, 1H), 6.88–6.85 (m, 1H), 5.16 (d, J = 0.9 Hz, 1H), 4.79 (d, J = 0.9 Hz, 1H), 
3.20 (s, 3H), 2.87 (ddd, J = 11.8, 10.7, 2.6 Hz, 1H), 2.79–2.66 (m, 2H), 2.65–2.52 (m, 1H), 
2.14–1.96 (m, 2H), 1.87–1.65 (m, 2H). 13C NMR (151 MHz, Chloroform-d) δ 206.3, 173.6, 
146.1, 144.1, 132.0, 129.1, 124.3, 122.5, 116.7, 108.8, 71.7, 42.6, 35.6, 32.4, 27.7, 26.4. 
HRMS (ESI) m/z calcd for C16H17NO2Na ([M+Na]+) 278.1157; found 278.1165. 
 
1'-methyl-7-methylene-3-phenylspiro[cycloheptane-1,3'-indoline]-2,2'-dione (2l). White 
solid (80 mg, 54%). Recrystallization from 1:1 dichloromethane/hexanes (slow evaporation 
method) yielded colorless block crystals (mp 153-154 °C) TLC: Rf 0.67 (40% EtOAc in Hex). 
IR (NaCl): 3069, 2936, 1732, 1657. 1H NMR (400 MHz, Chloroform-d) δ 7.49 (dd, J = 7.5, 1.2 
Hz, 1H), 7.30 (td, J = 7.8, 1.3 Hz, 1H), 7.24 (d, J = 4.3 Hz, 4H), 7.17 (h, J = 4.4 Hz, 1H), 7.11 
(td, J = 7.6, 1.1 Hz, 1H), 6.82 (d, J = 7.8 Hz, 1H), 5.29 – 5.26 (m, 1H), 4.91 (s, 1H), 4.37 (dd, J 
= 10.5, 3.6 Hz, 1H), 3.16 (s, 3H), 2.97–2.84 (m, 1H), 2.76 (dt, J = 14.1, 4.0 Hz, 1H), 2.29–2.13 
(m, 3H), 1.94–1.71 (m, 1H). 13C NMR (101 MHz, Chloroform-d) δ 204.4, 173.8, 145.5, 144.6, 
139.9, 129.4, 128.2 (2C), 128.1 (2C), 126.9, 125.7, 124.4, 122.3, 117.2, 109.0, 72.0, 56.4, 
36.2, 35.2, 31.8, 26.3. HRMS (ESI) m/z calcd for C22H22NO2 ([M+H]+) 332.1650; found 
332.1655. 
2l, 54% 
(dr > 98:2)
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1',3-dimethyl-7-methylenespiro[cycloheptane-1,3'-indoline]-2,2'-dione (2m). White 
sticky oil (30.5 mg, 47%). TLC: Rf 0.74 (40% EtOAc in Hex). IR (NaCl): 3059, 2936, 2363, 1734, 
1638. 1H NMR (600 MHz, Chloroform-d) δ 7.31 (td, J = 7.8, 1.2 Hz, 1H), 7.22 (dd, J = 7.6, 1.2 
Hz, 1H), 7.05 (td, J = 7.6, 1.0 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 5.16 (q, J = 0.8 Hz, 1H), 4.76 (t, 
J = 1.0 Hz, 1H), 3.20 (s, 3H), 3.19–3.15 (m, 1H), 2.82–2.71 (m, 1H), 2.69–2.60 (m, 1H), 2.12–
2.06 (m, 1H), 1.86–1.78 (m, 1H), 1.70–1.58 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 207.9, 173.9, 145.9, 144.5, 134.2, 129.2, 123.9, 122.4, 116.6, 108.9, 
71.8, 45.8, 36.6, 35.2, 31.8, 26.3, 17.8. HRMS (ESI) m/z calcd for C17H19NO2Na ([M+Na]+) 
292.1314; found 292.1322. 
 
4.5.3  GENERAL PROCEDURE FOR 5-MEMBERED 
 
To a teflon coated 20 mL vial was added heat activated 4 Å molecular sieves (100 mg/mmol 
of starting material), PPh3AuCl (20 mol %), and AgSbF6 (20 mol %).  This mixture was 
dissolved in 0.2 M dichloromethane and allowed to stir for 5 minutes at room temperature. 
The corresponding diazo compound 1 (0.55 mmol) was dissolved in 0.5 M CH2Cl2 and then 
2m, 47% 
(dr > 98:2)
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added to the catalyst solution stirring at room temperature. The 20 mL vial was sealed and 
allowed to stir at room temperature overnight. Once the reaction was completed, the 
crude mixture was filtered over a celite pad to remove the 4 Å molecular sieves. The filtrate 
was directly loaded to a silica gel column and purified using flash column chromatography 
eleuting with 10% EtOAc in Hex to afford spirocarbocycle product 2n–2p. 
 
1'-methyl-2-methylenespiro[cyclopentane-1,3'-indolin]-2'-one (2n). Faint yellow oil (32 
mg, 67%). TLC: Rf 0.71 (40% EtOAc in Hex). IR (NaCl): 3055, 2922, 2849, 1713, 1611. 1H NMR 
(600 MHz, Chloroform-d) δ 7.25 (t, J = 6.0 Hz, 3H), 7.10 (d, J = 7.5, 1H), 7.04 (t, J = 7.5, 1H), 
6.83 (d, J = 7.8 Hz, 1H), 4.94 (t, J = 2.1 Hz, 1H), 4.39 (t, J = 2.3 Hz, 1H), 3.20 (s, 3H), 2.83–2.72 
(m, 1H), 2.67–2.58 (m, 1H), 2.33–2.19 (m, 2H), 2.07–1.91 (m, 2H). 13C NMR (151 MHz, 
Chloroform-d) δ 179.9, 154.5, 143.7, 135.2, 123.0, 122.9, 108.2, 107.7, 58.4, 38.5, 33.7, 
29.7, 26.3, 24.3. HRMS (ESI) m/z calcd for C14H16NO ([M+H]+) 214.1232; found 214.1229. 
 
4',6'-dimethoxy-1'-methyl-2-methylenespiro[cyclopentane-1,3'-indolin]-2'-one (2o). 
Faint yellow oil (55 mg, 69%, mp 136-137 °C). TLC: Rf 0.61 (40% EtOAc in Hex). IR (NaCl): 
3075, 2936, 2849, 1709. 1H NMR (600 MHz, Chloroform-d) δ 6.16 (d, J = 2.0 Hz, 1H), 6.10 
N
O
2n, 67%
N
O
2o, 69%
OMe
MeO
Ch. 4 – Metal Carbene Initiated Synthesis of 5-, 6-, and 7-membered Spirocarbocycles 243 
(d, J = 2.0 Hz, 1H), 4.87 (t, J = 2.2 Hz, 1H), 4.37 (t, J = 2.2 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 
3.15 (s, 3H), 2.70 (dt, J = 14.9, 7.2 Hz, 2H), 2.61 (dt, J = 15.6, 7.3 Hz, 2H), 2.30 (dt, J = 12.2, 
7.0 Hz, 1H), 2.18–2.07 (m, 2H), 2.04–1.96 (m, 1H). 13C NMR (151 MHz, Chloroform-d) δ 
181.1, 161.3, 155.6, 154.0, 145.8, 112.6, 106.1, 92.6, 88.0, 57.2, 55.6 (2C), 35.3, 34.2, 26.4, 
24.7. HRMS (ESI) m/z calcd for C16H20NO3 ([M+H]+) 274.1443; found 274.1442. 
 
1'-(3,4-dimethylbenzyl)-7',7'-dimethyl-2-methylene-1',7'-dihydro-2'H-
spiro[cyclopentane-1,3'-pyrano[2,3-g]indol]-2'-one (2p). Faint yellow oil (53 mg, 54%). 
TLC: Rf 0.71 (30% EtOAc in Hex). IR (NaCl): 2955, 2924, 2852, 1712, 1608. 1H NMR (600 
MHz, Chloroform-d) δ 6.87 (d, J = 8.1 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.51 (d, J = 8.0 Hz, 
1H), 6.48 (d, J = 2.3 Hz, 1H), 6.36 (dd, J = 8.4, 2.3 Hz, 1H), 6.32 (d, J = 10.1 Hz, 1H), 5.46 (d, J 
= 10.1 Hz, 1H), 5.04 (d, J = 17.4 Hz, 1H), 5.00 (t, J = 2.3 Hz, 1H), 4.92 (d, J = 17.3 Hz, 1H), 4.55 
(t, J = 2.3 Hz, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 2.33 (td, J = 13.1, 7.3 Hz, 1H), 2.29–2.23 (m, 1H), 
2.07 (dt, J = 12.0, 7.2 Hz, 1H), 1.95 (dp, J = 13.9, 7.4 Hz, 1H), 1.36 (s, 3H), 1.33 (s, 3H). 13C 
NMR (151 MHz, Chloroform-d) δ 181.4, 160.0, 157.2, 155.2, 153.0, 138.8, 130.4, 127.6, 
126.5, 123.1, 117.4, 117.1, 110.7, 108.2, 106.8, 104.1, 98.7, 74.8, 57.5, 55.4, 40.3, 40.0, 
33.6, 29.7, 27.5, 27.0, 24.0. HRMS (ESI) m/z calcd for C27H30NO4 ([M+H]+) 432.2175; found 
432.2138. 
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O
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CHAPTER 5 
 
 [3+2] Annulations of a-Diazoketones for  
the Synthesis of Spiroketals and Spiroaminals 
  
 
 
5.1  INTRODUCTION 
 
 The spiroketal moiety is considered a highly privileged scaffold that is found in 
numerous natural products and drugs (Figure 5.1).[1] Molecules that contain the spiroketal  
 
Figure 5.1. Biologically active natural products and drug molecules containing 
spiroketals/aminals 
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backbone have at least two oxacyclic rings in which the oxygen atoms, that belong to their 
own respective rings, share a common spiro-carbon atom. Currently, the isolation and 
characterization of new spiroketals is a continually growing field, therefore new methods 
for the laboratory synthesis of these scaffolds is highly appreciated by the chemical 
community.[1b] Synthetic efforts completed by laboratories can provide insight into possible 
biosynthetic pathways that lead to the natural synthesis of spiroketal containing natural 
products. 
 
Scheme 5.1. Synthesis of benzannulated spiroketals developed by Sharma et al. 
 
 Recently in 2014, Sharma et al. developed a solvent-dependent stereoselective 
spiroketalization using Sc(OTf)3 and exo-glycal epoxides having alcohol side chains (Scheme 
5.1).[2] The reaction proceeds through a Sc(III) mediated epoxide opening which forms a 
stabilized oxocarbenium ion that undergoes O-alkylation by the flanking hydroxyl group to 
provide the desired benzannulated spiroketals (Scheme 5.1). Subsequently in 2017, Liang 
et al. developed a Sc(OTf)3/PPh3AuOTf catalyzed spiroketalization using exo-enol ethers 
and ortho-quinone methides.[3] The authors propose this reaction proceeds through a Au(I) 
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catalyzed cyclization of an alkyne to form an exo-enol ether. Simultaneously, Sc(III) 
generates the ortho-quinone methide through a dehydration sequence. When these two 
intermediates react, they undergo a [4+2] annulation to form the desired benzannulated 
spiroketals (Scheme 5.2). 
 
Scheme 5.2. Synthesis of benzannulated spiroketals developed by Liang et al. 
 
 Given these insights into spiroketal synthesis from the literature, we began to 
hypothesize different methods to access this scaffold using our previously developed 
Rh(II)/Au(I) catalytic cocktail and taking inspiration from the systems developed by Sharma 
et al. and Liang et al in Schemes 5.1 and 5.2. As stated in Chapter 3, when analyzing 
spiroethers and azaspiro-ring systems, we dissected these molecules in half to create two 
ambiphilic reacting partners that would combine to form our desired spirocenter. 
However, when we applied this dissection to spiroketals it was determined that a cyclic 
diazo whose diazo substituted-carbon was directly bound to a heteroatom would be 
needed (Figure 5.2). No known syntheses of diazos of this nature can be found in literature, 
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presumably due to a lack of stability of the desired compound.[4]  After many failed 
attempts at developing a synthesis for a diazo compound of this nature, it was determined 
that this retrosynthetic design would be unsuccessful. 
 
Figure 5.2. Attempted retrosynthetic disconnection of spiroketals 
 
5.1.1  PRELIMINARY IDENTIFICATION OF REACTIVITY OF a-DIAZOKETONES 
 With the limitation of this unique diazo synthesis consistently in our minds, we 
came across a serendipitous discovery that was based on the reactivity of a-diazoketones. 
As previously mentioned in Chapter 2, during the substrate scope expansion of the 
carboxylic acid O–H insertion/Conia-ene cascade we identified the formation of a [3.1.0]-
fused ring system when non-terminal alkynes were applied in our Rh(II)/Au(I) catalytic 
system (Scheme 5.3a).[5] This product was confirmed to form through a cyclopropanation 
of the resulting furanone produced during the premixing of 3-pentynoic acid with the 
Rh(II)/Au(I) catalytic cocktail via a 5-endo-dig self-lactonization. Interested in expanding the 
scope of this serendipitous finding, we exposed a-diazoketone 1a to these conditions, 
however an unexpected rearrangement occurred to form dihydropyranone 2a in 28% yield. 
We decided to further optimize this transformation through screening different Lewis acids  
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Scheme 5.3. a) Synthesis of [3.1.0]-fused ring system through Rh(II)/Au(I) catalyzed 
cyclopropanation; b) Serendipitous finding in system when a-diazoketones were used. 
 
Table 5.1. Optimization of Dihydropyranone Synthesis 
 
entry catalysts temp, t yield (%)b 
1 Rh2(esp)2/AgOTf/PPh3AuCl rt, 15 min 28% 
2 Rh2(esp)2/AgSbF6/PPh3AuCl rt, 15 min 29% 
3 Rh2(esp)2/PPh3AuCl/(CuOTf)2-tol rt, 15 min 55% 
4 Rh2(esp)2/PPh3AuCl/(CuOTf)2-tol 0 ºC, 30 min 72% 
5 Rh2(esp)2/PPh3AuCl rt, 24 h 0% 
6 Rh2(esp)2/(CuOTf)2-tol rt, 24 h 0% 
All optimization reactions were performed by adding 3-pentynoic acid (2.5 equiv.) to a solution of 
the Lewis Acid (10 mol%) and Rh2(esp)2 (1 mol%) in 0.1 M of the appropriate CH2Cl2. Once the 
furanone was visualized on TLC, diazo 1a (1 equiv.) was added dropwise via syringe pump. Once the 
addition was complete the desired product was isolated by column chromatography.  
 
 
O
OEt
N2
HOOC
Me
	Rh2(esp)2/
PPh3AuSbF6
CH2Cl2,	
Instantly
+
Me
O
O O
Me
via
COMe
EtO2C
O O Me
64%,	dr	>	98:2
O
O
Ph
Me
O
Rh2(esp)2
PPh3AuSbF6
CH2Cl2,	rt
Ph O
H N2
+
O-acylation
2a,	28%
HOOC
Me1a
–
COMe
CO2EtN2
Rh2(esp)2PPh3AuSbF6
a) b)
O O
Me
via
COPh
HN2
Rh2(esp)2PPh3AuSbF6
O
N2
Ph
H
HO O
+
Me
OPh O
Me O1a
2a
conditionsa
Ch. 5 – [3+2] Annuations of a-Diazoketones for the Synthesis of Spiroketals 271 
(Table 5.1). Switching the silver salt to AgSbF6 had little effect on increasing the yield of the 
transformation, therefore we decided to screen the mixture of PPh3AuCl/(CuOTf)2-tol that 
was used in Chapter 4 for a more controlled activation of the alkyne in our system. This 
change significantly increased the yield of 2a to 55% (Table 5.1, entry 3). Next, we 
decreased the temperature of the reaction to 0 ºC and the yield increased to 72% (Table 
5.1, entry 4). Lastly, we screened PPh3AuCl and (CuOTf)2-tol separately in the presence of 
Rh2(esp)2 and neither Lewis acid was able to cyclize 3-pentynoic acid into the corresponding 
furanone, therefore diazo 1a underwent carboxylic acid O–H insertion into 3-pentynoic 
acid. 
Once the optimized conditions were identified we investigated the applicability of 
this method to different substrates (Scheme 5.4). The electron rich para-methoxy ketone 
diazocarbonyl participated in the reaction and the desired compound 2b was isolated in 
92% yield. Next, the para-bromo ketone diazocarbonyl was exposed to the optimized 
reaction conditions and the desired compound 2c was isolated in a 68% yield.  
 
Scheme 5.4. Substrate scope of dihydropyranones 
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 After extending the substrate scope to different a-diazoketones, we were able to 
propose a possible reaction mechanism as illustrated in Scheme 5.5. When exposed to a 
mixture of PPh3AuCl/(CuOTf)2-tol, 3-pentynoic acid undergoes a 5-endo-dig self-
lactonization to form furanone 4. Next, the Rh(II)-carbene of the a-diazoketone is attacked  
 
Scheme 5.5 Proposed mechanism of dihydropyranone synthesis providing insight into 3 
possible pathways of reactivity 
 
by the electron-rich furanone to form the active zwitterionic intermediate 5. This 
intermediate has the ability to pursue three differing pathways: 1) C-alkylation to form a 
cyclopropane, 2) O-alkylation to form a furano-furan derivative, or 3) O-acylation to form 
a six-membered lactone, kicking out a methyl-ketone as a leaving group. The latter pathway  
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is the favored mode of reactivity for this transformation, leading to a variety of 
dihydropyranone derivatives. Further experimentation is needed to provide thorough 
justification for the preference for O-acylation/6-membered lactonization. 
 With preliminary insights into the differing reactivity of a-diazoketones, we wanted 
to extend the reaction seen in Scheme 5.5 to electron-rich alkenes that would not be prone 
to pursue pathway #3 as seen in the mechanism. To initiate our studies, we exposed 
commercially available dihydrofuran to the parent a-diazoketone 1a, however only 
cyclopropanation was observed (Scheme 5.6). We postulated that a change in our a-
diazoketone was needed that would prefer O-alkylation of an oxo-carbenium ion over C-
alkylation, therefore we decided to peruse the literature in search of a different a-
diazoketone. 
 
Scheme 5.6. Attempted extension to dihydrofuran endo-alkene 
 
 Recently in 2013, Kitamura et al. found that diazonaphthoquinones can react with 
enol ethers to provide dihydronaphthoruans through an O-alkylation of an oxo-carbenium 
ions (Scheme 5.7).[6] The authors propose that diazonaphthoquinones (7) form a Rh(II) 
carbene complex in the presence of Rh2(OAc)4 that reacts with enol ethers to form the 
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active zwitterionic intermediate 9. This intermediate aromatizes to form a Rh(II)-bound 
phenolate 10 that proceeds to undergo O-alkylation to form the desired 
dihydronaphthofuran 11. Taking these findings as inspiration, we decided to use 
phenanthrenone diazo 12a, which has many similarities to the diazo used by Kitamura et 
 
Scheme 5.7. Synthesis of dihydronapthofurans by Kitamura et al. 
 
al., and expose it to dihydrofuran in the presence of Rh2(esp)2 alone (the Au(I)/Cu(I) mixture 
was not needed due to a pre-cyclized endo-alkene being used). Once the reaction was 
complete, the desired benzannulated furano-furan 13a was isolated in 76% yield.   
 
Scheme 5.8. Synthesis of benzannulated furano-furans through [3+2] annulation 
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 Inspired by these results, we sought to identify a variety of quinone-type 
diazocarbonyls that would provide similar reactivity as identified with phanenthrenone 
diazo 12a. Recently in literature, diazo quinones synthesized from 2-aminophenol 
derivatives have been shown to form metal-quinoid carbenes when in the presence of 
varying metal catalysis.[7] These active metal-quinoid carbenes have been shown to 
undergo aromatic C–H arylations with electron rich arenes[7b] and C–H functionalizations 
with arylphosphine oxides[7a], however no report of the corresponding C–H 
functionalization followed by O-alkylation of oxo-carbenium ions to form furan-derivatives 
with these types  
 
Scheme 5.9. Application of diazo quinone in developed methodology 
 
of diazo quinones has been reported. With this insight, we exposed diazo quinone 12b to 
commercially available dihydropyran in the presence of Rh2(esp)2 in refluxing 
dichloromethane, upon completion of the reaction benzannulated furano-furan 13b was 
isolated in 61% yield (Scheme 5.9). We proceeded to extend this methodology to a variety 
of electron rich alkenes (Scheme 5.10). Dihydropyran performed similarly to dihydrofuran  
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Scheme 5.10. Substrate scope of benzannulated furano-furans 
 
to provide 13c in 65% yield. Next, we exposed the electron rich endo-alkene synthesized 
from glucose to our optimized conditions and obtained the desired compound 13d in 56% 
yield. Lastly, we applied our method to an endo-alkene which was electron rich due to a 
para-methoxy aryl substituent. This alkene underwent the desired transformation to 
provide 13e in 41% yield.  
 
Scheme 5.11. Proposed mechanism of furano-furan sysnthesis mediated by metal-quinoid 
carbenes to provide thermodynamically favored cis-junction 
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 A plausible mechanism for the formation of the benzannulated furan-ring systems 
is shown in Scheme 5.11. When in the presence of Rh2(esp)2 the diazo quinones form active 
Rh(II)-quinoid carbenes 14 that undergo C–H functionalization with the electron-rich 
alkenes to form a zwitterionic intermediate 15 that quickly aromatizes to give the metal-
bound phenolate complex 16. This complex undergoes O-alkylation onto the oxo-
carbenium ion to form the thermodynamically stable cis-ring junction in 13. 
 Through a thorough understanding of the reactivity of a-diazoketones in hand, a 
new retrosynthesis was designed that “splits” spiroketals in a different manner (Figure 5.3). 
We hypothesized that by applying this newly identified mode of reactivity of metal 
carbenes derived from a-diazoketones and also metal-quinoid carbenes to electron-rich 
exo-alkenes, we could access a variety of spiroketals and spiroaminals through 
stereoselective [3+2] annulations. 
 
Figure 5.3. New retrosynthetic disconnection for spiroketals 
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5.2  SYNTHESIS OF SPIROKETALS AND SPIROAMINALS 
5.2.1  OPTIMIZATION OF CATALYTIC CONDITIONS 
 With our interest intently set on the development of a mild and efficient method 
that provides access to a variety of spiroketals using metal-carbene mediated 
methodology, we proceeded to synthesize electron-rich exo-alkene 17a from readily 
available 2-iodobenzoic acid using literature known protocols. Once this alkene was 
obtained it was exposed to a variety of metal catalysts in the presence of a-diazoketone 
1a. When the reaction was conducted in the with of Rh2(esp)2 a 7:3 ratio of the desired 
product 19a to the cyclopropane 18a was isolated in a total 37% yield (Table 5.2). The  
 
Table 5.2 Optimization of [3+2] Annulation of Exo-Alkene 
 
entry catalysts temp, t 18a:19a 19a %yield 
1 Rh2(esp)2 rt, 30 min 30:70 26% 
2 Rh2(esp)2 rt, 4 hr 0:100 43% 
3 Rh2(OAc)4 rt, 4 hr 0:100 35% 
4 Rh2(R-DOSP)4 rt, 4hr 0:100 42% 
5 Rh2(esp)2 reflux, 2 hrb 0:100 64% 
All optimization reactions were performed by adding 1a (2.5 equiv.) to a solution of Rh(II)(5 mol%) 
in 0.2 M of CH2Cl2. b 1a was added via syringe pump to a refluxing solution of 17a, no cyclopropane 
intermediate was observed with this method of addition 
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reaction gave valuable insight into the possible reaction mechanism; however, we were 
curious whether the highly substituted polarized cyclopropane could undergo 
rearrangement to the desired product 19a. Therefore, 18a was stirred at room 
temperature overnight and the next day clean conversion to 19a was observed. With these 
insights, we repeated the reaction with Rh2(esp)2 and increased the reaction time to 4 
hours, assuming this would be enough time for any necessary rearrangement, and isolated 
19a in 43% yield (Table 5.2, entry 2). Next, we repeated these conditions in the presence 
of Rh2(OAc)4 and the desired product was isolated in 35% yield (Table 5.2, entry 3). 
Subsequently, we screened the chiral Rh(II)-salt, Rh2(R-DOSP)4, in hopes of inducing 
enantiomeric excess (ee) in the transformation but no ee was induced (Table 5.2, entry 4). 
Lastly, we revisted Rh2(esp)2 but added the a-diazoketone dropwise via syringe pump to a 
refluxing solution of exo-alkene 17a and Rh2(esp)2 in hopes of increasing the yield of the 
desired product. These conditions provided the desired compound 19a in a 64% isolated 
yield.  
 
5.2.2  APPLICATION TO SUBSTRATE SCOPE 
 With the optimal conditions in hand we proceeded to extend the substrate scope 
to access a variety of spirocyces. When a non-terminal electron-rich alkene was used the 
desired spiroketal 19c was isolated as a single diastereomer in 47% yield (Scheme 5.12a). 
The yield of this reaction was low despite all attempts at optimization. This was presumably  
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Scheme 5.12. a) Synthesis of spiroketal 19c; b) Non-terminal exo-alkene was not able to 
react with diazo quinone. 
 
due to the electron-rich alkene that was formed in the final product that is of equal 
reactivity to the alkene found in the starting material. To solve this problem, we believed 
the use of diazo quinones in this transformation would increase the yield because there 
would be no reactive alkenes present in the final product. However, when diazo quinone 
12b was reacted with the non-terminal alkene 17b under our optimized conditions the 
[3+2] annulation was not successful and the diazo quinone instead underwent hydration to 
form para-bromo phenol (Scheme 5.12b). We theorized that the steric hindrance of alkene 
17b was not ideal for this transformation with diazo quinones, therefore we screened 
terminal electron-rich exo-alkenes 17a and 17c with the diazo quinone. These substrates 
successfully underwent the desired transformation to form benzannulated spiroaminal 19d 
and sprioketal 19e in 68% yield and 63% yields respectively (Scheme 5.13).  
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Scheme 5.13. a) Synthesis of benzannulated spiroaminal 19d; b) Synthesis of 
benzannulated spiroketal 19e. 
 
 
5.2.3  PROPOSED MECHANISM 
 After applying the methodology to a brief substrate scope, we were able to propose 
a plausible reaction pathway for the Rh(II)-carbene catalyzed spirocyclization (Scheme 
5.14). Decomposition of the a-diazoketone or diazo quinone in the presence of Rh2(esp)2 
forms their respective carbene species. In the case of a-diazoketone carbenes (Scheme 
5.14a), a cyclopropanation is presumed to occur initially, however this polarized 
cyclopropane 20 is highly susceptible to fragmentation to form a zwitterionic species 
consisting of an enolate and oxo/aza-carbenium ion (21). This intermediate undergoes O-
alkylation to form the desired spiroketal/spiroaminal. Comparatively, in the case of Rh(II)-
quinoid carbenes (Scheme 5.14b), the initial C–H functionalization by the electron rich 
alkene occurs to form a reactive zwitterionic intermediate 22 that immediately undergoes 
aromatization to form intermediate 23 thereby prohibiting cyclopropanation. This 
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phenolate-zwitterionic intermediate then undergoes O-alkylation to provide the desired 
spiroketal/spiroaminal. 
 
Scheme 5.14. a) Mechanism of spiroketalization using a-diazoketones; b) Mechanism of 
spiroketalization using diazo quinones 
 
5.3  SUMMARY 
 In conclusion, we have developed methodology to access a variety of heterocyclic 
scaffolds, including dihydropyranones, benzannulated furano-furans, spiroketals, and 
spiroaminals, through use of a-diazoketones and electron-rich alkenes. The unique 
reactivity of metal carbenes derived from a-diazoketones and metal-quinoid carbenes to 
prefer O-alkylation over C-alkylation and the thermal rearrangement of polarized 
cyclopropanes was crucial to the success of these efforts. Further application of this 
methodology to a wider range of scaffolds and optimization of enantioselective 
transformations are currently being pursued in the Sharma laboratory and will be reported 
in due time.  
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5.5  EXPERIMENTAL SECTION 
5.5.1  GENERAL PROCEDURE FOR SYNTHESIS OF DIHYDROPYRANS 
To a teflon coated 20 mL vial was added heat activated 4 Å molecular sieves (100 mg/mmol 
of starting material), Rh2(esp)2 (1 mol %), PPh3AuCl (10 mol %), and (CuOTf)2-toluene (10 
mol %). This mixture was dissolved in 0.2 M dichloromethane and allowed to stir for 5 
minutes at room temperature before 3-pentynoic acid (2.5 equiv.) was added. The reaction 
was stirred for 15 minutes or until the acid was consumed via TLC and a more non-polar 
spot (the desired furanone) formed. The corresponding diazo compound 1 (1.0 equiv.) was 
dissolved in 0.5 M dicholoromethane and then added to the catalyst solution stirring at 0 
ºC via syringe pump. Once the addition was completed, the crude mixture was filtered over 
a celite pad to remove the 4 Å molecular sieves.  The filtrate was directly loaded to a silica 
gel column and purified using flash column chromatography eluting with 10%–25% EtOAc 
in Hex to afford the dihydropyran. 
 
4-acetyl-6-phenyl-3,4-dihydro-2H-pyran-2-one (2a). 1H NMR (600 MHz, Chloroform-d) δ 
7.61 (dd, J = 6.7, 2.9 Hz, 2H), 7.37 (dd, J = 5.3, 1.9 Hz, 3H), 5.91 (d, J = 5.6 Hz, 1H), 3.62 (q, J 
= 6.0 Hz, 1H), 3.00 (dd, J = 16.2, 5.7 Hz, 1H), 2.72 (dd, J = 16.2, 6.6 Hz, 1H), 2.29 (s, 3H). 13C 
NMR (151 MHz, Chloroform-d) δ 203.8, 166.7, 152.1, 128.6, 124.8, 96.8, 44.6, 29.5, 28.0. 
O O
Me O
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4-acetyl-6-(4-methoxyphenyl)-3,4-dihydro-2H-pyran-2-one (2b). 1H NMR (400 MHz, 
Chloroform-d) δ 7.99 – 7.93 (m, 2H), 6.99 – 6.93 (m, 2H), 3.89 (s, 3H), 3.08 (dd, J = 19.1, 6.4 
Hz, 1H), 2.76 – 2.64 (m, 2H), 2.59 (dd, J = 6.4, 4.7 Hz, 1H), 1.64 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 192.6, 175.4, 163.9, 130.5, 113.9, 72.7, 55.6, 55.6, 38.1, 33.7, 23.8, 12.9. 
 
4-acetyl-6-(4-bromophenyl)-3,4-dihydro-2H-pyran-2-one (2c). 1H NMR (600 MHz, 
Chloroform-d) δ 7.50 (q, J = 8.5 Hz, 4H), 5.91 (d, J = 5.6 Hz, 1H), 3.62 (q, J = 6.1 Hz, 1H), 3.01 
(dd, J = 16.2, 6.0 Hz, 1H), 2.74 (dd, J = 16.2, 6.6 Hz, 1H), 2.30 (s, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 203.5, 166.3, 151.3, 131.9, 126.3, 97.3, 44.6, 29.5. 
 
5.5.2 GENERAL PROCEDURE FOR SYNTHESIS OF BENZANNULATED FURANO-
FURANS 
To a teflon coated 20 mL vial was added heat activated 4 Å molecular sieves (100 mg/mmol 
of starting material), Rh2(esp)2 (5 mol %), and the endo-alkene (3.0 equiv.). This mixture 
was dissolved in 0.2 M dichloromethane then the corresponding diazo compound 1 (1.0 
equiv.) was added, the reaction was then heated to reflux until complete. Once complete, 
the crude mixture was filtered over a celite pad to remove the 4 Å molecular sieves.  The 
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filtrate was directly loaded to a silica gel column and purified using flash column 
chromatography eluting with 5%–10% EtOAc in Hex to afford the benzannulated furano-
furan. 
 
9a,11,12,12a-Tetrahydrofuro[2,3-b]phenanthro[9,10-d]furan (13a). TLC: Rf 0.5 (9:1 
hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 8.69 – 8.66 (m, 2H), 8.15 (dd, J = 7.8, 1.3 Hz, 
1H), 7.77 (dd, J = 9.0, 1.0 Hz, 1H), 7.70 – 7.60 (m, 3H), 7.53 (ddd, J = 8.3, 7.0, 1.4 Hz, 1H), 
6.67 (d, J = 5.9 Hz, 1H), 4.43 (dd, J = 8.3, 6.1 Hz, 1H), 4.17 (t, J = 8.5 Hz, 1H), 3.70 (ddd, J = 
11.9, 8.8, 5.2 Hz, 1H), 2.43 (tdd, J = 11.9, 8.6, 7.6 Hz, 1H), 2.35 (dd, J = 12.0, 5.0 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 152.7, 131.5, 129.4, 127.4, 127.2, 127.0, 126.7, 123.7, 123.6, 
122.9, 122.6, 122.6, 121.3, 113.7, 112.0, 67.5, 46.9, 31.6. 
 
5-Bromo-2,3,3a,8a-tetrahydrofuro[2,3-b]benzofuran (13b). TLC: Rf 0.4 (9:1 
hexanes/EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.30 (m, 1H), 7.24 (ddd, J = 6.7, 2.1, 0.7 
Hz, 1H), 6.69 (d, J = 8.5 Hz, 1H), 6.31 (d, J = 5.7 Hz, 1H), 4.09 (t, J = 8.1 Hz, 1H), 3.99 (dd, J = 
8.4, 5.9 Hz, 1H), 3.62 (ddd, J = 12.1, 8.8, 4.9 Hz, 1H), 2.30 (tdd, J = 12.2, 8.6, 7.7 Hz, 1H), 2.05 
(ddd, J = 12.4, 4.8, 0.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 158.6, 131.5, 130.1, 127.7, 
112.8, 111.4, 110.8, 67.3, 46.5, 33.4. 
O
O
O H
H
Br
O
Ch. 5 – [3+2] Annuations of a-Diazoketones for the Synthesis of Spiroketals 287 
 
6-Bromo-3,4,4a,9a-tetrahydro-2H-pyrano[2,3-b]benzofuran (13c). TLC: Rf 0.3 (9:1 
hexanes/EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.26 – 7.25 (m, 2H), 6.5 (d, J = 8.4 Hz, 1H), 
5.89 (d, J = 6.3 Hz, 1H), 3.81 – 3.69 (m, 2H), 3.32 (q, J = 5.9 Hz, 1H), 2.11–2.02 (m, 1H), 1.90–
1.83 (m, 1H), 1.68 – 1.62 (m, 1H), 1.57 – 1.50 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 157.5, 
131.9, 131.1, 126.9, 112.9, 111.4, 104.5, 61.1, 38.8, 22.6, 19.9. 
 
3,4-Bis(benzyloxy)-2-((benzyloxy)methyl)-6-bromo-3,4,4a,9a-tetrahydro-2H-pyrano[2,3-
b]benzofuran (13d). TLC: Rf 0.5 (8:2 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 7.38 – 
7.32 (m, 9H), 7.30 – 7.27 (m, 3H), 7.26 – 7.24 (m, 2H), 7.12 (d, J = 7.5 Hz, 2H), 6.72 (d, J = 
8.5 Hz, 2H), 6.10 (d, J = 6.9 Hz, 1H), 4.76 (d, J = 11.6 Hz, 1H), 4.64 – 4.56 (m, 3H), 4.53 (d, J 
= 12.1 Hz, 1H), 4.45 (d, J = 11.4 Hz, 1H), 3.82 – 3.72 (m, 3H), 3.71 – 3.66 (m, 2H), 3.52 (t, J = 
6.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 157.3, 137.9, 137.7, 132.5, 131.6, 128.6 (2C), 128.5 
(2C), 128.4 (2C), 128.1, 128.0 (2C), 127.9 (2C), 127.8, 127.8, 127.7, 127.6 (2C), 117.2, 111.2, 
110.0, 104.8, 79.9, 76.1, 73.5, 73.5, 73.0, 72.5, 69.1, 44.6. 
 
3a-(4-Methoxyphenyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran (13e). TLC: Rf 
0.5 (9:1 hexanes/EtOAc). 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 7.1 Hz, 1H), 7.35 (d, J = 8.8 
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Hz, 2H), 7.30 – 7.27 (m, 1H), 7.19 (d, J = 7.3 Hz, 1H), 7.06 – 7.02 (m, 1H), 6.86 (d, J = 8.7 Hz, 
2H), 4.00 (d, J = 8.7 Hz, 1H), 3.78 (s, 3H), 2.53 (dd, J = 13.8, 5.7 Hz, 1H), 2.25 – 2.13 (m, 2H), 
2.04 –  1.99 (m, 1H), 1.93 – 1.88 (m, 1H), 1.78 – 1.71 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 
159.1, 153.9, 135.6, 131.7, 130.1, 126.1 (2C), 124.1, 121.1, 118.4, 113.9 (2C), 101.5, 55.3, 
54.2, 41.8, 36.4, 25.0. 
 
5.5.3 GENERAL PROCEDURE FOR SYNTHESIS OF SPIROKETALS/AMINALS 
To a teflon coated 20 mL vial was added heat activated 4 Å molecular sieves (100 mg/mmol 
of starting material), Rh2(esp)2 (5 mol %), and the exo-alkene (1.0 equiv.). This mixture was 
dissolved in 0.2 M dichloromethane then the corresponding diazo compound 1 (2.0 equiv.) 
was added, the reaction was then heated to reflux until complete. Once complete, the 
crude mixture was filtered over a celite pad to remove the 4 Å molecular sieves.  The filtrate 
was directly loaded to a silica gel column and purified using flash column chromatography 
eluting with 10%–20% EtOAc in Hex. 
 
2'-benzyl-5-phenyl-3H-spiro[furan-2,1'-isoindolin]-3'-one (19a). 1H NMR (600 MHz, 
Chloroform-d) δ 7.95 – 7.83 (m, 2H), 7.31 (dq, J = 10.4, 3.6, 2.9 Hz, 5H), 7.16 (t, J = 7.3 Hz, 
3H), 5.45 (t, J = 2.9 Hz, 1H), 4.80 (d, J = 15.4 Hz, 1H), 4.54 (d, J = 15.6 Hz, 1H), 3.28 (dd, J = 
17.7, 2.5 Hz, 1H), 2.91 (dd, J = 17.8, 2.9 Hz, 1H). 
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3,5-diphenyl-3H,3'H-spiro[furan-2,1'-isobenzofuran] (19c). 1H NMR (500 MHz, Benzene-
d6) δ 7.73 – 7.66 (m, 2H), 7.33 (dt, J = 7.6, 0.9 Hz,10H), 7.25 – 7.20 (m, 2H), 7.12 – 6.97 (m, 
9H), 6.59 (dt, J = 7.5, 1.0 Hz, 1H), 5.55 (d, J = 2.3 Hz, 1H), 4.87 – 4.76 (m, 2H), 4.20 (d, J = 
12.8 Hz, 1H). 
 
2'-benzyl-5-bromo-3H-spiro[benzofuran-2,1'-isoindolin]-3'-one (19d). 1H NMR (600 MHz, 
Chloroform-d) δ 7.92 – 7.85 (m, 1H), 7.64 – 7.53 (m, 2H), 7.44 (d, J = 7.3 Hz, 1H), 7.30 (dd, 
J = 8.4, 2.1 Hz, 1H), 7.23 – 7.17 (m, 3H), 7.09 – 7.04 (m, 2H), 6.60 (d, J = 8.5 Hz, 1H), 4.78 (d, 
J = 15.7 Hz, 1H), 4.37 (d, J = 15.4 Hz, 1H), 3.56 (d, J = 17.4 Hz, 1H), 3.24 (d, J = 17.4 Hz, 1H). 
 
5-bromo-3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3'-one (19e). 1H NMR (600 MHz, 
Chloroform-d) δ 7.96 – 7.91 (m, 1H), 7.81 – 7.75 (m, 1H), 7.68 (t, J = 7.5 Hz, 1H), 7.61 (d, J = 
7.6 Hz, 1H), 7.44 (s, 1H), 7.37 (d, J = 2.2 Hz, 1H), 6.83 (d, J = 8.5 Hz, 1H), 3.80 – 3.74 (m, 1H), 
3.64 (d, J = 17.3 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 166.95, 156.74, 145.69, 
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134.99, 131.62, 131.45, 128.31, 127.79, 126.82, 126.73, 125.62, 122.71, 114.50, 113.58, 
111.72, 40.41. 
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CHAPTER 6 
 
  
Conclusions 
  
 
 
 The goal of the research completed within this dissertation was to utilize metal 
carbene initiated cascade reactions to conduct the efficient synthesis of spirocyclic 
scaffolds. The value of this research was centralized around the importance of spirocycles 
and their under-exploitation in the field of drug discovery. Upon completion of this work a 
better understanding of the reactivity of metal carbenes and their use in cascade 
spirocyclizations was obtained. Metal carbenes, which are ambiphilic in nature, provided 
the possibility of conducting sequential reactions with a nucleophile and electrophile 
inbuilt in the same molecule. This cascade reactivity allowed us to stereoselectively install 
spirocenters in “single pot” reactions. 
 Within this dissertation a new strategy to prepare a-acyloxy carbonyl scaffolds, g-
butyrolactones, and tetrahydrofurans from readily available starting materials was 
developed (Chapter 2). During the development of this methodology we were able to 
identify two novel catalytic systems that were critical to the success of our chemistry: 1) 
 304 
Rh2(esp)2 as a single catalyst for the efficient insertion of carboxylic acids into very stable 
A/A diazocarbonyls and 2) Rh2(esp)2/PPh3AuOTf as a synergistic catalytic combination for 
the O–H insertion/Conia-ene cascade. 
 After completing the aforementioned work, we were able to take the insights 
learned during that methodology development to equip ourselves with knowledge 
necessary for the development of methodology to access highly valuable spiroethers and 
azaspiro-ring systems (Chapter 3). The synthesis of these spirocyclic ring scaffolds were not 
achieved without encountering challenges. The challenges we confronted during the 
synthesis of spiroethers and azaspiro-ring systems caused us to explore different catalytic 
conditions, temperatures, and reagent addition methods providing valuable insight into 
the reactivity of metal carbenes in cascade reactions with different nucleophilic sources. 
 With the successful application of our Rh(II)/Au(I) catalytic system to the synthesis 
of spiroethers and azaspiro-ring systems, we gained confidence in our ability to apply this 
system to the difficult synthesis of all-carbon spirocenters. After thorough optimization and 
a modification that required the substitution of AgOTf with (CuOTf)2-tol as our Au(I) 
activator, we were able to extend our previously identified Rh(II)/Au(I) catalytic cocktail to 
a  general approach for the synthesis of 5-, 6-, and 7-membered oxindole hybridized 
spirocarbocycles (Chapter 4).  
 Lastly, we decided to let our ambition navigate our research in an attempt to apply 
our Rh(II)/Au(I) catalytic system to the synthesis of spiroketals, however, an unsuccessful 
retrosynthetic disconnection limited our ability to complete this task. Nevertheless, a 
serendipitous discovery using a-diazoketones provided us with insight into a different 
 305 
mode of reactivity that could be used in the synthesis of spiroketals using metal carbenes. 
With this insight, we identified a new retrosynthetic disconnection that exploited exo-
alkenes and metal carbenes obtained from a-diazoketones and metal-quinoid carbenes 
(Chapter 5). Upon completion of this work we were able to access a variety of spiroketals 
and spiroaminals. 
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